ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS

Abstract: Process for killing internal parasites, especially nematodes and cestodes affecting warm blooded animals such as sheep, cattle, swine, goats, dogs, cats, horses and humans as well as poultry by administering an effective amount of a compound of Formula (I). Certain of the compounds of Formula (I) are novel and in further embodiments of the invention provide novel compounds and compositions for use in the process of the invention. The compounds are readily prepared by conventional chemical reactions. Various pyridinyl acylhydrazones of Formula (I) demonstrate broad-spectrum anthelmintic activity in sheep upon oral and/or parental administration.

Description: ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS SUMMARY OF THE INVENTION This invention pertains to a new method for killing and controlling worms (Helminths), and new formulations for killing and controlling worms in animals, and new chemical compounds. The invention is more particularly directed to a new method for killing and controlling parasitic worms in animals with certain pyridinyl acylhydrazones, to new anthelmintic formulations comprising the same, and to new pyridinyl acylhydrazones. The anthelmintic pyridinyl acylhydrazones have the general structural formula I. BACKGROUND OF THE INVENTION The diseases or groups of diseases descr i bed generally as helminthiasis are due to infection of the animal with parasitic worms known as helminths . Helminthiasis and helminthosis are prevalent and may lead to serious economic problems in sheep , swine , cattle , goats , dogs , cats , horses , poultry and man . Among the helminths , the groups of worms known as nematodes , trematodes and cestodes cause widespread and often-tiraes serious infections in various species of animals including man. The most common genera of nematodes and cestodes infecting the animals referred to above are Dictyocaulus , Haemonchus , Tri chostrongylus , Oatertagia, Nematodirus , Cooperia, Bunos torn urn , Oesophagostomum, Chabertia, Strongyloides , Trichu is , Fasciola , Dicrocoelium, Enterobius , Ascaris , Toxascaris , Toxocara , Ascaridia, Capillaria, Heterakis , Ancylostoma, Uncinaria, Onchocerca , Taenia, Moniezia, Dipylidium, Metastrongylus , Macracanthorhynchus , Hyostrongylus , and Strongylαs . Some of these genera attack primarily the intestinal tract while others , inhabit the stomach , lungs , liver and subcutaneous tissues . The parasitic infections causing helminthiasis and helminthosis lead to anemia , malnutrition , weakness , weight loss , unthriftiness , severe damage to the gastrointestinal tract wall and , if left to run their course , may result in death of the infected animals. The anthelmintic activity of pyridinyl acylhydrazones has not been previously reported. DETAILED DESCRIPTION OF THE INVENTION The pyridinyl acylhydrazones of this invention, including hydrates or pharmaceu ically acceptable salts thereof, are represented by Formula I wherein X is (a) hydrogen; (b) Cι-Cι o alkyl; (c) C2-C6 alkenyl, preferably C2-C alkenyl; (d) C2-C6 alkynyl; (e) cyclo(C3*-C*ιo)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C4 alkenyl, C*|- C1. alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1-methylpyrrolidinyl; (i) 1- ethylpiperidinyl; (j ) C2-C6 alkoxyalkyl; (k) cyclo(C3-Cιo)alkyl(Cι-C4)alkyl; (1) phenyl (Cι-Cij)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (m) phenoxy (C1-C4) alkyl optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (n) naphthyl(C-|-C3)alkyl optionally substituted with one or two C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (o) Cι,-C6 alkoxy, preferably C1-C4 alkoxy; (p) diphenylmethoxy; (q) cyclo(C3-C6)alkyloxy optionally substituted with one or two C1-C3 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (s) benzyloxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C-*- C4 alkoxy, halo, or trifluoromethyl; with the proviso that when a 2- pyridinyl acylhydrazone and R-j , R 2 , R4 are hydrogen, R3 is not benzyl; (t) heteroaromatic optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C3 alkoxy, halo, C1-C3 alkylthio, or trifluoromethyl; (u) phenyl optionally substituted with one, 2 or 3 C-J-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C1-C3 alkylthio, nitro, or phenoxy optionally substituted with one, 2 or 3 C1-C alkyl, C1-C3 alkoxy, halo, or trifluoromethyl; (v) phenyl optionally substituted with the divalent C---C2 alkylenedioxy; (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C-J-C3 alkylthio, nitro; (x) bridged polycyclic hydrocarbon substituents of six to 10 nuclear carbons, optionally substituted with one, 2 or 3 (C1-C3) alkyl groups; (y) perhalo(C*|-C7)alkyl; wherein R* and 2, being the same or different, are hydrogen; hydroxy; C1-C alkyl, preferably C1-C3 alkyl; C1-C3 alkoxy; C1-C3 alkylthio; halo or trifluoromethyl; wherein R3 is hydrogen; C1-C4 alkyl; cyclo^-Cg.alkyl optionally substituted with one, 2 or 3 C1-C3 alkyl, preferably cyclo(C3-C5)alkyl optionally substituted; phenyl optionally substituted with one, 2 or 3 C1-C alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (C1-C3) alkyl optionally substituted with one, 2 or 3C1-C alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; or 1 , 3-dioxacyclohexan-5-yl; wherein R4 is hydrogen; C1-C2 alkyl; cyclo(C3-C6) l yl optionally substituted with one, 2 or 3 C1-C3 alkyl, preferably cyclo(C3-C5)alkyl optionally substituted; phenyl optionally substituted with one, 2 or 3 C1-C alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (C1-C3) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or C-1-C3 alkoxy; wherein n is zero or one. c - C means the carbon content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of. carbon atoms in the moiety. Thus (C1-C3) alkyl refers to alkyl of one to 3 carbon atoms, inclusive or methyl, ethyl, propyl, and isopropyl. Halogen atom (halo) refers to a bro o, chloro, iodo or fluoro atom. Hete oaromatic refers to an aromatic heterocycle of 5 to 10 members, containing one or two heteroatoms selected from the group consisting of oxygen, nitrogen or sulfur and includes quinoline, pyrrole, indole, benzofuran, benzothiophene, quinazoline, quinoxaline, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, pyridazine, pyrimidine, pyrazine , benzimidazole , benzothiazole , benzoxazole, pyridine, thiophene or fur an, as well as the N-oxides, hydrates and pharmaceutically acceptable salts thereof. Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacσlogically- toxicological point of view and to the manufacturing pharmaceutical chemist from a physical-chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. Examples of C 1 -C4 alkyl are methyl, ethyl, propyl, butyl and isomeric forms thereof. Examples of C -C3 alkoxy are methoxy, ethoxy, propoxy and isomeric forms thereof. Examples of phenoxy substituted with one, 2 or 3 C1-C4 alkyl are (o-, m-, or p-)tolyl, (0-, m-, or p- )ethylphenyl, p-tert-butylphenyl, 2, 5-dimethyl phenyl, 2, 6-dimethyl phenyl, 2, -dimethyl phenyl, (2,3,1-, 2,3,5-, 2,3,6-, 2,4,6- or 2, ,5-)trimethyl- phenyl . Examples of C2-C6 dialkylamino are dimethyl ami no , diethylamino, ethylethylamino, dipropylamino and ethyl propyl amino. Examples of phenyl (C 1-C3) alkyl are benzyl, phenylethyl and phenyl- propyl. Examples of phenyl(C-j-C3)alkyl substituted with one, 2 or 3 C1-C4 alkoxy, halo or trifluoromethyl include 4-chlorobenzyl , 2-chloro- phenyl ethyl, p-tolyl ethyl, 2-methyl benzyl, 4-methoxybenzyl. Examples of C1-C3 alkylthio include methylthio, ethyl thio, and n-propylthio. Examples of substituted cyclo(C3~C*ιo)alkyl are chrysanthemyl , 1-methylcyclopropyl and 2-methyl cyclopropyl. Examples of cyclo(C3-C*ιo)*~ alkyl(C-|-C4)alkyl are 2-cyclohexylethyl and cyclohexylmethyl . An example of substituted cyclo^-Cβ.alkyloxy is menthyl. Examples of naphthyl(C-j-C3)alkyl include 2-naphthylmethyl and 1-naphthylethyl. Examples of substituted naphthyl(C-|-C3)alkyl is ( 3, 8-dichl or o-1 -naphthyl) methyl; ( .-chloro-1 -naphthyl ) methyl; and (4-methoxy-1 -naphthyl )methyl. Examples of substituted naphthyl include 3 , 6-di chlor o- 1 -naphthyl ; 3.5-di chlor o-2-na phthyl ; 6-methyl-2-naphthyl ; and 4, 6-di chlor o-1 -naphthyl. Examples of bridged polycyclic hydrocarbon substituents of six to 10 nuclear carbons, optionally .substituted with one, 2 or 3 (0*1-03) alkyl groups include exo or endo-2-norbonyl, bicyclo[2,2,2]oct-1-yl, and 1-adamantyl. Examples of perhalo (C-J-C7) alkyl include trifluoromethyl, n-hepta- fluoropropyl and n-un decaf luoro pent yl. Preferred pyridinyl acylhydrazones of Formula I are 3-pyridinyl acylhydrazones or 4-pyridinyl acylhydrazones, most preferably are 4- pyridinyl acylhydrazones. Preferred R* and R2 include hydrogen, C1-C3 alkyl, C1-C3 alkoxy or a chlor-o atom. Preferred R3 includes hydrogen and methyl or ethyl. R4 is preferably hydrogen . Preferred X include hydrogen; C-1-C4 alkyl; cyclohexylethyl; phenyl optionally substituted with one, 2 or 3 C 1-C alkyl, C1-C2 alkoxy, trifluoromethyl and chloro; C1-C4 alkoxy; phenoxy optionally substituted with one, 2 or 3 C--C2 alkyl, C1-C2 alkoxy, trifluoromethyl and chloro. Most preferably X includes hydrogen, C1-C4 alkyl; cyclohexylethyl; phenyl; phenyl substituted with C1-C2 alkoxy and ethoxy. One embodiment of this invention includes, of course, the anthelmintic use and anthelmintic compositions of compounds of Formula I, IA, IB, IC, ID or IE, hydrates thereof or pharmaceutically acceptable salts thereof. Still another embodiment of this invention are the novel compounds, hydrates thereof or pharmaceutically acceptable salts thereof according to Formula I. Another embodiment of this invention are the compounds of Formula I, the hydrates thereof or pharmaceutically acceptable salts thereof where X is selected from (a) hydrogen; (b) C-j— C-j 0 alkyl; with the proviso that when X is methyl and the compound is a 2-pyridinyl acylhydrazone, and R-* , R2 and R4 are hydrogen, R3 is other than hydrogen or methyl; with the further proviso that when X is methyl and the compound is a 4-pyridinyl acylhydrazone, and R-- , R and R4 are hydrogen, R3 is other than hydrogen; (c) C2-C6 alkenyl; (d) C2-C6 alkynyl; (e) cyclo(C3~C6)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C alkenyl, C1-C alkoxy, tri l oromethyl, or halo; ( j ) C -C6 alkoxyalkyl; (k) cyclo(C4-Cιo)alkyl(C*|-C4)alkyl; (1) phenyl(C*|-C3)alkyl optionally substituted with, one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; with the proviso that when X is phenylmethyl and R-] , 2 and R4 are hydrogen, R3 is other than hydrogen or methyl; (m) phenoxy(C * ι-C4)alkyl optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; with the proviso that when X is phenoxymethyl substituted with 4-chloro, 2, -di chloro or 2,4,5-trichloro and R-] , 2 and R4 are hydrogen, R3 is other than hydrogen (n) naphthyl(C*]-C3)alkyl optionally substituted with one or 2 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; with the proviso that when X is 1-n ' aphthylmethyl and R-* , R2 and R4 are hydrogen, R3 is other than hydrogen or methyl; (o) C-j— Cg alkoxy, with the proviso that when the compound is a 4-pyridinyl acylhydrazone and R-j , R2, R3 and R4 are hydrogen, X is other than methoxy; with the further proviso that when the compound is a 3-pyridinyl acylhydrazone and R-j , R2 and R4 are hydrogen and R- is methyl, X is other than ethoxy; with the further proviso that when the compound is a 2-pyridinyl acylhydrazone and R- * , R2 and R4 are hydrogen, X is other than methoxy when R3 is methyl, or ethoxy when R3 is hydrogen or methyl; (p) diphenylmethoxy; (q) cyclo(C3- C6)alkyloxy optionally substituted with one or two C1-C3 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (s) benzyloxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; with the proviso that when a 2-pyridinyl acylhydrazone and R-- , R , R4 are hydrogen, R3 is not benzyl; (u) phenyl optionally substituted with one, 2 or 3 C1-C alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C1-C3 alkylthio, nitro, or phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C3 alkoxy, halo, or trifluoromethyl; with the proviso that when X is phenyl and R* and R2 are hydrogen, either R3 or R4 is other than hydrogen; with the further proviso that when X is phenyl and the compound is a 2- or 4-pyridinyl acylhydrazone and R-* , R2 and R4 are hydrogen, R3 is other than hydrogen; with the further proviso that when X is phenyl, R-\ is 2-ethyl, R2 . R3 and R4 are hydrogen, the compound is other than a 4-pyridinyl acylhydrazone; with the further proviso that when X is phenyl substituted with 4-dimethylamino and R-| , R2, R3 and R4 are hydrogen, the compound is other than a 4-pyridinyl acylhydrazone; with the .further proviso that when X is phenyl substituted with 4-methyl, the compound is a 2- or 4-pyridinyl acylhydrazone, either R-j , R 2 , R3 or R4 is other than hydrogen; with the further proviso that when X is phenyl substituted with 4-methoxy, R3 is methyl, and R-- , R2 and R4 are hydrogen, the compound is other than a 4-pyridinyl achlhydrazone; with the further proviso that when X is phenyl substituted with 3,-4-dimethoxy, R-j is 2-ethyl and R2, R3 and R4 are hydrogen, the compound is other than a 4-pyridinyl acylhydrazone; with the further proviso that when X is phenyl substituted with 4-t-butyl and R-j , R 2 , R3 and R4 are hydrogen, the compound is other than a 3-pyridinyl acylhydrazone; with the further proviso that when X is phenyl, R-- , 2 and R4 are hydrogen, and R3 is benzyl, the compound is other than a 2-pyridinyl acylhydrazone; with the further proviso that when X is phenyl substituted with 2-nitro, either R2, R3 or R4 is other than hydrogen; with the further provison that when X is phenyl substituted with 4-nitro, R-j is 2-ethyl, and R2 . R3 and 4 are hydrogen, the compound is other than a 4-pyridinyl acylhydrazone; with the further proviso that when X is phenyl substituted with 4-nitro, R3 is methyl, and R-* , R2 and R4 are hydrogen, the compound is other than a 4-pyridinyl acyl¬ hydrazone; (v) phenyl optionally substituted with the divalent Z -Z~ alkylenedioxy; and (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C1-C3 alkylthio, nitro; Another embodiment of this invention are the compounds of 13 and the novel compounds of Formula IA, IC, ID or IE; the hydrates thereof or pharmaceutically acceptable salts thereof. Another embodiment of this invention are the novel compounds of Formula IA, the hydrates thereof or pharmaceutically acceptable salts thereof where R5, R5 and Rγ are the same or different and are selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C3 alkoxy, trifluoromethyl, a halogen atom, C1-C4 alkylthio, phenoxy optionally substituted with a halogen atom, trifluoromethyl, C1-C4 alkyl, C1-C3 alkoxy; with the provisio that at least either R5, 6 or R ~ is other than hydrogen. Preferred R5, Rg and Rγ include hydrogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl and chloro. Another embodiment of this invention are the novel compounds of Formula IB, the hydrates thereof or pharmace tically acceptable salts thereof where R3 and Rg are the same or different and are selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C3 alkoxy, trifluoro-*- ethyl, a halogen atom, C1-C4 alkylthio, C2-C6 dialkylamino and nitro. Preferred R3 and R9 include hydrogen, methyl, ethyl, methoxy, ethoxy, trifluoromethyl and chloro. Another embodiment of this invention are the novel compounds of Formula IC , the hydrates thereof or pharmace tically acceptable salts thereof where -OR' 5 is selected from the group consisting of (o) C-j-Cg alkoxy, preferably C1-C4 alkoxy; (p) diphenylmethoxy; (q) cyclop- Cg)alkyloxy optionally substituted with one or two C1-C3 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; or (s) benzyloxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl. Another embodiment of this invention are the compounds of Formula IC, the hydrates thereof or pharmaceutically acceptable salts thereof where -OR'5 is selected from the group consisting of (o) C*]-C6 alkoxy, preferably C1-C alkoxy; (p) diphenylmethoxy; (q) cyclo(C3-C6) alkyloxy optionally substituted with one or two C1-C3 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; or (s) benzyloxy optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; with the. proviso that when a 4-pyridinyl acylhydrazone and R-- , 2, R3 and R4 are hydrogen, -OR '5 is other than methoxy; with the further proviso that when a 3-pyridinyl acylhydrazone and R-| , R2 and R4 are hydrogen and R3 is methyl, -OR '5 is other than ethoxy; with the further proviso that when a 2-pyridinyl acylhydrazone and R*- , R 2 and R4 are hydrogen, -OR' 5 is other than (a) methoxy when R3 is methyl, or (b) ethoxy when R3 is hydrogen or methyl. Another embodiment of this invention are the novel compounds of Formula ID, the hydrates thereof or pharmaceutically acceptable salts ' thereof where -R n g is selected from the group consisting of (a) hydrogen; ( b) C-]-C * ιo a ky ; (c) C2-C6 alkenyl, preferably C2-C alkoxy; (d) C2- 5 alkynyl; (e) cyclo(C3-C6)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1-methylpyrrolidinyl; (i) 1-methyl- piperidinyl; (j) C2-C6 alkoxyalkyl; (k) cyclo(C4-C*ιo)alkyl(Cι-C4)alkyl; (1) phenyl (0*1-03) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C alkoxy, halo, or trifluoromethyl; ( ) phenoxy (C1-C4) alkyl optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; or (n) naphthyl(C*ι-C3)alkyl optionally substituted with one or 2 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl. R * I , R2 > R3, R4 and n are defined in Formulas IA, IB, IC, ID, and IE as in Formula I. Among the pyridinyl acylhydrazones of Formula IA: benzoic acid (3~pyridinylmethylene)hydrazide (Cpd -.6), benzoic acid (4-pyridinylmethylene)hydrazide (Cpd _.7) , benzoic acid [1-( 2-pyridinyl )ethylidene]hydrazide (Cpd #1), benzoic acid (2-pyridinylmethylene)hydrazide (Cpd #9, hydrate), 4-dimethyl amino benzoic acid (4-pyridinylmethylene)hydrazide, 4-methylbenzoic acid ( 2-pyridinylmethylene)hydrazide (Cpd #4, hydrate) , 4-methyl enzoic acid (4-pyridinylmethylene)hydrazide (Cpd #33), 4-methyl benzoic acid (2-pyridinylmethylene)hydrazide 1-oxide, 53 4-t-butylbenzoic acid (3~pyridinylmethylene)hydrazine, 2-nitrobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #69), 2-nitrobenzoic acid (2-pyridinylmethylene)hydrazide, 2-nitrobenzoic acid (3-pyridinylmethylene)hydrazide , 4-nitrobenzoic acid [(2-ethyl-4-pyridinyl)methylene]hydrazide, 10 benzoic acid C(2-ethyl-4-pyridinyl)methylene]hydrazide, 3, 4-dimethoxybenzoic acid [2-(ethyl-4-pyridinyl)methylene]hydra__ide, benzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #3), -met ho y benzoic acid [1-(4-pyridinyl)ethylidene]hydrazide, 4-nitrobenzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide, and ^ benzoic acid (α-2-pyridinylbenzylidene)hydrazide are known. See Y. Nishimoto and S. Toyashimo, Yakuguku Zasshi 87, 27- 32 (1967); Chem. Abstr, 66, 98544r; S.E. Livingstone and J.E. Oluka, Transition Met. Chem 3, 261-7 (1978); H. Schlesinger, U.S. Patent 3,066,023, 11/27/62 - cf . H. Schlesinger, Ger . Patent 1,101,145, 20 Appl. 12/19/58 - Chem. Abstr. 56, P2104b; S. Tanaka, T. Kato, S. Yaraamoto andH. Yoshiaka, Agric. Biol. Chem. 41 , 1953-1959 ( 1977) ; A. C . Sartorelli, .C. Agrawal, B.A. Booth, J. Pittman, D.G. Bartholomew and A.D. Bloom, J. Med. Chem. 19, 830-833 (1976); A. Pedrazzoli et al., Bull. Soc. Chim. Fr., 407-14 (1968), Chem. Abstr. 69, 27401T; I. Babic et al . , ' 25 Chim. Ther. 7, 220-2(1972); Y. Arataetal, Am. Rept. Fac. Pharm. Kanazawa Univ., No. 5, 46-9 (1955), Chem. Abst. 50, I4974e; Chem. Abst. 101, 1δ24ot. Among the pyridinyl acylhydrazones of Formula IC: ethyl[1-(3-pyridinyl)ethylidene]carbazate (Cpd -.71), 30 methyl ( 2-pyridinylmethylene )carbazate , ethyl(2-pyridinylmethylene)carbazate (Cpd #73), ethyl (4-pyridinylmethylene)carbazate (Cpd #75), and ethyl[1-(2-pyridinyl)ethylidene]carbazate (Cpd #70). are known. SeeR.U. Leraieux and R. Raap, U.S. Patent 3,654, 294, 04/04/72; 35 Chem. Abstr. 77, 5448b; J. Amat Badrinas, Spain Patent, ES 490,004 A1 , 04/01/81; Chem. " Abstr. 96, 3l898w; N.R. El-Rayyer and F.M. Al-Kharafi, Egypt. J. Chem. 23, 151-6 (1981); Chem. Abstr. 96, 14575X; N.R. El- Rayyes and A.H. Katric, J. Chem. Eng. Data 28, 132-4 (1983); and A.B. deMilo, R.E. Redfern and A.B. Borkovec, J. Agri. Food Chem. 31, 713-18 (1983). - J Among the pyridinyl acylhydrazones of Formula ID: acetic acid (4-pyridinylmethylene)hydrazide, acetic acid (2-pyridinylmethylene)hydrazide, acetic acid [1-(2-pyridinyl)ethylidene]hydrazide, 2,4,5-trichlorophenoxyacetic acid (4-pyridinylmethylene)hydrazide , 1U 2,4,5-trichlorophenoxyacetic acid (3~pyridinylmethylene)hydrazide, 2,4,5-trichlorophenoxyacetic acid (2-pyridinylmethylene)hydrazide, 2,4,-dichlorophenoxyacetic acid (4-pyridinylmethylene)hydrazide, 2,4,-dichlorophenoxyacetic ' acid (3-pyridinylmethylene)hydrazide, 2,4,-dichlorophenoxyacetic acid (2-pyridinylmethylene)hydrazide, 4-chlorophenoxyacetic acid (4-pyridinylmethylene)hydrazide, 4-chlorophenoxyacetic acid (3-pyridinylmethylene)hydrazide, 4-chlorophenoxyacetic acid (2-pyridinylmethylene)hydrazide, 1-napthylacetic acid [1-(3-pyridinyl)ethylidene]hydrazide, 1-napthylacetic acid [1-(4-pyridinyl)ethylidene]hydrazide, I- 1-napthylacetic acid [1-(2-pyridinyl)ethylidene]hydrazide , 1-napthylacetic acid (2-pyridinylmethylene)hydrazide, 1-napthylacetic acid (3-pyridinylmethylene)hydrazide, 1-napthylacetic acid (4-pyridinylmethylene)hydrazide, phenylacetic acid [1-(2*-pyridinyl)ethylidene]hydrazide, " phenylacetic acid [1-(3-pyridinyl)ethylidene]hydrazide, phenylacetic acid Cl-(4-pyridinyl)ethylidene]hydrazide (Cpd #157), phenylacetic acid (2-pyridinylmethylene)hydrazide, phenylacetic acid (3-pyridinylmethylene)hydrazide, and phenylacetic acid (4-pyridinylmethylene)hydrazide 30 are known. See G. Palla, C. Pelizzi, G. Predieri ,and C. Vignalo, Grazz. Chim. Ital. 112 (7-8), 339-41 (1982) - Cnem. Abstr. 98, (13), 106703V; C. Mochon and G. Azira, Microchem. Journal, 1981, 26 (4), 463-71 - Chem. Abstr. 96 (8), 62225t; S.E. Livingstone and J.E. Oluka, Trans. Met. Chem. 3, 261-7 (1978); J. Klosa, J. Prakt. Chem., 31 (1-2), 35 20-33 (1966) - Chem. Abstr. 64, 11124a; N.B. Mahishi, B.H. Iyer and M. Sirisi, J. Indian Chem. Soc, 42 (2), 67-74 (1965) - Chem. Abstr. 62, l6654g; H. Bojarska-Dahlig, Acta Polon. Pharm., 20 (4), 293-302 (1963) - Chem. Abstr. 62, 2975i; N.R. El-Rayyes and F.M. Al-Kharafi, Egypt. J. Chem., 23, 151-6 (1981) - Chem. Abstr., 96, 142575X; H. Bojarska- Dahlig, Acta Polon. Pharm., 21 (4), 337-41 (1967) - Chem. Abstr. 62, 104016; Y. Takeda, Y. Maejima and H. Namekata, Japan. J. Tuberc. 2, 184-5 (1954), Chem. Abstr. 49, 13243i. Among the pyridinyl acylhydrazones of Formula IE: isonicotinic acid (2-pyridinylmethylene)hydrazide (Cpd #221), isonicotinic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #217), 10 picolinic acid (2-pyri-dinylmethylene)hydrazide, picolinic acid [1-( 4-pyridinyl )ethylidene]hydrazide, picolinic acid C(6-methyl-2-pyridinyl)methylene]hydrazide , quinaldic acid C(6-methyl-2-pyridinyl)methylene]hydrazide , 4, 5-dimethyl-2-furancarboxylic acid (4-pyridinylmethylene)hydrazide, 15 4,5-dimethyl-2-f urancarboxylic acid (3-pyridinylmethylene)hydrazide , 4, 5-dimethyl-2-f urancarboxylic acid (2-pyridinylmethylene)hydrazide, 5-ethyl-2-f rancarboxylic acid (4-pyridinylmethylene)hydrazide, 5-ethyl-2-f urancarboxylic acid (3~pyridinylmethylene)hydrazide, 5-ethyl-2-f urancarboxylic acid (2-pyridinylmethylene)hydrazide, 20 5*-methyl-2-f urancarboxylic acid (4-pyridinylmethylene)hydrazide, 5-methyl-2-f urancarboxylic acid (3-pyridinylmethylene)hydrazide, 5-methyl-2-furancarboxylic acid (2-pyridinylmethylene)hydrazide, nicotinic acid (3-pyridinylmethylene)hydrazide , indole-3-carboxylic acid (4-pyridinylmethylene)hydrazide, 25 indole-2-carboxylic acid (4-pyridinylmethylene)hydrazide, indole-2-carboxylic acid (3-pyridinylmethylene)hydrazide, indole-2-carboxylic acid (2-pyridinylmethylene)hydrazide, isonicotinic acid (3-pyridinylmethylene)hydrazide, nicotinic acid (2-pyridinylmethylene)hydrazide, 3Ω nicotinic acid (4-pyridinylmethylene)hydrazide , picolinic acid (2-pyridinylmethylene)hydrazide , picolinic acid (3~pyridinylmethylene)hydrazide , picolinic acid (4-pyridinylmethylene)hydrazide, isonicotinic acid (4-pyridinylmethylene)hydrazide (Cpd #220), or pyrazine-2-carboxylic acid C(2-ethyl-4-pyridinyl)methylene]hydrazide, nicotinic acid C(2-ethyl-4-ρyridinyl)methylene]hydrazide, isonicotinic acid [(2-ethyl-4-pyridinyl)methylene]hydrazide , 2-ethyl pyridine-4-car bo xylic acid [(2-ethyl-4-pyridinyl)methylene]- hydrazide, 4, 5-dichloroquinolinic-2-carboxylic acid (4-pyridinylmethylene)- hydrazide, 4,5-dichloroquinoline-2-carboxylic acid (3 _ pyτ*idinylmethylene)- hydrazide, 6-methyl-3-pyridinecar bo ylic acid [1-(6-methyl-3-pyridinyl)ethyl- idene]hydrazide, 3~n-propyl-1 , 4-dioxoquinoxaline-2-carboxylic acid (2-pyridinyl- methylene )hydrazide , 3-methyl-1 ,4-dioxoquinoxaline-2-carboxylic acid (2-pyridinylmethyl- ene)hydrazide, 3~ethyl-1 , 4-dioxoquinoxaline-2-carbo xylic acid (2-pyridinylmethyl- ene)hydrazide, 4-methyl-2-pyridinecarboxylic acid ( α-2-pyridinyl benzyl idene)- hydrazide, picolinic acid (α-2*-pyridinylbenzylidene)hydrazide, 5-n-butyl-2-pyridinecarboxylicacid (4-pyridinylmethylene)hydrazide, 5-n-butyl-2-pyridinecar bo xylic acid (3-py idinylmethylene)hydrazide, 5-n-butyl-2-pyri dine car bo xylic acid (2-pyridinylmethylene)hydrazide , isonicotinic acid N-oxide [1-(4-pyridinyl)ethylidene]hydrazide, isonicotinic acid [1-( -pyridinyl )ethylidene]hydrazide 1-oxide, isonicotinic acid N-oxide [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide, isonicotinic acid [1-(6-methyl-2-pyridinyl)ethylidene]hydrazide, isonicotinic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #219), nicotinic acid [1-( 2-pyridinyl )ethylidene]hydrazide (Cpd #200), nicotinic acid [1-(6-methyl-2-pyridinyl)ethylidene]hydrazide, isonicotinic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #218), nicotinic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #199), isonicotinic acid ( -2-pyridinylbenzylidene)hydrazide, thiophene-2-carboxylic acid Cl-(2-pyridinyl)ethylidene]hydrazide , furan-2-carboxylic acid (2-pyridinylmethylene)hydrazide (Cpd #216, hydrate) , quinaldic acid (2-pyridinylmethylene)hydrazide , 5-n-butyl-2-pyridine car bo xylic acid [1-methyl-3-pyridiniu__]hydrazide methanes ulfonate , indazole-3-carboxylic acid (4-pyridinylmethylene)hydrazide; isonicotinic acid C(3-hydroxy-4-ρyridinyl)raethylene]hydrazide; and pyridazine carboxylic acid (4-pyridinylrπethelene)hydrazide are known. See M. Nonoyama, Inorg. Chim. Acta. 10, 133-137 (1974); A. L. Mndzhoyan, V. G. Afrikyan, R. S. Organesyan, A. 0. Shakhmur dova, L. D. Zhuruli, S. G. Karagezan and V. G. Sarafyar, Arm. Khim. Zh. 21, 340-7 ( 1968) ; D. Koruncev, S. Cvetnicandl. Babic, Acta. Pharm. Jugoslav, 23, 1-8 (1973); D. Koruncev, I. Babic, D. Cvek and A. Deljac, Acta. Pharm. Jugoslav, 24, 9-11 (1974); M. Kawai , U.S. Patent 3,503,987, January 17, 1970. Chem. Abstr., 72, 121378z; . Durckheimer, H. Hartung and E. Schrinner, Ger. Offen. DE 2002712, July 29, 1971; Chem. Abstr. 75, 98595u; F. Capitan, F. Salinas and J. Gimenez Plaza, Afinidad, 35, 263-5 (1978); F. H. Case, J. Heterocycl. Chem., 10, 353-5 (1973); H. Vogt and H. Mayer, Arzneim. Forsch., 20, 1532-6 (1970); A. Risaliti and L. Lolli, Farmaco (Pavic) Ed. Sci., 12, 705-11 (1957), Chem. Abstr., 52, ' 11038f; N. P. Buu-Hoi and N. Dut Xuong., Bull. Soc. Chim. France, 1377-9 (1961); M. L. Vitalo, J. Webb and P. Saltman, J. Inorg. Biochem., 20, 255-62 (1984); A. Aleraany, M. Bernabe , C. Elorriagu, E. F. Alvarez, M. Lora-Tamajo and J. Ofelia Nieto, Bull. Soc. Chim. France, 2486-2497 (1966); F. Capitan, F. Salinar and J. Gimenez Plaza, Ars. Pharm., 16, 293-304 (1975); Chem. Abstr., 84, 11787X; S. E. Livingstone and J. E. Oluka, Trans. Met. Chem. , 3, 261-7 (1978) ; E. Re uena, J. J. Laserna, A. Novar, and F. G. Sanchez, Analyst, 108, 933-38 (1983); E. Baker et al, Biochemical Pharmacology, 37, 3011-3017 (1985); H. Bojarska-Dahlig, Rec. Trav. Chim. 83, pp. 177-85 (1964), Chem. Abstr., 60, I4467d. The preparation of piperonylic acid (4-pyridinylmethylene)hydrazide (Cpd #19) and 3, 4, 5-trimethoxy benzoic acid (4-pyridinylmethylene)hydrazide (Cpd #224) is described in G. Mazzone et al, J. Heterocyclic Chem., 21, 181 (Jan. -Feb. 1984). The pyridinyl acylhydrazones of this invention (Formula I) are readily prepared by reacting the appropriate pyridyl ketone (II) with the acylhydrazide/carbazate (III) (Chart A, Scheme A) or by heating the pyridyl ketone (II) with the appropriate hydrazine (IV) to form the hydrazone intermediate (V) which is then acylated with the halide or anhydride (VI) to form the pyridinyl acylhydrazone (I) (Chart A, Scheme B). The pyridinyl acylhydrazone N-oxides (formula I where n = 1 ) are generally prepared by first oxidizing the pyridylketone (II) to furnish 5 the pyridylketone N-oxide (VII) (Scheme C). The ketone VII is then reacted with the appropriate acylhydrazide or carbazate (III) to give the pyridinyl acylhydrazone N-oxide (I) or alternatively the pyridinyl- acylhydrazone (I) is formed by first reacting the ketone VII with a hydrazine IV to form hydrazone intermediate N-oxide VIII which is in *- Q the final step is acylated with the halide VI to furnish the pyridinyl acylhydrazone N-oxide I. The reaction of Scheme A is carried out in the presence of a suitable solvent, for example, water, alcohols, ethers, halogenated hydrocarbons, hydrocarbons and include methanol, ethanol, isopropanol, " propanol, hexane, tetrahyd ofuran, dioxane, raethylene chloride, preferably ethanol. A catalyst such as glacial acetic acid, hydrochloric acid, sulfuric acid or p-toluenesulfonic acid can be utilized to. enhance the yield/rate of the reaction, particularly when 3 is alkyl of 3 or more atoms, arylalkyl or aryl. 20 The acylation reaction of Scheme B is carried out in the presence of a suitable base such as a tertiary amine, for example, triethylamine or preferably, pyridine. The base may also be the solvent. The desired N-oxide is prepared by oxidizing the appropriate ketone using a peracid such as perbenzoic, m-chlorobenzoic, performic, 25 peracetic or generating the peracid in situ preferably with hydrogen peroxide/acetic acid to furnish the pyridinyl ketone N-oxide which is reacted with the appropriate hydrazide or carbazate (Chart A, Scheme C). The starting compounds are known or can be readily prepared by 30 known methods. R. L. Frank and C. Weatherbee, J. Am. Chem. Soc, 70, 3482-3 (1948); N. B. Mahishi, et al., J. Indian Chem. Soc, 42, 67-74 (1965) andM. Ogata and H. Kano, Chem. Pharm. Bull (Tokyo), 11, 32 (1963). The following detailed examples/procedures describe how to prepare various pyridinyl acylhydrazones of the invention and are to be construed 35 as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations from the procedures both as to reactants as well as to reaction conditions and techniques. Procedure 1 Preparation of benzoic acid [1-( -pyridinyl )ethyl- idene]hydrazide , Compound 1 A mixture of 6.81 gm (0.05 mole) of benzhydrazide, 6.06 gm (0.05 mole) of 2-acetylpyridine and 100 ml of ethanol is stirred at reflux 2 hr. Then sufficient dioxane is added to the boiling mixture to furnish a solution. The hot solution is filtered. The filtrate is diluted to the cloud point with water, cooled to room temperature, and then chilled in the refrigerator. The product is collected and dried to yield 7.61 gm (64$) of the title compound having a melting point of 151.6°C. Analysis Calcd: C, 70.29; H, 5.44. Found: - C, 70.28; H, 5.43- Procedure 2 Preparation of 2-methylbenzoic acid [1-( 4-pyridinyl )- ethyl i dene ]hydrazide, Compound 10 A mixture of 3.63 gm (0.03 mole) of 4-acetylpyridine, 4.51 gm (0.03 mole) of o-toluic acid hydrazide and 100 ml of 95. ethanol is refluxed 8 hr. The hot solution is filtered. The filtrate is diluted with water to the cloud point and cooled to room temperature. The mixture is chilled in the refrigerator and the product collected, washed with water, and dried to yield 4.78 gm (63.-) of the title compound having a melting point- of 187. °C. Analysis Calcd: C, 71.15; H, 5.93; N, 16.60. Found: C, 70.82; H, 5.86; N, 16.61 Procedure 3 Preparation of benzoic acid [1-( 4-pyridinyl )ethylidene]- hydrazide 1-oxide, Compound 48 A mixture of 5.48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 5.45 gm (0.04 mole) of benzhydrazide and 100 ml of absolute ethanol is refluxed for a total of 4 hr and cooled. The reaction mixture is evaporated in vacuo to yield a solid which is crystallized from ethanol to yield 7.82 gm (77. ) of the title compound having a melting point of 248.9°C (decomp). Analysis Calcd: C, 65.88; H, 5.10; N, 16.47. Found: C, 65.44; H, 5.23; N, 16.39. Procedure 4 Preparation of benzoic acid [1-( 4-pyridinyl )propyl- idene]hydrazide, Compound 51 mixture of 4.05 gm (0.03 mole) f 4-propionylpyridine, 4.08 g (0.03 mole) of benzhydrazide and 100 ml of Ethanol is refluxed 6 hr. The hot solution is filtered. The filtrate is cooled to room temperature and then chilled in the refrigerator. The product is collected, washed with Skellysolve B and dried to yield 5.36 gm (71. ) of the title compound having a melting point of 177.6°C. Analysis Calcd: C, 71.15; H, 5.93; N, 16.60. Found: C, 71.13; H, 5.98; N, 16.77. Procedure 5 Preparation of 2- phenoxy benzoic acid [3-methyl-1-(4*- pyridinyl)butylidene]hydrazide , Compound 54 Following the general method of procedure 4 and making noncritical variations, except 12 drops of glacial acetic acid is added as a catalyst, 9.00 gm (0.055 mole) of isobutyl 4-pyridyl ketone and 12.59 gm (0.055 mole) of 2-phenoxybenzhydrazide yield 13.89 gm (67. ) of the title compound having a melting point of 137.6°C. Analysis Calcd: C, 73-97; H, 6.21; N, 11.25. Found: C, 74.16; H, 6.24; N, 11.19. Procedure 6 Preparation of benzoic acid 1 -__ethyl-2-[1-( 4-pyridinyl )- ethyl i dene ]hydrazide , Compound 55 To 100 ml of pyridine is added successively, under dry nitrogen, 8.83 gm (0.0592 mole) of 1-methyl-2-[ 1-( 4-pyridinyl )ethylidene]hydrazine and 6.87 gm (0.0592 mole) of benzoyl chloride. Upon addition of the acid chloride the color changes from clear orange to a clear, deep rose color which changes to an orange solid within about 5 minutes. The reaction mixture is stirred at room temperature overnight, the pyridine removed via a Buchi evaporator at 70 °C and the cooled residue slurried with water to yield 6.32 gm (42$) of the title compound having a melting point of 128.3°C. Analysis Calcd: C, 71.13; H, 5.97; N, 16.59. Found: C, 71.02; H, 6.02; N, 16.27. Procedure 7 Preparation of benzoic acid [1-( 3 w py-'idinyl)propyl- i ene]hydrazide, Compound 58 A mixture of 6.76 gm (0.05 mole) of 3-proρionyl pyridine, 6.81 gm (0.05 mole) of benzhydrazide and 100 ml of absolute ethanol is refluxed 8.5 hr. The hot solution is filtered. The filtrate is cooled to room temper ature and then chilled. The crystals that separate are collected and dried to yield 10.18 gm (80$) of the title compound having a melting point of 169.4°C. Analysis Calcd: C, 71.15; H, 5.93; N, 16.60. Found: C, 71.46; H, 5.97; N, 16.52. Procedure 8 Preparation of benzoic acid [1-( 4-pyridinyl )pentyl- idene]hydrazide, Compound 60 A mixture of 5.97 gm (0.0366 mole) of n_-butyl 4-pyridinyl ketone, 5.45 gm (0.04 mole) of benzoic acid hydrazide and 100 ml of absolute ethanol is refluxed 4.5 hr. The hot solution is filtered. The filtrate is diluted with water to the cloud point, cooled to room temperature and chilled. The solids which deposit are collected, washed with water and dried to yield 7.89 gm (77$) of the title compound having a melting point of 142.1°C. Analysis Calcd: C, 72.60; H, 6.76; N, 14.95. Found: C, 72.83; H, 6.86; N, 14.90. Procedure 9 Preparation of 2-methoxybenzoic acid [3-methyl-1*-(4pyri- dinyl)butylidene]hydrazide, Compound 65 To 9.00 gm (0.0551 mole) of isobutyl 4-py idyl ketone in 100 ml of absolute ethanol is added 9.20 gm (0.0551 mole) of 2-methoxybenzhydrazide and 12 drops of glacial acetic acid. The reaction mixture i3 refluxed on the steam bath overnight, filtered hot, the volume reduced to 1/3, titrated with cold water to the cloud point and set aside. Crystals do not form at room temperatu e nor in the freezer. The product is extracted in chloroform, the extracts washed 2x with water, dried with saturated sodium chloride solution and anhydrous sodium sulfate and the solvent removed via a rotoevaporator at 70 °C until a solid forms (2 hours); mp. 130.4°C. Analysis Calcd: C, 69.43; H, 6.80; N, 13-49. Found: C, 69.03; H, 6.72; N, 13-30. Procedure 10 Preparation of benzoic acid C2-phenyl-1-( -pyridinyl )- ethylidene]hydrazide, Compound 61 Following the general method of procedure 9 and making non-critical variations, except 12 drops of glacial acetic acid was used, 6.00 gm (0.0304 mole) of benzyl 4-pyridyl ketone and 4.14 gm (0.0304 mole) of benzhydrazide yield 8.90 gm (93$) of the title compound in two crops melting at 84.4° and 90.9°. Analysis Calcd: C, 76.17; H, 5-43; N, 13.32. Found: C, 75-15; H, 5-45; N, 13-19- C, 74.88; H, 5-42; N, 13-03- Procedure 11 Preparation of ethyl [1-(2-pyridinyl)ethylidene]carbazate, Compound 70 A mixture of 6.06 gm (0.05 mole) of 2-acetyl pyridine, 5.21 gm (0.05 mole) of ethyl ca azate and 100 ml of absolute ethanol is refluxed 2 hr. The hot solution is filtered. The filtrate is cooled to room temperature and then chilled in the refrigerator. The product is collected, washed with Skellysolve 3 and dried to yield 3.8 gm (37$) of the title compound having a melting point of 113.2°C. Analysis Calcd: C, 57.97; H, 6.28; N, 20.29. Found: C, 58.05; H, 6.33; M, 20.64. Procedure 12 Preparation of benzyl (α-2-pyridinylphenethylidene)- carbazate, Compound 77 A mixture of 8.31 gm (0.05 mole) of carbobenzoxyhydrazide, 9-86 gm (0.05 mole) of benzyl 2-pyridyl ketone and 100 ml of 95$ ethanol is refluxed 6 hr . The reaction mixture is treated with decolorizing carbon and filtered. The heated filtrate is dilute with water to the cloud point. The mixture is cooled to room temperature and -then chilled in the refrigerator. The product is collected, washed with water and dried to yield 11.06 gm (64$) of the title compound having a melting point of 155-1°C. Analysis Calcd: C, 73-04; H, 5-51; N, 12.17- Found: C, 73.06; H, 5.71; N, 12.30. The title compound is resynthesized employing the above procedure, at about 6X scale-up to yield 58.4 gm (60$) having a melting point of 158.7°C. Found: C, 72.73; H, 5-43; M, 11-96. Procedure 13 Preparation of 1 , 1-dimethylethyl (α-4*-pyridinylbenzyl- i dene) carbazate, Compound 81 To 6.61 gm (0.05 mole) of t*- butyl carbazate dissolved in 100 ml of warm water is added 9-16 gm (0.05 mole) of 4-benzoyl pyridine in 30 ml of ethanol. The mixture Is refluxed 7 hr . Cooling several weeks yields 1.77 gm (12$) of the title compound having a melting point of 131- 5°C. Analysis Calcd: C, 68.69; H, 6.4Q; N, 14.14. Found: C, 69.06; H, 6.44; N, 14.22. Procedure 14 Preparation of methyl (4-pyridinylmethylene)carbazate hydrate, Compound 83 A solution of 2.70 gm (0.03 mole) of methyl carbazate, 3-21 gm (0.03 mole) of 4-pyridinecarboxaldehyde and 50 ml of anhydrous methanol is refluxed 8 hr. The hot solution is filtered. The filtrate is diluted with water to the cloud point and cooled to room temper ature. The mixture is chilled in the ref igerator. The crystals are collected, washed with water and dried to yield 5-87 g (99$) of the title compound having a melting point of 159.6°C. (decomp.). Analysis Calcd: C, 52.32; H, 5.18; N, 22.89- Found: C, 52.70; H, 5-03; N, 22.81. Procedure 15 Preparation of benzyl (4-pyridinylmethylene)carbazate, Compound 84 A mixture of 8.31 gm (0.05 mole) of carbobenzoxyhydrazide , 5-36 gm (0.05 mole) of 4-pyridinecarboxaldehyde and 100 ml of 95$ ethanol is refluxed 4 hr. The hot solution is filtered. The filtrate is cooled to room temperature and then chilled in the refrigerator. The cream crystals are collected and dried to give 9-47 gm (74$) of the title compound having a melting point of 133-8°C. Analysis Calcd: C, 65.88; H, 5-10; N, 16.47. Found: C, 65.49; H, 5-07; N, 16.54. Procedure 16 Preparation of diphenylmethyl (4-pyridinylmethylene)- carbazate, Compound 86 To 24.11 gm (0.1 mole) of benzhydryl carbazate in 200 ml of warm absolute ethanol is added 10.66 gm (0.1 mole) of 4-pyridinecarbox¬ aldehyde in 75 ml of absolute ethanol. The mixture is refluxed 7 hr and cooled. The solvent is removed in vacuo . Recrystallization from ethanol/Skellysolve B yields 26.03 gm (78.5$) of the title compound having a melting point of 159-160°C. Analysis Calcd: C, 72.49; H, 5.17; N, 12.68. Found: C, 72.39; H, 5-36; N, 12.77- The title compound is resynthesized using the above procedure at a 5X scale-up to yield 137-5 gm (41$) of the title compound having a melting point of 158-159°C. Found: C, 72.44; H, 5.10; N, 12.46. Procedure 17 Preparation of diphenylmethyl (4-pyridinylmethylene)- carbazate monohydrate, Compound 87 To 10.89 gm (0.045 mole) of benzhydryl carbazate in 100 ml of warm ethanol is added 4.82 gm (0.045 mole) of 4-pyridinecarboxaldehyde in 50 ml of ethanol. The mixture is refluxed 4.5 hr and cooled. The solvent is removed in vacuo to give the crude product. Recrystallization of the crude material from ethanol yields 14.6 gm (93$) " of the title compound having a melting point of 96.9°C. Analysis Calcd: C, 68.77; H, 5-44; N, 12.03- Found: C, 69.07; H, 5.42; N, 11.50. Procedure 18 Preparation of ethyl [1-( 4-pyridinyl ) propyl idene]carbazate, Compound 90 A solution of 4.05 gm (0.03 mole) of 4-propionylpyridine, 3.12 gm (0.03 mole) of ethyl carbazate and 100 ml of absolute ethanol is refluxed 6 hr. The hot solution is filtered. The filtrate is diluted with water to the cloud point. The mixture is cooled to room temperature and then chilled in the refrigerator to give crystals which are collected, washed with Skellysolve B and dried to ' yield 3-25 gm (49$) of the title compound having a melting point of 1 7-1°C. Analysis Calcd: C, 59.73; H, 6.79; N, 19-00. Found: C, 59-83; H, 6.96; N, 18.99. Procedure 19 Preparation of 1 , 1-diraethylβthyl [ 1-( 4-pyridinyl )propyl- i dene] carbazate, Compound 91 A solution of 4.05 gm (0.03 mole) of 4-propionylpyridine, 3.96 gm (0.03 mole) of t-butylcarbazate and 100 ml of absolute ethanol is refluxed 6 hr . The reaction mixture is treated with decolorizing carbon and filtered. The filtrate yields crystals on cooling. The product is collected, washed with Skellysolve 8 and dried to yield 3.16 gm (40$) of the title compound having a melting point of 1 0.1°C. Analysis Calcd: C, 62.65; H, 7-63; N, 16.87- Found: C, 62.67; H, 7.79; N, 17-05. The title compound is resynthesized two times, employing the above proced'ure at a scale-up of 2.3X and 11.56X to yield 11.9 gm (68$) and 57-5 gm (67$), respectively. Analysis Found: C, 62.60; H, 7.67; N, 16.89; mp 183-0°C. Found: C, 62.69; H, 7-59; N, 16.85; mp 181.5 i -l82°C. Procedure 20 Preparation of methyl [1-(4-pyridinyl )propylidene]- carbazate, Compound 93 A solution of 4.05 gm (0.03 mole) of 4-propionylpyridine, 2.70 gm (0.03 mole) of methyl carbazate and 100 ml of absolute ethanol is refluxed 6 hr. The solution is evaporated in vacuo to give a solid. The crude product is crystallized from ethyl acetate/Skellysolve B to yield 3.90 gm (63$) of the title compound having a melting point of 216.2°C. (decomp.). Analysis Calcd: C, 57-97; H, 6.28; N, 20.29. Found: C, 57.67; H, 6.35; N, 20.58. Procedure 21 Preparation of phenyl [1-(4-pyridinyl)ethylidene_carba__ate, Compound 94 A solution of 5.66 gm (0.03 mole) of phenyl carbazate hydrochloride , 3-63 gm (0.03 mole) of 4-acetylpyridine and 50 ml of ethanol is refluxed 2 hr. The solution is cooled and evaporated to dryness in vacuo to give an oil. The oil is triturated with ethyl acetate- ethanol to afford a solid. The solid- is dissolved in 50 ral of water and treated with 50 ml water containing 5 gm sodium carbonate. A gummy solid separates which solidifies on standing. The crude product is collected and crystallized from ethyl acetate-Skellysolve 3 to yield 4.13 gm (54$) of the title compound having a melting point of 120.4°C (decomp.). Analysis Calcd: C, 65.88; H, 5.10; N, 16.47. Found: C, 66.01; H, 5.12; N, 16.33- Procedure 22 Preparation of phenyl [1-(4-pyridinyl)ethylidene]carbazate monohydrochloride, Compound 95 A mixture of 12.11 gm (0.1 mole) of 4-acetylpyridine, 18.85 gm (0.1 mole) of phenyl carbazate hydrochloride and 250 ml of absolute ethanol is refluxed 6 hr and cooled. The reaction mixture is evaporated to dryness in vacuo to give a rose-colored solid. The crude product is crystallized from absolute ethanol to yield 28.13 gm (97$) of the title compound having a melting point of 159-1°C. Analysis Calcd: C, 57-63; H, 4.80; Cl, 12.18; N, 14.41. Found: C, 57-84; H, 4.86; Cl, 11.87; N, 14.25- Procedure 23 Preparation of ethyl (α-4-pyridinylbenzylidene)carbazate, Compound 96 A mixture of 9.16 gm (0.05 mole) of phenyl 4-pyridyl ketone, 5-21 gm (0.05 mole) of ethylcarbazate and 75 ml of glacial acetic acid is heated at 100°C for 8 hr . The acetic acid is removed in vacuo. The residue is slurried with ethyl ether and collected to yield 5.76 gm (39$) of the title compound having a melting point of 138.7°C. Analysis Calcd: C, 67-91; H, 5.58; N, 15.61. Found: C, 67-39; H, 5-61; N, " 15-36. Procedure 24 Preparation .of 5-raethyl-2-( 1-methyl3thyl)cyclohexyl [1 -(4-pyridinyl) ethyl i ene ]carbazate, Compound .97 A solution of 6.43 gm (0.03 mole) of l_-menthyl carbazate, 3-63 g (0.03 mole) of 4-acetylpyridine and 100 ml of absolute ethanol is refluxed 3 hr. The solvent is evaporated in vacuo to give a solid. The product is crystallized from ethyl acetate/Skellysolve 3 to yield 4.07 gm (43$) of the title compound having a melting point of 138. °C. Analysis Calcd: C, 68.14; H, 8.52; N, 13-25- Found: C, 67-76; H, 8.59; N, 13-24. Procedure 25 Preparation of 1 , 1-dimethylethyl [1-(4-pyridinyl)pentyl- i dene ] car ba zate , . C ompo und 98 A solution of 11.2 gm (0.0751 mole) of tv-butyl 4-pyridyl ketone, 9.80 gm (0.0741 mole) of butyl carbazate, 100 ml of tetrahydrof ran and 0.1 gm of p-tol enesulfonic acid is refluxed 17 hr . The reaction mixture is poured into 300 ml of ice and water with stirring to give a white solid. The crude product is collected, washed with water and dried. The crude product is crystallized from acetone/hexane to yield 9.27 gm (44$) of the title compound having a melting point of 15δ.2°C. Analysis Calcd: C, 64.98; H, 8.30; N, 15.16. Found: C, 64.89; H, 8.50; N, 14.87- Procedure 26 Preparation of ethyl [1-( 4-pyridinyl) pent ylidene]carbazata, Compound 99 A mixture of 8.3 gm (0.055 mole) of n- but l 4-pyridyl ketone, 6.1 gm (0.059 mole) of ethyl carbazate and 150 ml of absolute ethanol is refluxed 17 hr. A Tic (3$ Me0H/CH2Cl on Silica gel) shows 50$ starting material remaining. p-Toluenesulfonic acid (0.3 gm) is added and the reaction mixture refluxed 17 hr more. Tic shows no remaining starting materials. The reaction is concentrated in vacuo. The residue is slurried with water and the solid collected, washed with water and dried. Crystallization yields 7-41 gm of the title compound having a melting point of 102.1°C. Analysis Calcd: C, 62.63; H, 7.68; N, 16.85- Found: C, 62.51; H, 7-73; N, 17.39. Procedure 27 Preparation of phenyl (4-pyridinylmethylene) carbazate mo nohydro chloride, Compound 101 A solution of 6.43 gm (0.06 mole) of 4-pyridinecarboxaldehyde, 11.31 gm (0.06 mole) of phenyl carbazate hydrochloride and 300 ml of 95$ ethanol is refluxed 4 hr . The reaction mixture is evaporated to dryness. The crude product is suspended in 200 ml of boiling absolute ethanol and sufficient methanol added to give a solution. The hot solution is filtered, the filtrate cooled to room temperature and then chilled in the freezer. The crystals are collected, washed with Skelly¬ solve 3 and dried to yield 11.0 gm (66$) of the title compound having a melting point of 224.4°C (decomp). Analysis Calcd: C, 56.22; H, 4.32; Cl, 12.79; N, 15.14. Found: C, 56.13; . H, 4.46; Cl, 12.62; N, 15.35. Procedure 28 Preparation of ethyl [ T ' -(4-pyridinyl)ethylidene]carbazate 1-oxide, Compound 109 A solution of 5.48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 4.16 gm (0.04 mole) of ethyl carbazate and 100 ml of absolute ethanol is refluxed 6 hr . The solution is evaporated in vacuo to give a solid. The crude product is crystallized from ethyl acetate/ ethanol to yield 6.47 g (73$) of the title compound having a melting point of 220.1°C. Analysis Calcd: C, 53-81; H, 5-83; N, 18.83- Found: C, 53-63; H, 5.78; N, 13.63. Procedure 29 Preparation of phenyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide, Compound 112 To 6.61 gm (0.04 mole) of 4-butyryl pyridine 1-oxide in ca. 100 ml of ethanol is added 7-54 gm (0.04 mole) of phenyl carbazate hydro¬ chloride and the mixture heated on the steam bath for a total of 6 hr. After 4 hr the solution is allowed to evaporate to less than 100 ml and cooled. The mixture i3 chilled in the freezer to yield 5.17 gm (43$) of the title compound having a melting point of 206.5°C (decomp). Analysis Calcd: C, 63-99; H, 6.25; N, 13-92. Found: C, 64.20; H, 5.72; N, 14.04. Procedure 30 Preparation of phenyl [1-(4-pyridinyl)ethylidene]carba- zate 1-oxide monohydrochloride, Compound 113 A mixture of 5.48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 7-54 gm (0.04 mole) of phenyl carbazate hydrochloride and 100 ml of absolute 5 ethanol is refluxed 4 hr. The solvent is stripped in vacuo to give a . solid. The crude product is crystallized from ethanol/ ethyl acetate to yield 8.45 gm (78$) of the title compound having a melting point of 196.8°C. Analysis Calcd: C, 54.63; H, 4.55; Cl, 11.54; N, ' 13-66. 10 Found: C, 54.27; H, 4.66; Cl, 11.58; N, 13-44. Procedure 31 Preparation of benzyl [1-( 4-pyridinyl )ethylidene]carbazate 1-oxide hydrate, Compound 119. A mixture of 5-48 gm (0.04 mole) of 4-acetylpyridine-1-oxide, 6.64 gm (0.04 mole) of benzyl carbazate and 200 ml of absolute ethanol is • j _5 refluxed 7 hr. The solvent is removed in vacuo to give a solid. The crude product is recrystallized from isopropyl alcohol to yield 10.14 gm (87$) of the title compound having a melting point of 219.4°C (decomp). Analysis Calcd: C, 61.98; H; 5.37; N, 14.46; H2O, 1.86. Found: C, 61.86; H, 5.76; N, 13-93; H 2 0, 1-73- 20 Procedure 32 Preparation of 1 , 1-dimethylethyl [ 1-( 4-pyridinyl ) ethyl- i dene] ca bazate 1-oxide, Compound 120 A mixture of 5-48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 5.29 gm (0.04 mole) of butyl carbazate and 100 ml of absolute ethanol is refluxed 7 hr . The reaction mixture is evaporated to dryness iτ vacuo 25 to furnish a solid. The crude product is crystallized from ethanol to yield 4.5 gm (45$) of the title compound having a melting point of 214.3°C. Analysis Calcd: C, 57-37; H, 6.77; N, 16.73- Found: C, 57-29; H, 6.76; N, 16.77- Procedure 33 Preparation of 4-trifluorcmethylbenzoic acid [1-(4pyri- 3Q dinyl)ethylidene]hydrazide, Compound 121 A mixture of 2.97 gm (0.0245 mole) of 4-acetylpyridine, 5.0 gm (0.0245 mole) of 4-trifluoromethylbenzhydrazide and 100 ml of absolute ethanol is refluxed for 6 hr. The hot solution is filtered. The filtrate is diluted with water to the cloud point, cooled to room 35 temperature and chilled. The cry3tal3 which separate are collected, washed with water and dried to yield 6.29 gm (84$) of the title compound having a melting point of 198.4°C. Analysis Calcd: C, 58.63; H, 3.91; N, 13-68. Found: C, 58.48; H, 4.05; N, 13.76. Procedure 31 Preparation of acetic acid [1-(4-pyridinyl)ethylidene]- hydrazide, Compound 136 A mixture of 2.22 gm (0.03 mole) of acetic acid hydrazide, 3.63 gm (0.03 mole) of 4-acetylpyridine and 100 ml of absolute ethanol is refluxed 2 hr. The hot solution i3 filtered. The filtrate is diluted with water to the cloud point. The mixture is cooled to room temperature and then chilled in the refrigerator. The product is collected, washed with water and dried to yield 3-63 gm (69$) of the title compound having a melting point of 178.1°C. Analysis Calcd: C, 61.02; H, 6.21. Found: C, 61.22; H, 6.24. The title compound is remade, with a scale-up of 3X, using the above procedure to yield 34.4 gm (66$) having a melting point of 177- 5-178.5°C. Analysis Calcd: C, 61.02; H, 6.21; N, 23-73. Found: C, 60.99; H, 6.52; N 23-88. Procedure 35 Preparation of (2, 4, 5-trichlorophenoxy )acetic acid [1-( 4-pyridinyl )ethylidene]hydrazide, Compound 137 A solution of 5.39 gm (0.02 mole) of 2,4,5-trichlorophenoxyacetic acid hydrazide, 2.42 gm (0,02 mole) of 4-acetylpyridine, 125 ml of dioxane and 2 ml of acetic acid is refluxed 4 hr. The hot solution i3 filtered. The filtrate is diluted with water until cloud point. The mixture is cooled to room temperature and then chilled in the refrigerator. The product is collected to yield 6.24 gm (83$) of the title compound having a melting point of 227.4°C (decomp). Analysis Calcd: C, 48.32; H, 3-22; N, 11.28. Found: C, 48.47; H, 3.28; N, 11-33- Procedure 36 Preparation of benzoic acid [1 ,3~dioxan-5-yl)-3-pyridinyl- methylene]hydrazide, Compound 421 Following the general method of procedure 56 and making non-critical variations, except overnight refluxing is required, 12 drops of concentrated hydrochloric acid is used and no methyl ene chloride extraction in the work-up is employed, 9.66 gm (0.05 mole) of 1 ,3-dioxan-5-yl 3~ pyridyl ketone and 6.81 gm (0.05 mole) of benzhydrazide yield 6.58 gm (42$) of the title compound having a melting point of 131-8°C. Analysis Calcd: C, 65-58; H, 5.50; N, 13-50. Found: C, 65-02; H, 5.57; N, 13-14. Procedure 37 Preparation of formic acid [1-(4-pyridinyl)pentylidene]- hydrazide, Compound 141 A solution of 14.26 gm (0.0956 mole) of n_-butyl 4-pyridyl ketone, 5.70 gm (0.0956 mole) of forraylhydrazine, 50 ml of THF, 30 ml of absolute ethanol and 0.1 gm of p-toluenesulfonic acid is refluxed 24 hr. The reaction is chilled to give a white solid which is collected and dis¬ carded. The filtrate is concentrated in vac o to furnish a solid. This material is dissolved in methylene chloride. The methylene chloride solution is washed with saturated sodium bicarbonate solution; then brine. The organic layer is dried over magnesium sulfate and concentrated i_n vacuo in the presence of excess hexane to yield 5-14 gm (26$) of the title compound having a melting point of 143.4°C. Analysis Calcd: C, 64.47; H, 7-33; N, 20.73- Found: C, 64.47; H, 7-33; N, 20.73- Procedure 38 Preparation of butyric acid [1-(4-pyridinyl)ethylidene]- hydrazide oxalic acid salt, Compound 145 A mixture of 6.15 gm (0.03 mole) of butyric acid [1-(4-pyridinyl)- ethylidene]hydrazide (Compound 144), 2.70 gm (0.03 mole) of oxalic acid and 100 ml of absolute ethanol is refluxed 3 hr. The mixture is cooled and then chilled in the refrigerator. Two crops of the product are collected and dried to yield 6.9 gm (78$) of the title compound having a melting point of 207.2°C. Analysis Calcd: C, 52.88; H, 5.76; N, 14.24. Found: C, 52.60; H, 6.13; N, 13-15- Found: C, 52.47; H, 6.31; N, 13-13- Procedure 39 Preparation of butyric acid [1-(4-pyridinyl)ethylidene]- hydrazide 1-hydroxy-2-naphthoic acid salt, Compound 1 7 A mixture of 8.2 gm (0.04 mole) of butyric acid [1-( 4-pyridinyl)- ethylidene]hydrazide (Compound 144), 7-53 gm (0.04 mole) of 1-hydroxy-2- naphthoic acid and 100 ml of absolute ethanol is refluxed 7 hr. Cooling the reaction mixture to room temperature and then chilling yields a solid which is collected and dried to provide 13-67 gm (87$) of the title compound having a melting point of 158.7°C. Analysis Calcd: C, 67-18; H, 5.85; N, 10.69. Found: C, 67-06; H, 5.86; N, 10.71. Procedure 40 Preparation of butyric acid [1-(4-pyridinyl)ethylidene]- hydrazide phenoxyacetic acid salt, Compound 151 A mixt-ure of 8.2 gm (0.04 mole) of butyric acid [1-(4-pyridinyl)- ethylidene]hydrazide (Compound 144), 6.09 gm (0.04 mole) of phenoxyacetic acid and 100 ml of absolute ethanol is refluxed 7-5 hr . The reaction mixture is evaporated to dryness in vacuo . The solid is crystallized from ethanol to yield 9-48 gm (66$) of the title compound having a melting point of 105.8°C. Analy3is Calcd: C, 63.37; H, 6.44; N, 11.76. Found: C, 63-41; H, 6.54; N, 11.87- Found: C, 63-80; H, 6.59; N, 11.88. Procedure 41 Preparation of cyclohexanecarboxylic acid [1-(4-pyri- dinyl)ethylidene]hydrazide, Compound 159 A solution of 4.26 gm (0.03 mole) of cyclohexanecarboxylic acid hydrazide, 3.63 gm (0.03 mole) of 4-acetylpyridine and 100 ml of ethanol is refluxed 7 hr . The solvent is evaporated in vacuo to give a white solid. The product is crystallized from ethyl acetate to yield 5-38 gm (73$) of the title compound having a melting point of 195.3°C. Analysis Calcd: C, 68.57; H, 7-76; N, 17-14. Found: C, 68.54; H, 8.00; N, 17-27- Procedure 42 Preparation of 2-methoxybenzoic acid ( -pyridinyl enzy 1- idene)hydrazide monohydrochloride , Compound 285 To 9.16 gm (0.05 mole) of 4-benzoylpyridine in 100 ml of absolute ethanol and 4.4 ml (0.05 mol) concentrated hydrochloric acid (yellow solution) was added 8.31 gm (0.05 mole) of 2-methoxybenzylhydrazide. The reaction mixture was refluxed 12 hrs and filtered. The filtrate was concentrated to about 1/2 volume and cooled. The yellow crystals which formed were collected, worked with cold absolute ethanol and dried to give 17-4 gm (95$) of the title compound having a melting point of 242.1°. Analysis Calcd: C, 65-31; H, 4.93; N, 11.42; Cl, 9-64. Found: C, 65.08; H, 5.03; N, 11.53; Cl, 9-36. Procedure 43 Preparation of cyclohexanecarboxylic acid [ 1-( 4-pyridinyl )- ethylidene]hydrazide 1-oxide, Compound 287 A mixture of 5.48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 5-68 gm (0.04 mole) of cyclohexanecarboxylic acid hydrazide and 100 ml of absolute ethanol is refluxed 4 hours. The reaction mixture is concentrated in vacuo to dryness to give a solid. The solid is crystallized from isopropanol to furnish 8,20 gm (79$) of the title compound; mp 245-3°. Analysis Calcd: C, 64.37; H, 7.28; N, 16.09- Found: C, 63-77; H, 7-55; N, 15.84. Procedure 44 Preparation of butyric acid [1-(4-pyridinyl)ethylidene]- hydrazide 1-oxide hydrate, Compound 289 A mixture of 5.48 gm (0.04 mole) of 4-acetylpyridine 1-oxide, 4.09 gm (0.04 mole) of butyric acid hydrazide and 100 ml of absolute ethanol is refluxed 6 hours. The reactions mixture is evaporated in vacuo to give a solid. The crude product is crystallized from ethyl acetate/ ethanol to yield 7-41 gm (84$) of the title compound; mp 209.7°. • Analysis Calcd: C, 59.25; H, 6.32; H, 18.85. Found: C, 59.18; H, 6.94; N, 18.53. Procedure 45 Preparation of cyclobutanecar bo ylic acid [1-(4-pyridinyD- ethylidene]hydrazide , Compound 290 A mixture of 6.06 gm (0.05 mole) of -acetylpyridine, 5-7 gm (0.05 mole) of cyclobutanecarboxylic acid hydrazide, and 100 ml of absolute ethanol is refluxed 5 hours. The reaction mixture is evaporated in vacuo to give a solid. The product is crystallized from ethanol/- ethylacetate/diethylether to give 2.92 gm (27$) of the title compound; mp 138.6°. Analysis Calcd: C, 66.36; H, 6-91; N, 19-35. Found: C, 65-97, H, 6.81; N, 19-11- Procedure 16 Preparation of 4-nitrobenzoic acid [1-(4-pyridinyl)ethyl- idene]hydrazide, Compound 291 A mixture of 3.62 gm (0.02 mole) of pj-nitrobenzhydrazide , 2.42 gm (0.02 mole) of 4-acetylpyridine and 100 ml of absolute ethanol is refluxed 3 hours. Sufficient dimethylformamide is added to the mixture at boiling to give a solution. The hot solution is filtered. The filtrate is diluted with water to the cloud point. The mixture is chilled in the refrigerator. The product is collected, washed with ether and dried to yield 4.46 gm (79$) of the title compound; mp 251.2°. Analysis Calcd: C, 59.15; H, 4.23;N, 19-72. Found: C, 59.24; H, 4.80; N, 19.79- Procedure 47 Preparation of 2-methylcyclopropaneca bo xylic acid [1- (3-pyridinyl)propylidene]hydrazide, Compound 313 A mixture of 8.0 gm (0.07 mole) of 2-methylcyclopropanecarboxylic acid hydrazide, 9-46 gm (0.07 mole) of ethyl-S-pyridyl ketone, 10 drops of glacial acetic acid and 100 ml of ΞtOH was refluxed 20 h . Tic (9:1 Skellysolve B/Ethyl acetate on silica gel) shows no remaining starting material. The reaction mixture was cooled to room temperature and evaporated in vacuo to give a liquid. The liquid solidified on standing. The solid was slurried in ether, collected and dried to give 4.77 gm (29$) of the title compound having a melting point of 137.3°C. Analysis Calcd: C, 67.51; H, 7.41; N, 18.86. Found: C, 66.99; H, 7.48; N, 18.08. Procedure 48 Preparation of 3-trif luoromethylbenzoic acid [1-(3~ pyridinyl)propylidene]hydrazide, Compound 316 A mixture of 10.21 gm (0.05 mole) of 3-trif luoromethyl enzoic acid hydrazide, 6.76 gm (0.05 mole) of ethyl-3-pyridyl ketone, 10 drops of glacial acetic acid and 100 ml of absolute ethanol was refluxed 15 hr. The reaction mixture was diluted with water to the cloud point and cooled to room temperature then chilled in the refrigerator. The solids that separated were collected, washed with Skellysolve 3 and dried to give 11.88 gm (74$) of product having a melting point of 119-4°C. Analysis Calcd: C, 59.81; H, 4.39; 13-07; F, 17-74. Found: C, 59.65, H, 4.49; 13-14; F, 18.25. Procedure 49 Preparation of acetic acid [1-(6-methyl-3-pyridinyl)- ethylidene]hydrazide, Compound 327 A mixture of 6.76 gm (0.05 mole) of 2-met hyl-5 -ace tyl pyridine, 3.7 gm (0.05 mole) of acetic acid hydrazide and 100 ml of ethanol was refluxed 5 hr. The solution was diluted with Skellysolve B until cloudy. The mixture was cooled to room temperature and then chilled in the freezer. The product was collected, washed with Skellysolve 3 and dried to afford 7-93 gm (83$) of the title compound having a melting point of 178.5°C. Analysis Calcd: C, 62.81; H, 6.35; N, 21.97- Found: C, 62.33; H, 6.83; N, 22.03- Procedure 50 Preparation of 3-trif luoromethylbenzoic acid [1-(3~ pyridinyl )ethylidene]hydrazide, Compound 301 A mixture of 10.21 gm (0.05 mole) of 3-trif luoromethylbenzoic acid hydrazide, 100 ml of ethanol and 10 drops of glacial acetic acid was refluxed for 14 hr. The solution was cooled to room temperature and then chilled in the freezer. The product was collected, washed with water and dried to give 11.77 gm (77$) of white solid which had a melting point of 183-3°C. Analysis Calcd: C, 58.64; H, 3-94; N, 13.67- Found: C, 58.36; H, 4.08; N, 13-68. Procedure 51 Preparation of 3-nitro-1-naphthalenecarboxylic acid [1- ( 4-pyridinyl )ethylidene]hydrazide, Compound 342 A mixture of 5.0 gm of (0.0216 mole) of 3~ni ro-1-naphthalene- carboxylic acid hydrazide, 2.62 gm (0.0216 mole) of -acetylpyridine, 400 ml of ethanol, 100 ml of tetrahydrof uran, and 20 drops of glacial acetic acid was refluxed 10 hr. The hot solution was filtered. The filtrate was cooled to room temperature and then chilled. The product was collected, washed with Skellysolve B and dried to furnish 6.31 gm (87$) of the title compound having a melting point of 228.5°C. Analysis Calcd: C, 64.67; H, 4.22; N, 16,75. Found: C, 64.56; H, 1.55; N, 16.29. Procedure 52 Preparation of nicotinic acid (phenyl-4-pyridinylmethylene)- hydrazide, Compound 353 A mixture of 9.16 gm (0.05 mole) of 4-benzoyl pyridine, 6.86 gm (0.05 mole) of nicotinic acid hydrazide, 100 ml of ethanol and 4.4 ml of concentrated hydrochloric acid was refluxed 16 hr . The reaction mixture was cooled to room temperature. An equal volume of water was added containing 5-4 gm (0.05 mole) of sodium carbonate. The mixture was placed in the refrigerator. The product which separated was collected, washed with water and dried to give 8.21 gm (54$) of the title compound having a melting point of 74.0°C. Analysis ' Calcd: C, 71.51; H, 4.67; N, 18.13. Found: C, 71-66; H, 4.98; N, 18.20. Procedure 53 Preparation of formic acid [ 1-(3-chloro-1 -pyridinyl )- ethylidene]hydrazide, Compound 391 A mixture of 6.30 gm (0.0405 mole) of 4-acetyl-3-chloropyridine, 2.46 gm (0.041 mole) of formic acid hydrazide and 100 ml of ethanol was refluxed 13 hr. The mixture was chilled in the freezer to give a solid which was collected in two crops. The product was purified by chromatography [keiselgel 60 (230-400 mesh)] and eluting with 5$ methanol/methylene chloride to give 2.56 gm (32$) of white flakes which have a melting point of 175-2°C. . Analysis Calcd: C, 48.62; H, 4.08; N, 21.26; Cl, 17- 94. Found: C, 48.29; H, 4.14; N, 20.92; Cl, 17.93- Procedure 54 Preparation of butyric acid [1-(3-chloro-4-pyridinyl)- ethylidene]hydrazide, Compound 395 A mixture of 5.20 gm (0.0335 mole) of 4-acetyl-3--chloropyridine, 3.43 gm (0.0336 mole) of butyric acid hydrazide and 100 ml of ethanol was refluxed 18 hr . The mixture was chilled in the freezer. The solid which separated was collected to give 2.01 gm ' (25$) of white solid having a melting point of 103-8°C. Analysis Calcd: C, 55.12; H, 5.89; N, 17.53; Cl, 14.79. Found: C, 54.97; H, 5.92; N, 17-12; Cl, 14.83- Procedure 55 Preparation of cyclopropanecarboxylic acid [1-(6-chloro- 3-pyridinyl)ethylidene]hydrazide, Compound 414 Following the general method of procedure 53 and making non-critical variations, except the product was purified by recrystallization from absolute ethanol rather than by chromatography, 5-25 gm (0.0337 mole) of 3-acetyl-6-chloropyridine and 3.40 gm (0.034 mole) of cyclopropane¬ carboxylic acid hydrazide yield 6.52 gm (81$) of the title compound having a melting point of 218.1°C. Analysis Calcd: C, 55.59; H, 5.09; N, 17.68; Cl, 14.92. Found: C, 55.40; H, 5-18; N, 17-56; Cl, 15-02. Procedure 56 Preparation of ethyl [( 1 , 3~dioxan-5*-yl)-3-pyridinyl- methylene] ca bazate, Compound 422 To 8.30 gm (0.043 mole) of 1 , 3~dioxan-5-yl- 3 ' -pyridyl ketone in 100 ml of absolute ethanol is added 4.47 gm (0.043 mole) of ethyl carbazate and one equivalent of concentrated hydrochloric acid. The reaction mixture is refluxed for 8 hr , then treated with activated charcoal and filtered hot. The filtrate is concentrated to about 100 ml volume and one equivalent of sodi m carbonate in warm water added to give a final Ph of 8. The solution is concentrated to approximately 100 ml total volume (nearly all ethanol stripped) on the rotoevaporator . The aqueous solution is extracted with 3 x 75 ml methylene chloride. The combined chloride extracts are washed with brine, dried over sodium sulfate, then evaporated to give a solid. The product is crystallized from absolute ethanol to give 4.97 gm (40$) of the title compound having a melting point of 131-8°C. Analysis Calcd: C, 55.91; H, 6.14; N, 15-04. Found: C, 55.62; H, 6.36; N, 14.70. Procedure 57 Preparation of propanoic acid [( 1 , 3-dioxan-5--yl)-4- pyridinyl-methylene]hydrazide , Compound 433 Following the general method of proced'ure 56 and making non-cri ical variations, except 12 drops of glacial acetic acid is used and extraction with methylene chloride in the work-up is not required, 8.36 gm (0.0433 mole) of 1 ,3-dioxan-5-yl 4-pyridyl ketone and 3.81 gm (0.0433 mole) of propanoic acid hydrazide yields 3.04 gm (27$) of the title compound having a melting point of 125-7°C. Analysis Calcd: C, 59-30; H, 6.51; N, 15.60. Found: C, 58.92; H, 6.63; N, 15-45. Procedure 58 Preparation of ethyl [( 1 , 3-dioxan-5~yl)-4-pyridinyl- methylene] carbazate , Compound 31 Following the general method of proced'ure 56 and making non-cri ical variations, except extraction with methylene chloride in the work-up is not required and the product is crystallized from aqueous ethanol, 8.30 gm (0.043 mole) of 1 ,3~dioxan-5-yl 5-pyridyl ketone and 4.47 gm (0.0430 mole) of ethyl carbazate yield 6.13 gm (55$) of the title compound in two crops having melting points of 64.9°C and 65.0°C. Analysis Calcd: C, 55-91; H, 6.14; N, 15.04. Found: C, 55.23; H, 5-95; N, 14.99- Procedure 59 Preparation of benzoic acid [( 1 , 3-dioxan-5-yl)-4-pyridinyl- methylene]hydrazide, mo nohydro chlo ide, Compound 423 Following the general method of procedure 56 and making non-critical variations, except no neutralization with sodium carbonate is used and extraction with methylene chloride in the work-up is not required, 4.23 -31- • " gm (0.0219 mole) of 1 , 3~dioxan-5-yl -pyridyl ketone and 2.98 gm (0.0219 mole) of benzhydrazide yield 5.29 gm (77$) of the title compound having a melting point of 157.7°C. Analysis Calcd: C, 58.71 ; H, 5.22; N, 12.08; Cl, 10.19- Found: C, 58.37; H, 5.15; N, 11.97; Cl, 10.58. The compounds prepared according to Procedures 1-59 are tabulated in Table A along with other illustrative compounds of the invention prepared following the general procedure indicated (Procedures 1-59) and making non-critical variations, except starting with the appropriate pyridyl ketone (II) and acyl hydrazide/ carbazate (III). Compounds 404, 406-407, 418 and 427-429 can be prepared by following the general procedure indicated in Table A and making non-critical variations, except starting with the appropriate pyridyl ketone (II) and acyl hydrazide/ ca bazate (III). The pyridinyl acylhydrazones of this invention are effective against worms, particularly parasitic worms of warm-blooded animals and more particularly helminth parasites in ovines (sheep) and bovines (cattle). Although a significant number of the pyridinyl acylhydrazones of this invention have failed to demonstrate signi icant activity against Nematospiroides dubius in mice or Caenorhabditis elegans in vitro, observations in sheep experimentally infected with Haemonchus contortus in accordance with Procedure I, generally confirm anthelmintic activity at 100 mg/kg of body weight upon oral and/ or parenteral administration as set forth in Table I. Pyridinyl acylhydrazones which are toxic at 100 mg/kg of body weight are expected to exhibit anthelmintic activity at a lower non-toxic dose, see for example compound No. 139- Further observations in sheep naturally infected with various helminths also confirmed broad-spectrum anthelmintic activity of various pyridinyl acylhydrazones of this invention. See Procedure II and the results as set forth in Table II. Procedure No. I In individual experiments all sheep are treated identically, however non-critrcal variations occur between experiments. All of the sheep used in this procedure are treated twice with levamisole hydro- chloride orally at 3 mg/kg or once each. with ivermectin parenterally at 200 μg/kg and levamisole hydrochloride orally at 3 mg/kg. The second treatment in each case is administered 4-7 days after the first treatment. Two weeks after the second treatment all sheep are inoculated per os with -3,500 to -7,500 infective larvae of H_. contortus. Rectal fecal samples are taken from each sheep 26-41 days post- inocul ion (PI) , and these samples are examined for eggs of H. contortus using the McMaster counting chamber technique. All sheep harboring good infections of H_. contortus are randomly allocated to a treatment group; those which do not exhibit suitable infections are dropped from the study. One- three days later on days 27-42 PI each sheep remaining in the study (excluding ] _0 the nontreated controls) is treated with a test compound (orally or parenterally at 100 rag/kg unless indicated otherwise) or a standard (levamisole hydrochloride orally at 8 mg/kg) or is used as untreated control. All sheep received food and water ad lib, throughout the experiment. ] _ Prior to administration, all solid compounds are finely ground using a mortar and pestle. Oral compounds are suspended in 20-30 ml of sterile vehicle #98 (each ml contains: carboxymethylcellulose - 10 mg, polysorbateδO -4 mg, propylparaben - 0.42 mg) using a sonicator and administered along with a tap water wash via a stomach tube. The 20 parenteral com-pounds are similarly suspended in 20-30 ml of the sterile vehicle and given by intraperitoneal injection using a 13 gauge, 2 inch needle and a 50 ml syringe. All test compounds are given to a single sheep/route of administration. Two or more sheep are treated with levamisole hydrochloride and five are used as nontreated controls. All 25 animals are monitored for signs of toxicity following treatment. The sheep are sacrificed 7-12 days after treatment (days 35-49 PI), and the abomasum is ligated and removed from each sheep. Each abomasum i3 longitudinally sectioned and rinsed into an 80 mesh sieve. Sieve contents are collected in individual containers and fixed in 30 formol-alcohol. Later each sample is transferred to a 1000 or 2000 ml beaker and the volume brought to 100-1000 ml with tap water. " The total number of worms in a 10-100 ml aliquot (10$) is determined. When no worms are found in the 10$ aliquot, the entire sample is examined. Total worm number/sheep and percentage clearance for each treatment are 35 calculated. Percentage clearance for a particular test compound in a given trial is determined according to the following formula: Percentage Clearance = [(Mean number of worms recovered from nontreated (Test Compound) control sheep - Number of worms recovered from treated sheep)/Mean number of worms recovered from nontreated control sheep] x 100. Sheep which die within 21 hr following treatment are not examined for worm3, while any that die between 24 hr pos - treatment and necropsy are examined in an identical manner as that described above. The results of various trials are combined and reported in Table I as percentage clearance. Procedure No. II Parasitized sheep are randomly assigned to groups of five animals based on parasitic burden, weight, sex, and farm origin. Sheep are double ear-tagged, weighed, housed in a barn in community pens, fed hay supplemented with calf starter pellets or 1/2 lb corn/head/ day. Water was given ad lib. Animals were allowed to acclimate for one-two weeks prior to treatment. Each group of sheep receives a test compound either orally or parenterally at a dosage rate of 100 mg/kg. A group of sheep is treated with 8 mg/kg of levamisole hydrochloride and another group serves as an untreated control group. Orally administered compounds are suspended in 20-30 ml of sterile vehicle #98 (each ml contains: carboxymethyl¬ cellulose - 10 mg, polysorbateδO -1 mg, propylparaben - 0.12 mg) , using a sonicator and administered along with a tap water wash via a stomach tube. For parenteral administration, compounds are similarly suspended in 20-30 ml of the sterile vehicle and given by intraperitoneal injection using a 13 gauge, 2 inch needle and a 50 ml syringe. Following treatment, all animals are observed for signs of toxicity. The number and classification of helminth eggs per gram of feces (e.p.g.) are determined for each sheep during the acclimation period and in some cases at necropsy. Egg counts are made using the McMaster counting chamber technique and rectal fecal samples. Animals dying during the 21 hours immediately following dosing are not subjected to necropsy. Sheep that die 1-6 days posttreatment are posted and complete worm counts performed. All. remaining animals are sacrificed on days 7-8 posttreatment; equal numbers of sheep are sacrificed from each group on each day when necropsy requires more than one day. Each sheep is euthanised and bled out prior to opening the abdominal cavity. Ligatures are placed at the re iculo-omasal junction, the pyloric valve, and the ileo-cecal junction. The abomasum and small intestine are freed of fat and mesenteric attachments, longitudinally opened, and their contents placed in individual containers. The mucosal surface of each is washed with tap water, rubbed clean, and rinβed several times. Washings and ingesta for each organ are made up to 1 or 5 liters and a 10 or 20$ aliquot in formalin is stored for later examination. The cecura, large intestine, and colon are freed of mesenteric attachments, each is longitudinally opened, and their contents washed, collected, and made up to 1 or 5 liters in 10$ formalin. A 20$ aliquot or the entire sample is stored. All carcasses are incinerated. Ten percent of the total contents collected from the abomasum and small intestine and 10$ or the entire contents of the large intestine, cecum, and colon are examined under stereoscopic magnification (10X). All worms are identified to genus and in some instances species. Separate adult and larval counts are determined. .The mean percentage clearance against specific helminths in the test sheep is calculated by subtracting the mean number of helminths observed in the treated sheep at necropsy from the mean number observed in the nontreated controls at necropsy, dividing the remainder by the latter mean number and multiplying by 100. The mean percentage clearances against the various helminths identified in the test sheep are calculated. The results from various trials for particular pyridinyl acylhydrazones of Formula I are combined and set forth in Table II. From an evaluation of the test results set forth in Tables I and II, it is clear that the pyridinyl acylhydrazones of this invention are ef icacious, broad- spectrum anthelmintic agents. Eight pyridinyl acylhydrazones; benzoic acid [1-(3-pyridinyl)ethyl- idene]hydrazide, butyric acid [ 1-(1-pyridinyl)ethylidene]hydrazide , butyric acid (4-pyridinyl methylene) hydrazide, 4-ethoxy benzoic acid [1- ( 4- pyridinyl) ethyl i dene ]hydrazide, 2-methyl propionic acid [1-(4-py idinyl)- ethylidene]hydrazide , 3-^cyclohexanepropionic acid [1-(4-pyridinyl)~ ethylidene]hydrazide 1-oxide, formic acid [ 1-( -pyridinyl ) thyl i dene] - hydrazide 1-oxide and ethyl (2-pyridinylmethylene)carbazate (Compounds 2, 144, 153, 16, 275, 160, 203 and 73); have been selected as -33- " 4 representative of the class and the test results from various trials of the foregoing compounds are combined and set forth in Table HA. 4-Ethoxy benzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Compound #16) has been tentatively identified for further evaluation in sheep while 2-methoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide (Compound #275) has been tentatively identified for further evaluation in cattle. The results of a multidose study of butyric acid [ 1-( 4-pyridinyl )- ethylidene]hydrazide, compound 144, are set forth in Table III. Five sheep were used for each dosage level, medicated and unmedicated controls in accordance with Procedure III. Procedure III Forty (40) sheep were selected from a flock of forty-six (46) pastured animals which had been placed in concrete-floored pens and allowed to acclimate for 12 days. The animals were selected and allocated (5/group) on the basis of weight, sex, fecal egg count, and number of parasite species observed in the fecal egg counts. The animals were treated two days after grouping. Througho t the study, lambs were fed alfalfa hay and given water ad lib. One group of lambs each (Groups 1-6, respectively) received 100, 50, or 25 mg of compound 144 per kg of body weight by either an oral or parenteral route. Lambs in the remaining two groups (7 and 8, respectively) received a standard (levamisole hydrochloride, 8 mg/kg orally) treatment or served as nontreated controls. Groups 1, 2 and 4 each had one sheep die after allocation to groups and prior to treat¬ ment. In addition, one lamb in Group 4 was not included in the data for that group because the animal was moribund shortly after treatment and it was felt that his response was altered significantly by his condition at the time of treatment. One lamb in Group 5 and two lambs in Group 8 died following treatment, but egg and worm counts taken at the time of death were considered with data taken at necropsy for the remaining animals in each of these groups. Helminth Egg Counts The number and species of helminth eggs per gram of feces (e.p.g.) were determined for each lamb on days 0-2 of the acclimation period, on the day of treatment, and at necropsy. Egg counts were made using the double centrifugal flotation technique and rectal fecal samples. Necropsy All lambs were necropsied on day 7 posttreatment. Each animal was euthanized prior to opening the abdominal cavity. Ligatures were placed at the reticulo-omasal junction, the pyloric valve, and the ileo-cecal junction. Contents of the abomasum and small. intestine were placed in individual jars and preserved with 10$ formalin, while both organs were incubated separately in a physiological saline solution for 6-8 hours at 37°C. Following the incubation period, both organs were washed, and then the wash plus the digest for each were added together and fixed with 10$ formalin. The combined cecum, large intestine, and colon contents were washed numerous times using a 100 mesh screen with openings of 0.53 mm and then fixed in 10$ formalin. All carcasses were incinerated. Helminth Counts Aliquots from each abomasum and small intestine totaling 10$ for contents and 20$ for digests plus each total cecum, large intestine, colon sample were examined under stereoscopic magni ication (15x), and all worms which were found were collected and stored. Worms were later identified to species and stage of development (L4, L5, or adult). L5's were those worms which possessed adult reproductive organs without eggs in the uterus or darkened spicules. Few immature worms were recovered and, therefore, only adult worms were considered. Signs of toxicosis were observed following treatment in animals given the high dosage of Compound No. 144 by either route or the medium dosage administered parenterally. Discomfort persisted in affected lambs for several hours . DETAILED DESCRIPTION (cont'd) The pyridinyl acylhydrazones of Formula I (IA, IB, IC, ID or 12) can be used as the pure compounds or as mixtures of pure compounds but for practical reasons the compounds are preferably formulated as anthelmintic compositions and administered as a single or multiple dose, alone or in combination with other anthelmintics (e.g. avermectins, benzimidazoles , levamisole, praziquantel, etc.). For example, aqueous or oil suspensions can be administered orally, or the compounds can be formulated with a solid carrier for feeding. Furthermore, an oil suspension can be converted into an aqueous emulsion by mixing with water and injecting the emulsion intramuscularly, subcutaneousl or into the peritoneal cavity. In addition, the active compound(s) can be administered topically to the animal in a conventional pour-on formula. Pure compounds, mixtures of the active compounds, or combinations thereof with a solid carrier can be administered in the animal's food, or administered in the form of tablets, pills, boluses, wafers, pastes, and other conventional unit dosage forms, as well as sustained/ controlled release dosage forms which deliver the active compound over an extended period of days, weeks or months. All of these various forms of the active compounds of this invention can be prepared using physiologically acceptable carriers and known methods of formulation and manufacture. Representative solid carriers conveniently available and satisfactory for physiologically acceptable, unit dosage formulations include corn starch, powdered lactose, powdered sucrose, talc, stearic acid, magnesium stearate, finely divided bentonite, and the like. The- active agent can be mixed with a carrier in varying proportions from, for example, about 0.001 percent by weight in animal feed to about 90 or 95 percent or more in a pill or capsule. In the latter form, one might use no more carrier than sufficient to bind the particles of active compound. In general, the compounds can be formulated in stable powders or granules for mixing in an amount of feed for a single feeding or enough feed for one day and thus obtain therapeutic efficacy without complica- tion. It is the prepared and stored feeds or feed premixes that require care. A recommended practice Is to coat a granular formulation to protect and preserve the active ingredient. A prepared hog-feed containing about 0.2 percent of the active compound will provide a dosage of about 100 mg per kg body weight for each 100 lb pig in its daily ration. A solid diluent carrier need not be a homogeneous entity, but mixtures of different diluent carriers can include small proportions of adjuvants such as water; alcohols; protein solutions and suspensions like skimmed milk; edible oils; solutions, e.g., syrups; and organic adjuvants such as propylene glycols, sorbitol, glycerol, diethyl carbonate, and the like. -41- * . - * "* ι The solid carrier formulations of the inventions are conveniently prepared in unit dosage forms, to facilitate administration to animals. Accordingly, several large boluses (about 20 g weight) amounting to about 54 g of active compound would be required for a single dosage to a 900 lb horse at a dosage rate of 50 mg/kg of body weight. Similarly, a 60 lb lamb at a dosage rate of 100 mg/kg of body weight would require a pill, capsule, or bolus containing about 2.7 g of active compound. A small dog, on the other hand, weighing about 20 lbs. wouid require a total dosage of about 225 mg at a dosage rate of 25 mg/kg of body weight. The solid, unit dosage forms can be conveniently prepared in various sizes and concentrations of active ingredient, to accomodate treatment of the various sizes of animals that are parasitized by worms . Liquid formulations can also be used. Representative liquid formulations include aqueous (including isotonic saline) suspensions, oil solutions and suspensions, and oil in water emulsions. Aqueous suspensions are obtained by dispersing the active compound in water, preferably including a suitable surface-active dispersing agent such as cationic, anionic, or non-ionic surface-active agents. Representative suitable ones are polyoxyalkylene derivatives of fatty alcohols and of sorbitan esters, and glycerol and sorbitan esters of fatty acids. Various dispersing or suspending agents can be included and representative ones are synthetic and natural gums, tragacanth, acacia, alginate, dextran, gelatin, sodium carboxymethylcellulose, methyl cellulose, sodium pol y vinyl pyrroli done, and the like. The proportion of the active compound in the aqueous suspensions of the invention can vary from about 1 percent to about 20 percent or more. Oil solutions are prepared by mixing the active compound and an oil, e.g. an edible oil such as cottonseed oil, peanut oil, coconut oil, modified soybean oil, and sesame oil. Usually, solubility in oil will be limited and oil suspensions can be prepared by mixing additional finely divided compound in the oil. Oil in water emulsions are prepared by mixing and dispersing an oil solution or suspension of the active compound in water preferably aided by surface-active agents and dispersing or suspending agents as indicated above. -42- " - .-.. ' In general, the formulations of this invention are administered to animals so as to achieve therapeutic or prophylactic levels of the active compound. At present, it is known that a dose of 100 mg/kg of body weight in sheep of various pyridinyl acylhydrazones of this invention will effectively combat a wide variety of parasites. Much lower effective dosages are contemplated, e.g., in the range of 1 to 75 mg/kg of body weight. In other animals, and for other kinds of parasitic worms, definitive dosages can be proposed. Contemplated are dosage rates of about 1 mg to about 800 mg/kg of body weight. A preferred, contemplated range of dosage rates is from about 5 mg to about 400 mg/kg of body weight. In this regard, it should be noted that the concentration of active compound in the formulation selected for administration is in many situations not critical. . One can administer a larger quantity of a formulation having a relatively low concentration and achieve the same therapeutic or prophylactic dosage as a relatively small quantity of a relatively more concentrated formulation. More frequent small dosages will likewise give results comparable to one large dose. One can also administer a sustained release dosage system (protracted delivery formulation) so as to provide therapeutic and/or prophylactic dosage amounts over an extended period. Unit dosage forms in accordance with this invention can have anywhere from less than 1 mg to 500 g of active compound per unit. Although the anthelmintic agents of this invention will find their primary use in the treatment and/or prevention of helminth parasitisms in domesticated animals such as sheep, cattle, horses, dogs, swine, goats and poultry, they are also effective in treatment that occurs in other warm blooded animals including man. The optimum amount to be employed for best results will, of course, depend upon the particular pyridinyl compound employed, species of animal to be treated, the regimen treatment and the type and severity of helminth infection. Generally good results are obtained with compounds of Formula I by the oral or parenteral route of administration of about 1 to 200 mg/kg of animal bodyweight (such total dose being given at one time, in a protracted manner or in divided doses over a short period of time such as 1-4 days). The technique for administering these materials to animals are known to those skilled in the veterinary and medical fields. It is contemplated that the pyridinyl acylhydrazones of Formula I can be used to treat various helminth diseases in humans, including those caused by Ascaris, Ente obi us , Ancylostoma, Trichuris, Strongyloides, Fasciola, Taenia, and/or Onchocerca or other filaria at a dose of from 5 1 mg/kg to 200 mg/kg of body weight upon oral and/or parenteral admin¬ istration. DEFINITIONS The definitions and explanations below are for the terms as used throughout the entire patent application including both the specification j _g and claims. All temperatures are in degrees Celsius. TLC refers to thin-layer chromatography. Brine refers to an aqueous saturated sodium chloride solution. When solvent pairs are used, the ratio of solvents used are l~ volume/volume (v/v). Alkyl of to carbon atoms, inclusive i3 used, it means and includes isomers thereof where such exist. Halogen atom' refers to a bromo, chloro, iodo or fluoro atom. Pharmaceutically acceptable refers to those properties and/or 20 substances which are acceptable to the patient from a pharmacological- toxicological point of view and to the manufacturing pharmaceutical chemist from a physical-chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability. 25 30 35 TABLE A C a n 5.1 5.2 .3 R4 X m.p, P_ H 1 2 0 H H CH 3 H Ph 151.6 1 - 4 2 0 H H H H 1-CH 3 Ph 155.3 1 + 5 3 0 H H CH3 H I-CH3PI1 164.8 1 - 6 3. 0 H H H H Ph 188.4 1 - 7 4 0 H H H H Ph 205.3 1 - 8 4 0 H H Ph H Ph 114.4 1 + 9 2 0 H H f. H Ph 36.4 1 + 10 4 0 H H CH3 H 2-CH3PU 187-4 2 - 11 4 0 H H CH3 H 3-CH3PI 146.3 2 - 12 4 0 H H CH3 H 2-O_30Ph 152.0 2 - 13 4 0 H H CH3 H I-CH3OPI1 171.4 2 - 14 4 0 H H CH3 H 2-CH3CH2OPI1 163.5 2 - 15 4 0 H H CH3 H 3~CH3CH2θPh 137.4 2 - 16 4 0 . H H CH3 H 4--CH3CH20Ph 185-6 2 - 17 4 0 H H CH3 H 3,4,5-(CH3θ)3Ph 198.4 2 - 18 4 0 H H CH3 H 3,4-(CH3θ)2Ph ' 181.7 2 - 19 4 0 H H H H 3,4-(0CH 2 0)Ph 214.6 2 - 20 4 0 H H CH3 H 2-Ph0-Ph 134.8 2 - 21 4 0 H H H H 2-CH3Ph 186.2 2 - 22 4 0 H H CH3 H 3-CH30Ph 155.3 2 - 23 4 0 H H CH3 H 3,5-(CH3θ) 2 Ph 190.7 2 - 24 4 0 H H CH3 H 2-ClPh 158.3 2 - 25 4 0 H H CH3 H 4-CH3P.1 (2 crops) 189.1 ' 2 - 190.6 26 4 0 H H CH3 H 2,4-(Cl) 2 Ph 189-1 2 - 27 4 0 H H CH3 H 3,4-(Cl)2Ph 223-2 2 - 28 4 0 H H H H 2,4-(Cl) 2 Ph 193-7 2 - 29 4 0 H H H H 3,4-(Cl) 2 Ph 164.3 2 + 30 4 0 H H H H 2-CH3OPI 110.5 2 + 31 4 0 H H H H 3-CH 3 0Ph 164.0 2 - 31 A 4 0 H H H H 3-CH 3 Ph 175-7 2 - * ' -.' .5- TABLE A (cont'd) a n _ι 5? -3 5. X m.p . P_ H 32 4 0 H H H H 1-CH 3 0Ph 180.2 2 - 33 4 0 H H H H 1-CH 3 Ph 186.5 2 - 31 4 0 H H H H IH-H3CH2OPI1 207-6 2 - 35 4 0 H H H H 3,5-(CH 3 o)2Ph 185.2 2 - 36 4 0 H H H H 2-ClPh 119.9 2 - 37 4 0 H H H H 4-t-C4HgPh 195-0 2 - 38 2 0 H H CH3 H 4-t-C4H9Ph 1 8.3 2 - 39 4 0 H H CH3 H 4-t-C4H9Ph 194-7 2 - 10 2 0 H H H H -t-C H9Ph 200.1 2 + 11 3 0 H H H H 4-t-C H9Ph 138.1 2 + 12 3 0 H H CH3 H 4-t-C4H9Ph 169.6 2 - 13 2 0 H H H H 2-Ph0Ph 169-4 2 - 11 4 0 H H H H 2-CH3CH20Ph 100.4 2 - 15 2 0 H H CH3CH H 2-CH3CH2θPh 137-3 2 - 16 3 0 ■ H H CH3CH H 2-CH3CH20Ph 115.6 2 - 47 4 0 H H CH3CH2CH2 H 2-CH3CH2θPh 120.5 2 - 47A 4 1 H H CH3CH2CH2 H 2-CH3 ' CH20Ph 156.3 2 - 18A 4 1 H H H H 4-CF 3 Ph 270.7 3 - 19 4 1 H H CH3 H 2-Ph0Ph 227.2 3 _. 50 4 0 H H CH3CH2CH2 H 2-PhOPh 116.1 2 - 51 4 0 H H CH3CH2 H Ph 177-6 4 - 52 4 0 H H CH3CH2 H 4-ClPh 170.5 4 - 53 4 0 H H CH3CH2 H 3,1-(CH3θ)2Ph 182.0 4 - 51 4 0 H H --C4H9 H 2-PhOPh 137-6 5 - 55 4 0 H H CH3 CH3 Ph 128.3 6 - 56 4 1 H H CH3 H 2-CH30Ph 248.3 3 - 57 2 0 6-CH3 H H H 2-CH3OPI1 glass 2 - 58 3 0 H H CH3CH2 H Ph 169.4 7 _-_ 59 3 0 H H CH3CH2 H 1-ClPh 176.1 7 - 60 4 0 H H n-C Hg H Ph 142.1 8 .- 61 4 0 H H PhCH 2 H Ph (2 crops) 84.4 10 I - 90.9 62 4 1 H H CH3 H 2,1-(Cl)2Ph 269.4 3 . TABLE A (cont'd) 63 3 0 H H H H 2,1-(Cl) Ph 196.0 3 - 64 3 0 H H CH3 H 2,4-(Cl)2Ph 175.1 3 - 65 4 0 H H --C4H9 H 2-CH3OPI 130.1 9 - 66 4 0 H H n-C4Hg H 2,4(Cl)2Ph 135.7 3 - 67 2 0 6-CH3 H H H Ph 150.2 1 - 68 4 0 H H CH3 H 2- 02?h 150.5 2 - 69 4 0 H H H H 2-N02Ph 201.1 2 - 70 2 0 H H CH3 H CH3CH2O 113-2 11 - 71 3 0 H H CH3 H CH3CH2O 116.9 11 - 72 4 0 H H CH3 H CH3CH2O 176.5 11 - 73 2 0 H H H H CH3CH2O 128.9 11 - 74 3 0 H H H H CH3CH2O 158.1 11 - 75 4 0 H H H H CH3CH2O 176.1 11 - 76 4 0 H H CH3 H t-C4H9θ 118.3 11 - 77 2 0 H H PhCH H PhCH2θ (2 exp.) 155.1 12 - 158.7 73 2 0 H H CH3 H PhCH2θ 155.1 12 - 79" 4 0 H H CH3 H PhCH2θ 151.7 12 - 80 4 0 H H CH3 H Ph2CH0 (2 exp.) 172.9 12 - 179.5 80 A 2 0 H H CH3 H Ph2CH0 210.1 12 - 81 4 0 H H Ph H t-C H9θ 131-5 13 ~ 82 4 0 H H Ph H PhCH20 124.3 13 - 84 4 0 H H H H PhCH 0 133-8 15 - 85 4 0 H H CH3 H CH3O 178.4 15 - 86 4 0 H H H H Ph 2 CHO (2 exp.) 159-160 16 - 158-159 86A 4 1 H H H H 4-ClPh 244.2 16 - 87 4 0 H H H H Ph 2 CH0 96.9 17 + 88 2 0 H H CH3 H CH3O 137.3 15 - 89 3 0 H H CH3 H CH3O 141.4 15 •- 90 4 0 H H CH3CH2 H CH3CH2O 147.1 15 - 91 4 0 H H CH3CH2 H t-C H9θ 170.1 19 - TABLE A (cont'd) 92 4 0 H H CH3CH2 H PhCH2θ 134-8 3 - 93 4 0 H H CH3CH2 H CH3O 216.2 20 •- 91 4 0 H H CH3 H PhO 120.1 21 - 95 4 0 H H CH3 H PhO • HC1 159-1 22 - 96 4 0 H H Ph H CH3CH2O 188.7 23 " 97 4 0 H H CH3 H 1-menthyl-Q 138.2 24 - 98 4 0 H H n-C4Hg H t-C H9θ 156.2 25 - 99 4 0 H H n-C Hg H . CH3CH2O 102.1 26 - 100 4 0 H H CH3CH2CH2 H PhO • HC1 203-3 22 - 101 4 0 H H H H PhO • HC1 221.4 27 - 102 4 0 H H H H 1-menthyl-O 131-1 18 - 103 3 0 H H CH3CH2 H t-C4HgO 176.6 18 - 101 2 0 H H CH3CH2 H CH3O 115.1 18 - 105 2 0 H H CH3CH2 H CH3CH2O 131 -0 18 106 2 0 H H CH3CH2 H t-C4H9θ 184.4 18 - 107 3 ' 0 H H CH3CH2 H CH3CH2O 115.8 18 - 108 4 0 H H CH3CH2CH2 H t-C H9θ 169-4 18 - 109 4 1 H H CH3 H CH3CH2O 220.1 28 - 110 4 0 H H CH3CH2CH2 H CH3CH2O 127-9 20 - 111 4 1 H H CH3 H CH3O 228.4 22 - 112 4 1 H H CH3CH2CH2 H PhO 206.5 29 - 113 4 1 H H CH3CH2CH2 H t-C H9θ 186.2 29 - 114 4 1 H H CH3CH2CH2 H CH3CH2O 196.6 29 - 115 4 0 H H I-C4H9 H PhO • HC1 200.5 29 - 116 4 0 H H i"C H9 H t-C4H9θ 163-4 29 * ■ 117 4 0 H H --C4H9 H 1-menthyl-O 143.4 29 - 118 4 1 H H CH3 H PhO • HC1 196.8 30 - 119 4 1 H H CH3 H PhCH2θ 219.4 31 + 120 4 1 H H CH3 H t-C4H9θ 214.3 32 - 121 4 0 H H CH3 H 4-CF3Ph 198.4 33 - 122 2 0 H H H H 4-(CH 3 ) 2 NPh 223-9 33 - 123 3 0 H H H H 4-(CH 3 ) 2 NPh 250.8 33 - 124 4 0 H H H H 4-(CH 3 ) 2 NPh 239.8 33 - 125 3 0 H H CH3 H 4-(CH3)2NPh 168.4 33 - .. -18- TABLE A (cont'd) c_ a n ϋι R2 R3 5.1 X m.p . P_ H 126 4 0 H H CH3 H -(CH3)2 Ph 233-0 33 - 127 3 0 H H CH3 H I-CF3PI 203-5 33 s - 128 3 0 H H H H I-CH3OPICH2O 156.9 33 - 129 4 0 H H H H 1-CH 3 OPhCH2θ 164.3 33 - 130 3 0 H H CH3 H I-CH3OPICH2O 138.7 33 + 131 4 0 H H CH3 H 1--CH3θPhCH2θ 157.6 33 - 132 2 0 6-CH3 H H H CH3CH2O 102.8 2 + 133 2 0 H ■ H H H 4-CH 3 OPhCH2θ 121.3 2 - 134 3 0 H H CH3CH2 H PhCH2θ 99.7 2 - 135 4 0 H H i-C4H9 H CH3CH2O 99-0 2 - 136 4 0 H H CH3 H CH3 177-5 -178.5 34 - 137 4 0 H H CH3 H 2,4,5-(Cl)3Ph0CH2 227.4 35 - 138 2 0 6-CH3 H H H H 158.5 34 - 140 3 0 H • H CH3 H H 165-6 31 - 141 4 0 H H nc-C H9 H H 143.4 37 - 142 2 0 6-CH3 H H H PhCH2 96.6 31 - 143 2 0 H H CH3 H CH3CH2CH2 123.5 31 - 144 4 0 H H CH3 H CH3CH2CH2 131.8 31 - 145 4 0 H H CH3 H CH3CH2CH2 • (C02H) 207-2 38 - 146 4 0 H H CH3 H CH3CH2CH2 • panoic 291.5 38 - acid salt 1 7 4 0 H H CH3 H CH3CH2CH2 • 1-0H-2- 158.7 39 - naphthoic acid salt 148 4 0 H H CH3 H CH3CH2CH2 • 3-0H-2- 149-1 39 - naphthoic acid salt 149 4 0 H H CH3 H CH3CH2CH2 • CH2(C02H)2 140.0 39 - 150 4 0 H H CH3 H CH3CH2CH2 • P CH2C02H 102.3 39 - 151 4 0 H H CH3 H CH3CH2CH2 ' Ph0CH2C02H 105.8 40 - 152 4 0 H H CH3 H CH3CH2CH2 • P--SCH2CO2H 97.2 40 - 153 4 0 H H H H CH3CH2CH2 156.6 34 - 154 4 0 H H H H CH3CH2CH2 * (C02H)2 175.4 38 - 156 3 0 H H CH3 H CH3CH2CH2 106.7 31 - .. " -- -49- TABLE A (cont'd) C_ a n 5.1 5.2 53 5.1 X m.p. -. 157 4 0 H H CH3 H PhCH2 148.5 31 - 158 4 0 H H CH3 H 2-Cl-4-N02Ph 232.2 2 - 159 4 0 H H CH3 H C-C6H11 195.3 11 - 160 4 1 H H CH3 H C-C6H11-CH2CH2 183-1 3 - 161 4 0 H H CH3 H 1 -naphthyl 183-7 2 - 162 4 0 H H CH3 H 2- naphthyl 206.5 2 - 163 4 0 H H 4<*ClPh H CH3CH2O • HC1 216.9 42 - 161 4 0 H H H H 1-naphthylCH2 185.2 2 - 165 3 0 H H CH3 H 1-naphthylCH2 159.3 2 - 166 4 0 H H CH3 H 1-naphthylCH2 168.6 2 - 167 2 0 6- CH3 H H H C-C6H1 -1 102.4 2 + 163 2 0 6~ CH3 H H H CH3CH2CH2 115.1 2 - 169 2 0 6- CH3 H H H (CH3)2CH 99.2 2 - 170 4 0 H H PhCH 2 H CH3CH2CH2 108.9 2 - 171 4 1 H H CH3 H 1 -naphthyl 251.7 2 - 172 3 o • ' H H H ' H 1 -naphthyl (2 crops) 197-1 2 - 199.5 173 4 0 H H PhCH 2 H 1 -naphthyl 187-9 2 - 171 3 0 H H CH3CH2 H 3 -pyridyl 163.5 2 - 175 4 0 H H n-C Hg H 3-pyridyl 125.6 2 - 1 6 4 0 H H n-C4H9 H 2-thienyl 176.6 2 - 177 4 0 H H CH3 H 2-thienyl 198.4 2 - 178 3 0 H H CH3 H 2-thienyl 159.8 2 - 179 3 0 H H H H 2-thienyl 223-9 2 - 180 4 0 H H H H 1 -naphthyl 199.2 2 - 181 4 0 H H H H 2-thienyl 200.9 2 - 182 4 0 H H H H 3,4,5-(CH 3 0) 3 Ph 187-8 2 - 183 2 0 6- ■ CH3 H H H C-C4H7 120.0 2 - 184 2 0 6- • CH3 H H H CH3 156.9 2 - 185 3 0 H H CH3CH2 H C-C4H7 153.6 2 - 186 3 0 H H CH3CH2 H 1 -naphthyl 166.7 2 - 187 3 0 H H CH3 H 1 -naphthyl 166.9 2 . 188 4 0 H H CH3 H 4-ClPh 182.0 2 - 189 4 1 H H CH3 H 4-ClPh 224.0 2 - " " -50- 1 TABLE A (cont'd) C_ a n 5.1 52 -3 5.1 X m.p . P. 190 3 0 H H CH3 H 1--ClPh 180.9 2 191 2 0 6-CH3 H H H 4-ClPh 169.3 2 192 4 0 H H PhCH 2 H CH3CH2O 131-133 2 193 4 0 H H H H 4-ClPh 170.5 2 194 3 0 H H H H 4-ClPh 233-5 2 195 2 0 H H CH3 H 1 -naphthylCH2 201.2 3 196 4 0 H H CH3CH2 H CH3CH2CH2 151-3 3 197 4 ' 0 H H CH3CH2 H PhCH2 147-2 3 198 4 0 H H CH3 H 3-pyridyl 143.7 3 199 3 0 H H CH3 H 3-pyridyl 166.7 3 200 2 0 H H CH3 H 3-pyridyl 178.0 3 201 4 0 H H CH3 H chrysanthemyl 161.9 3 202 4 1 H H CH3 H (CH 3 )3CH 251.3 3 204 2 0 H H CH3CH2 ' H CH3 173.1. 3 206 4 1 H H CH3 H C-C3H5 292.4 3 207 4 1 H H CH3CH2CH2 H H (3 crops) 221.3 3 221.2 215.9 208 4 1 H H CH3CH2CH2 H C-C3H5 238.5 3 209 4 1 a H CH3CH2CH2 H i-C 3 H 7 241.6 3 210 2 0 H H CH3CH2 H H 141.2 3 211 4 1 H H CH3CH2CH2 H CH3CH2CH2 199.2 3 212 4 1 H H CH3CH2CH2 H CH3 218.9 3 213 4 1 H H CH3CH2CH2 H C-C6H11 265.9d 3 21 3 0 H H CH3 H 2-furyl 130.6 3 215 2 0 H H CH3 H 2-furyl 123-9 3 216 2 0 H H H H 2-furyl 154.7 3 217 4 0 H H CH3 H 4-pyridyl 174.5 3 218 3 0 H H CH3 H 4-pyridyl 174.0 3 219 2 0 H H CH3 H 4-pyridyl 166.9 3 220 4 0 H H H H 4-pyridyl 234.4 3 221 2 0 H H H H 4-pyridyl 163.4 3 . -51- TA3LE A (cont'd) 222 4 0 H H CH3CH2 H 1 -naphthyl 201.3 3 223 3 0 H H H H 1-naphthylCH2 209.1 3 224 4 0 H H H H 3,1,5-(CH 3 0) 3 Ph 188.7 3 225 3 0 H H CH3 H 2-furyl 133.1 3 226 3 0 H H CH3CH2 H PhO ■ HC1 155.3 3 227 4 H H CH3 H C-C4H7 232.3 3 228 4 H H CH3 H CH3CH2OCH2CH2 202.1 3 229 4 H H H H 2-CH 3 0Ph 216.1 3 230 4 H H H H PhO • HC1 187.0 3 231 4 H H H H H 290. d 3 232 4 H H H H 3-pyridyl 255.6d 3 233 4 H H H H CH3CH2O 252.9d 3 234 4 H H H H Ph 231-1 3 235 4 H H H H CH3CH2CH2 250.8d 3 236 4 " H H H H 2-PhOPh 186.7 3 237 4 H H H H. --C3H7 238.5 3 238 4 H H H H C-C6H11 • 266.6 3 239 4 H H H H 2-thienyl 262. Id 3 240 4 H H H H 1 -pyridyl 273- Id 3 241 4 H H H H Gi " c 6Hι 1-CH2CH2 193-1 3 242 4 0 H H CH3CH2CH2 H CH3CH2CH2 112.8 9 243 4 0 H H --C4H9 H C-C6H1 -j-CH2CH2 166.2 9 244 4 0 H H i-C H9 H C-C3H5 210.8 9 245 4 0 H H --C4H9 H C-C6H11-CH2 1 -1.3 9 246 4 0 H H C-C5H9 H 0-C6H11 163-0 9 247 4 0 H H C-C5H9 H CH3CH2CH2 98.1 9 248 4 0 H H CH3CH2CH2 H C-C3H5 181.7 9 249 4 0 H H CH3CH2CH2 H (CH3)2CH 165.4 9 250 4 0 H H CH3CH2CH2 H C-C6H-] 1-CH2CH2 154.6 9 251 2 0 H H Ph H 2-furyl 139.6 9 252 4 0 H H CH3CH2CH2 H C-C6H11-CH2 151.4 9 253 4 0 H H CH3CH2CH H C-C6H11 184.1 9 254 4 0 Ή H i-C Hg H (CH3) CH 146.3 9 255 4 0 H H i-C H9 H 0-C6H11 178.2 9 .. -52- TABLE A (cont'd) 256 4 0 H H i-C H9 H CH3CH2CH2 106.0 9 - 257 4 0 H H --C4H9 H 2-CH3CH2OPI1 108.1 9 - 258 3 0 H H CH3 H C-C6H11-CH2 117.2 24 - 259 2 0 H H CΛ- H C-C6H11-CH2 116.3 24 - 260 2 0 H H Ά- H CH3CH2OCH2CH2 98.3 24 - 261 3 0 H H H H CH3CH2OCH2CH2 99-0 24 - 262 4 0 H H CH3 H CH3CH2OCH2CH2 116.7 24 - 263 4 0 H H CH3CH2CH2 H H 117-1 41 - 264 4 0 H H H H C-C4H7 178.1 41 - 265 4 0 H H CH3 H 3-C(1-CH 3 )-c-C5H9N] 112.8 41 - 266 4 0 H H CH3 H 2-[(1-CH3)-c-C5H9 ] 1 0.1 41 - 267 3 0 H H CH3 H 2-[(1-CH3)-c-C5H9N] 102.5 41 ' + 268 3 0 H H CH3 H 3-[( 1-0.3) * - C-C5H9N] 121.5 41 + 269 2 0 H H CH3 H C-C6H11 147.3 41 __ 270 4 0 H H H H o-C 6 Hi 1 159.3 41 - 271 • 3 0 . H H CH3CH2 H H 128.7 41 - 272 4 0 H H H H (CH 3 ) 2 CH 154.9 41 - 273 4 0 H H CH3 H C-C3H5 197-7 41 - 274 4 0 H H H H C-C3H5 191.6 41 - 275 4 0 H H CH3 H (CH3)2CH 149.2 41 - 276 4 0 H H CH3 H C-C6H11-CH2CH2 139.2 41 - 277 4 0 H H H H C ~ C 6H11-CH2CH2 131.2 41 - 278 4 0 H H H H C -C6H11-CH2 114.4 41 - 279 3 0 H H CH3 H C-C6H11 172.3 41 - 230 4 0 H H CH3 H C-C6H11-CH 159.3 41 - 281 4 0 H H CH3CH2 H CH3CH2OCH2CH2 123.1 41 - 232 4 0 H H CH3CH2 H C-C4H7 177.5 41 - 283 4 0 H H H H CH3CH2OCH2CH2 92.3 41 - 284 4 0 H H Ph H 2-CH3OP.1 • HC1 242.1 42 - 285 4 0 H - H Ph H 2-PhOPh • HC1 249.8 42 _- 286 4 0 H H Ph - H PhO • HC1 217.0d 42 - 287. 4 1 H H CH3 H C-C6H * ] 1 245-3 13 - 288 4 1 H H CH3 H C-C6H11-CH2 214.7 13 - TABLE A (cont'd) c_ a n 5.1 ? 53 5.1 X m.p. P_ H 289 4 1 H H CH3 H CH3CH2CH2 209.7 11 + 290 4 0 H H CH3 H C-C4H7 138.6 15 - 291 4 0 H H CH3 H 1-Nθ2Ph 251.2 16 - 292 4 0 H H CH3 H 3-N02Ph 238.6d 16 - 293 4 0 H H H H 2-Cl-1-N0 2 Ph 232.9 16 - 294 4 0 H H H H 1-N0 2 Ph 300.0 46 - 295 4 0 H H H H 3-N02Ph 289.3 16 - 296 3 0 H H CH3CH2 H CH3 123.2 21 - 297 3 0 H H CH3CH2 H CH3O 125.8 24 - 298 4 1 H H H H 1-CF 3 Ph 270.7d 3 - 299 2 0 H H CH3 H 1-O_30PhCH2-0 121.6 2 - 300 2 0 H H H H 1-naphthylCH2 119.2 2 + 301 2 0 H H CH3 H 3-CF3Ph 183.3 50 - 302 3 0 H H H H 3-CF 3 Ph 106-108 48 - 303 2 0 H H H H 2-FPh 144.9 ' 2 - 304 2 0 H H CH3 H 2-FPh .132.7 2 - ■ 305 2 0 H H CH3 H 3-FPh 154.3 3 - 306 2 0 H H H H 3-FPh 123-6 48 - 307 2 0 H H H H 2-CH3-C-C3H6 112.7 47 - 308 3 0 H H CH3CH2 H 3,1-(0O_20)Ph 142.5 2 - 309 3 0 H H CH3CH2 H 3,1-(CH3θ " )2PhCH2 140.0 2 - 310 3 0 H H CH3CH2 H CH3CH2 147.1 7 - 311 3 0 H H CH3 H CH3CH2 138.8 2 - 312 3 0 H H CH3 H I-CH3-C-C3H5 104.4 47 - 313 3 0 H H CH3CH2 H 2-CH3-C1-C3H5 137-3 17 - 311 3 0 H H H H 2-CH3-C-C3H5 101.7 17 - 315 3 0 H H H H 3-CF3PI1 153-6 2 - 316 3 0 H H CH3CH2 H 3-CF3Ph 119-1. 48 - 317 3 0 H H CH3 H 3-CF3Ph 157-2 48 - 318 3 0 H H CH3CH2 H 2-FPh 122.3 2 - 319 3 0 H H CH3CH2 H- • 3-FPh 156.9 4 ' 8 - 320 3 0 H H H H 2-FPh 187.7 2 - 321 3 0 H H CH3 H 2-FPh 134.6 2 - 322 3 0 H H H H 3-FPh 192.2 48 - .. -- - 51- TABLE A (cont'd) g_ a n 5. 1 5. 53 5.1 X m.p . 5. 2. 323 3 0 H H CH3 H 3-FPh 166.6 48 - 324 3 0 H H CH3CH H PI1CH2CH2CH2 93.7 2 - 325 3 0 H H H H PICH2CH2CH2 116.5 2 - 326 3 0 6- H3 H CH3 H H 175-1 2 - 327 3 0 6- • CH3 H CH3 H CH3 178.5 49 - 328 3 0 6- • CH3 H CH3 H i-C 3 H 7 111.8 49 - 329 3 0 6 J ■ CH3 H CH3 H CH3CH2CH2 1 5.1 2 - 330 3 0 6- ■ CH3 H CH3 H CH3CH2 170.4 48 - 331 3 0 6- ■ CH3 H CH3 H CH3O 128.6 48 - 332 3 0 6- • CH3 H CH3 H CH3CH2O 121.0 2 - 333 3 0 6- ■ CH3 H CH3 H t-C4Hg0 164.7 48 - 331 3 0 6- ■ CH3 H CH3 H PhO • HC1 209.6 7 - 335 3 0 6- -CH3 H CH3 H 1-menthyl-O 153.5 48 - 336 3 0 6- • CH3 H CH3 H Ph 161.2 48 - 337 3 0 6-- ■ CH3 H CH3 H -ClPh 207.6 2 - 338 3 0 6- ■ CH3 H CH3 ■ H 2-CH3CH2θPh 146.5 48 - 339 3 0 6- ■ CH3 H . CH3 H 1-CH3CH2θPh 184.2 48 - 310 4 0 H H CH3 H ' 2-norbornyl 191.0 2 - 311 4 0 H H CH3 H 2-CH3--1-naphthylCH 2 189-6 4 •- 312 4 0 H H CH3 H 3-NO2-I -naphthyl 228.5 51 * 313 4 0 H H CH3 H 5-N02-1 -naphthyl 232.0 4 ■- 311 4 0 H H CH3 CH3 CH3 80.7 6 - 315 4 1 H H H H t-C4HgO d>300 3 - 316 4 1 H H CH3 . H 3,1-(OCH2θ)Ph 266.3d 2 + 317 4 0 H H CH3 H 3,1-(OCH2-0)Ph 200.0 2 - 348 4 1 H H CH3 H 3,1-(CH3θ)2P CH2 242.9 2 + 349 4 0 H H H H 3,1-(CH 3 0)2PhCH2 138.0 2 - 350 4 0 H H CH3 H 3, -(CH3θ)2PhCH2 ' 145.5 2 - 351 4 0 H H H H CH3CH2 132.5 2 - 352 4 0 H H CH3 H CH3CH2 150.0 2 - 353 4 0 H H Ph H 3-pyridyl 74.0 52 - 354 4 0 H H CH3 H I-CH3-C-C3H5 122.0 47 - 355 4 0 H H H H I-CH3-C-C3H5 192.0 49 - 356 4 0 H H CH3 H 2-CH3-C-C3H5 165-4 2 - . -55- i 'ABLE A (cont'd) c_ a n 5.1 5253 5.1 X m.p . Z. _. 357 4 0 H H H H 2-CH 3 -c 4i C3H5 186.3 49 - 358 4 0 H H H H 3-CF 3 Ph 128.8 2 - 359 4 0 H H CH3 H 3<τ*CF3Ph 173.0 48 - 360 4 0 H H CH3CH2 H 2-CH3-C-C3H5 192.1 2 - 361 4 0 H H CH3CH2 H 3-CF3PI1 130.8 2 - 362 4 0 H H CH3CH2 H 2-FPh 122.3 2 - 363 4 0 H H CH3CH2 H 3-FPh 176.2 2 - 364 4 0 H H H H 2-FPh 164.3 2 .4 365 4 0 H H CH3 H 2-FPh 167.5 3 - 366 4 0 H H H H 3-FPh 154.3 3 ■ - 367 4 0 H H CH3 H 3-PhCH2CH2CH2 129-3 2 r- 368 4 0 H H CH3CH2 H 3-PICH2CH2CH2 129-3 2 - 369 4 0 H H H H 3-PhCH 2 CH2CH2 111.3 2 370 4 0 H H CH3 H 3-FPh 164.1 48 - 371 4 0 H H CH3CH2 H 2-CH3Ph 173- 3 2 - 372 4 0 H H CH3CH2 H 3-CH3Ph 169-3 • 2 - 373 4 0 H H CH3CH2 H --CH3P.1 171-4 2 - 374 4 0 H H CH3CH2 H 2-ClPh 161.5 2 - 375 4 0 H H CH3CH2 H 2-N02Ph 214.2 3 - 376 4 0 H H CH3 H 5 -CH 3 -2-thienyl 175.6 41 - 377 4 0 H H CH3CH2 H CH3 123-9 17 - 378 4 0 H H CH3CH2 H 2-furyl 125.4 17 - 379 4 0 H H CH3CH2 H 4-pyridyl 193-5 47 - 380 4 0 H H CH3CH2 H CH3CH2 136.2 47 - 331 4 0 H H CH3CH2 H i-C 3 H 7 194.3 ■ 2 - 382 4 0 H H CH3CH2 H 2-thienyl 217-9 5 - 383 4 0 H H CH3CH2 H PhO • HC1 196.4 47 - 384 4 0 H H CH3CH2 H l-menthyl-0 131.7 50 - 385 4 0 H H CH3CH H 2-CH3CH2OPI1 151-7 10 - 386 4 0 H H CH3CH2 H H 120.8 47 - 387 4 0 H H CH3CH2 H 4-ClPh 163-8 10 - 388 4 0 H H CH3CH2 H 4 * -a_3CH20Ph 156.7 10 - 389 4 0 H H CH3CH2 H 3-ClPh 155.6 10 - 390 4 0 H H CH3CH2 H 3,4,5-(CH3θ) 3 Ph 174.5 10 - eo CO ro r-o en o en o en 4= 4=r 4= * 4=r 4= * 4-r 4= 4= * 4= 4= 4~ 4T LO LO l\) iv) ro O O O O O O o o o O VD vD ro -_ o vo oo -^ cr. Ul 4= LO rv) -» o VD OO -4 CT. Ul . ω w -> O VD O LO OO OO LO OO LO LO LO LO LO LO OO LO LO OO OO UJ CO LO CO CO LO LO OO LO o O 0 O O O O O O O 0 0 0 O O 0 0 O O O 0 O O O O PC PC σι cr> o crι c* σι o*ι cr. _* cr. oτ crι i ro ro ro ro ro ro ro ro ro ro I I I I I I I ■ I ■ I - i i i i r i r t i i r i i i Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω Ω " Ω Ω Ω H-* I — ' l— * t— ■ »— • I— • I—* I — ' I — ' I — ' X-> 1-* t-> X-* X ac W PC PC PC PC PC PC PC PC PC PC 33 PC PC PC W PC PC 3. 3^ 3- 3_ 34 g fU r LO gfU CO LaO LaO LaO LaO LaO LaO LOaLOaLOaLO Ua- LaO LaO LOaLaO LaO OaO OaO OaO OaO OaO CaO LaO 3 1 1 I O. I Ω. Ul H> Ul H- I I I I _ _ C PC PC C PC PC C PC PC PC PC PC PC C C X C PC PC PC 34 PC PC PC PC ___ LO oo 00 oo Ul LO l Ul Ul Ul ui Ul Ul Ul Ul Ul Ul Ul Ul Ul Ul Ul l l Ul Ul Ul cr. σi pr 4=- σ*. 4= * 4=r 4=- l 4=r = 4= * -pr LO 4r oo cr. 4_- OO oo 4-r 4= * -pr 4=* 4= 1 1 I 1 r 1 1 1 1 1 1 r 1 1 * r 1 r r 1 t 1 TABLE A (cont'd) C_ a n R*| 5.253 R4 X m.p. P_ H 423 1 0 H H 1 , 3-di- H Ph - HC1 157.7 59 •- oxan-5-yl 121 0 H H H H H 222.4 53 - 125 0 H H H H H 124.5 54 - 426 0 H H H H H 114.9 54 - 427 0 H H CH3 H CF3CF2CF2 16 129 3 0 H H CH3 H CF3CF2CF2 16 430 3 0 H H 1 , 3-di- H CH3CH2CH2 116.1 56 - oxan-5-yl 431 4 0 H H 1 , 3-di- H CH3CH2O 65.0 58 - oxan-5-yl 432 3 0 H H 1 , 3-di- H CH30 141.0 56 - oxan-5-yl 133 1 0 H H- 1., 3-di- H C 2 H 5 125.7 57 - oxan-5-yl 131 3 0 H H 1 , 3-di- H C 2 H 5 118.5 36 - oxan-5-yl 135 1 0 H H 1 , 3-di- H n-C 3 H7 1 7-1 36 - oxan-5-yl 136 1 0 H H 1 , 3-di- H CH30 196.3 36 - oxan-5-yl C =_ Compound # a =_ pyridinyl attachment n _ 0 or 1 P =_ Procedure # H = Hydrate .p. - melting point centigrade (C°) TABLE I H. Contortus % Clearance Compound No. P.O. I. P. 1 99.6 100 2 100 100 3 100 93.7-100 4 M.T. N.T. 5 N.T. N.T. 6 98.9 87.7 7 100 100 8 99.9 N.T. 9 N.T. N.T. 10 61.9 N.T. 11 99.2 99.6 12 N.T. N.T. 13- N.T. N.T. 14 76.1 • 11.1 15 100 N.T. 16 100 100 17 85.9 100 18 100 94.3 19 99.6 86.5 20 96.6 100 21 N.T. N.T. 22 98.2 N.T. 23 91.1 100 24 N.T. N.T. 25 N.T. N.T. 26 99.8 75.0 27 100 N.T. 28 100 64.7 29 N.T. N.T. 30 100 97.1-98.8 31 99.6 N.T. 31 A 100 N.T. TABLE I (conf d) H. Contort us . Clearance Compound No. P.O. I. P. 32 N.T. N.T. 33 N.T. N.T. 31 97-0 93-5 35 99.2 N.T. 36 100 N.T. 37 N.T. N.T. 38 22.3 N.T. 39 N.T. N.T. 10 98.8 N.T. 41 91.4 N.T. 42 96.9 0 13 75-1 91.1 44 96.4 100 45 82.5 12.7 46 96.6 86.7 47 20.3 N.T. 47A 0 2.3 48 100 99.7 48A N.T. N.T. 49 98.9 100 50 29-8 12.7 51 97-9 100 52 99.6 N.T. 53 7.0 0 54 13-3 N.T. 55 75.8 N.T, 56 100 Toxic 57 100 19.6 58 N.T. N.T. 59 N.T. N.T. 60 100 N.T. 61 84.3 N.T. TABLE I (conf d) H. Contortus % Clearance Compound No. P.O. I. P. 62 N.T. N.T. 63 N.T. N.T. 64 N.T. N.T. 65 N.T. N.T. 66 33-9 65.3 67 100 100 68 5-7 0 69 79.0 N.T. 70 100 99.6 71 N.T. N.T. 72 98.6 99.3 73 100 98.9 74 Toxic 98.9 75 99.6 - ioo 76 99.3 100 ' . 77 0 N.T. 78 N.T. 0-69.0 79 99.9 0 80 99.9 N.T. 80 A 75.4 68.3 81 N.T. N.T. 82 N.T. N.T. 83 99.3 N.T. 84 100 0-99.6 85 97.9 100 86 73.7- • 99- .3 0-100 86A 100 99.8 87 N.T. N.T. 88 N.T. N.T. 89 98.9 Toxic 90 N.T. N.T. 91 21.1- • 99 .6 94-5-99-8 TABLE I (conf d) H. Contortus % Clearance Compound No. P.O. I. P. 92 89.0 98.9 93 100 Toxic 94 99.6-100 100 95 100 N.T. 96 N.T. N.T. • 97 73-8-84.6 97.6-98.6 98 55.5 53.7 99 89.3 91.1 100 43.1-70,2 46.1-75.1 101 99.9 98.9 102 67-4 36.6 103 100 100 104 85.6 ' N.T. 105 N.T. 100 106 ι " oo 98.9 107 100 N.T; 108 96.2 82.5 109 80.3 N.T. 110 99.6 100 111 98.9 100 112 35.5 67.0 113 98.8 95.7 114 99.9 94.5 115 38.4 0 116 8.2 91.0 117 3-5 0 118 100 99.7 119 100 32.8 1 0 69.4 • 100 121 100 100 1 2 99.9 100 1 3 96.7 0 TABLE I (conf d) H. Contortus . Clearance Compound No. P.O. I. . ■ 124 100 19.6 125 99.6 99.3 126 100 63.7 127 100 21.7 128 100 78.7 129 100 100 130 98.7 Toxic 131 100 99-6 132 91.0 97.9 133 100 N.T. 13 N.T. N.T. 135 N.T. N.T. 136 90.7" 100 N..T. 137 75.3 N.T. 138 31.0 98.5 1.39 Toxic Toxic 98.3++ Toxic++ 110 Toxic Toxic 111 76.9 100 112 98,6 100 113 Toxic N.T. 114 100 95.1 115 98.9- ■ 99.9 91.1-98.7 116 85.0 99.9 117 100 Toxi c 118 100 93.2 1 9 99.6 100 150 100 100 151 99.6 99.6 152 99.9 100 153 100 100 151 98.1 99.1 TABLE I (cont * d) H. Contortus % Clearance Compound No. P.O. I. P. 1 5 78.1- 100 87.8 156 100 99.6 157 99-6 99.6 158 0-19 -3 0 159 N.T. N.T. 160 99.6 99.6 161 99-6 98.3 162 99.3 N.T. 163 N.T. N.T. 161 99.1 100 165 97.1 100 166 99.6 14.5 167 100 100 168 100 96.7 169 N.T. N.T. ' 170 N.T. N.T. 171 99.6 N.T. 172 100 N.T. 173 N.T. N.T. 171 100 N.T. 1 5 N.T. N.T. 1 6 N.T. N.T. 1 7 100 99.1 178 100 N.T. 179 99.6 82.6 180 99.1 15.7 181 100 100 182 83-3 N.T. 183 100 99.6 181 100 100 185 N.T. N.T. 186 N.T. N.T. TABLE I (cont * d) H. Contortus . Clei arance Compound No. P.O. I. P. 137 N.T. N.T. 188 N.T. N.T. 189 100 N.T. 190 99.8 99.6 191 N.T. N.T. 1 2 N.T. N.T. 193 100 N.T. 194 100 N.T. 195 26.8 19.6 196 N.T. N.T. 197 92.4 100 198 100 Toxic 199 N.T. N.T. 200 Toxic N.T. 201 100 N.T. 202 100 100 203 99.1- 100 100 204 Toxic N.T. 205 100 94.3 206 98.9 87.8 207 N.T. 100 208 76.1 N.T. 209 92.2 99.2 210 Toxic N.T. 211 85.5 99.6 212 96.9 64.7 213 76.1 ' 50.5 21 99.9 99.6 215 98.8 84.7 5 -99.8 216 N.T. N.T. 217 100 100 218 N.T. N.T. 1 ABLE I (conf d) H. Contortus . Cle. arance Compound No. P.O. I. P. 219 49.1 68.7 220 N.T. N.T. 221 91.8 97-7 222 98.8 N.T. 223 46.8 . 0 224 N.T. 0-54.0 225 N.T. 99.6 226 100 100 227 100 0 228 100 99-5 229 100 N.T. 230 N.T. N.T. 231 N.T. N.T. 232 N.T. N.T. 233 N.T. N.T. 234 N.T. N.T. 235 N.T. N.T. 236 100 N.T. 237 N.T. N.T. 238 N.T. N.T. 239 99.8 99-9 240 N.T. N.T. 241 100 N.T. 242 99.2 N.T. 243 54.9 36.4 244 76.5 0 245 62.7 39-6 246 96.9 100 247 100 100 248 79.1 68.1 249 98.1 92.0 250 99.3 99.6 rn ABLE I (conf d) H. Contortus . Clearance Compound No. P.O. I. P. 251 N.T. N.T. 252 69.8 41.3 253 90.5 Toxic 254 86.7 0 255 87.4 0 256 0 52.5 257 N.T. N.T. 258 N.T. N.T. 259 N.T. N.T. 260 N.T. N.T. 261 N.T. N.T. 262 99.6 100 • 263 99.2 100 264 100 Toxic -265 N.T. N.T. 266 N.T. N.T. 267 N.T. N.T. 268 N.T. N.T. 269 N.T. N.T. 270 99.9 100 271 100 N.T. 272 98.9 97.3 273 100 100 274 70.2 100 275 99.8 100 276 100 100 277 99.9 100 273 100 100 279 99.6 N.T. 280 96.1- • 97 .2 85.8-96.6 281 100 0 282 99.6 99.6 TABLE I (conf d) H. Contortus . Clearance Compound No. P.O. I. . 283 99.6 N.T. 284 N.T. N.T. 285 N.T. N.T. 286 27-7 65.3 287 100 99.8 288 99.8 Toxic 289 100 100 290 99.7 N.T. 291 98.6 N.T. 292 51.7 N.T. 293 N.T. N.T. 294 N.T. N.T. 295 N.T. N.T. 296 N.T. N.T. 297 N.T. N.T. 298 N.T. N.T. 299 N.T. N.T. 300 39.6 49.9 301 100 N.T. 302 32.8 N.T. 303 100 N.T. 304 100 N.T. 305 100 N.T. 306 100 N.T. 307 99.3 N.T. 308 100 N.T. 309 N.T. N.T. 310 100 N.T. 311 100 99.9 312 Toxic N.T. 313 100 N.T. 314 Toxic N.T. TABLE I (conf d) H. Contortus % Clearance Compound No. P.O. I. P. 5 315 100 N.T. 316 100 N.T. 317 100 N.T. 318 100 N.T. 319 99.3 N.T. O 320 92.5 N.T. 321 100 N.T. 322 97.0 N.T. 323 99.3 N.T. 324 100 N.T. 5 325 100 N.T. 326 Toxic N.T. ' 327 77-6 N.T. 328 100 N.T. 329 100 N.T. 0 330 100 • N.T. 331 10.1 N.T. 332 70.1 N.T. 333 92.5 N.T. 331 100 N.T. 5 335 0 N.T. 336 92.5 N.T. 337 100 N.T. 338 77.6 N.T. 339 100 N.T. 0 310 N.T. N.T. 311 100 N.T. 312 32.8 N.T. . 313 N.T. N.T. 311 N.T. N.T. 5 315 N.T. N.T. 316 97.8 N.T. TABLE I (conf d) H. Contortus . Clearance Compound No. P.O. I. . 317 100 N.T. 348 77-6 N.T. 319 89.6 99.3 350 N.T. N.T. 351 100 100 352 99.9 N.T. 353 N.T. N.T. 351 100 N.T. 355 3-0* N.T. 356 Toxic N.T. 357 Toxic N.T. 358 100 N.T. 359 N.T. N.T. 360 99-3-100 N.T. 361 N.T. N.T. 362 100 N.T. 363 99.3 N.T. 361 100 N.T. 365 100 N.T. 366 100 N.T. 367 100 N.T. 368 100 N.T. 369 85.1 N.T. 370 100 N.T. 371 85.1 N.T. 372 62.7** N.T. 373 92.5 N.T. 371 92.5 N.T. 375 55.2 N.T. 376 N.T. N.T. 377 77.6 N.T. 378 100 N.T. TABLE I (cont' d) H. Contortus % Clearance Compound No. P.O. I. P. 379 92.5 N.T. 380 100 N.T. 381 92.5 N.T. 382 92.5 N.T. 383 92.5 N.T. 381 55.2 N.T. 385 100 N.T. 386 85.1 N.T. 387 N.T. N.T. 388 77.6 N.T. 389 85.1 N.T. 390 N.T. N.T. 391 100- N.T. 392 17.8 N.T. 393 85.1 N.T. 391 97.8 N.T. 395 92.5 N.T. 396 100+ N.T. 397 62.7 N.T. 398 0 N.T. 399 100 N.T. 400 85.1 N.T. 401 93.3 N.T. 402 70.1 N.T. 403 3.0 N.T. 10 N.T. N.T. 105 62.7 N.T. 106 N.T. N.T. 407 N.T. N.T. 108 55.2 N.T. 09 Toxic N.T. 110 85-1 N.T. TABLE I(cont'd) H. Contortus . Clearance Compound No. P.O. I. P. 411 92.5 N.T. 41 100 N.T. 413 92.5 N.T. 414 99.3 N.T. 415 85.1 N.T. 416 85.1 N.T. 417 0 N.T. 418 N.T. N.T. 419 N.T. N.T. 420 N.T. N.T. 421 100 N.T. 422 100 N.T. 423 100 N.T. 424 100 N.T. 425 95.5 N.T. 426 10.3 N.T. 427 N.T. N.T. 428 N.T. N.T. 429 N.T. N.T. 430 100 N.T. 431 100 N.T. 432 98.5 N.T. 133 100 N.T. 131 98.5 N.T. 135 100 N.T. 136 100 N.T. ++ 50 mg/kg I.P. = Parenteral administration * 95 mg/kg P.O. = Oral administration **60 mg/kg Toxic = Death within 21 hours post-treatment x 88 mg/kg +81 mg/kg N.T. = not tested - , means the compound was tested two or more times and the extreme values reported (for example, 0-97.6) TABLE II Percenta< ' - Clearance of Adult Worms by Species (100 mg/kg) Cmp._ Rout. 5 H.C. Ost.c. T.a. T.c. C.c. N.s. Str.p. Trich.o. Oes.v. ' M.e, 144 Oral 100 . 100 100 41.4 100 100 61.5 0 100 80 144 IP 96.7 96.0 91.1 17.1 100 97.5 30.8 50.0 100 40 136 Oral 98.2 0 100 50.0 55.6 0 15.4 0 155 Oral 91.2 85.9 0 100 71.8 97.6 0 41.2 0 + 72 IP 98.3 93.9 44.9 19.3 31.9 93.8 70.7 55.6 83.3 91 Oral 98.8 59.1 100 83.3 0 73.4 0 100 - 91 IP 97.1 86.4 100 0 100 50.0 100 100 .1 CM ω 86 Oral 93.6 100 100 55.6 100 5.6 100 100 - t- -J 1 ω «-_ 86 IP 94.2 88.6 35.0 0 100 0 0 63,6 t- 3 Oral 100 96.6 34.3 79.4 3.2 100 3 Oral 98.3 94.2 13.9 27.4 16.4 38.6 75.8 87.1 0 30 Oral 100 18.5 0 84.4 100 85.0 30 IP 100 0 0 42.2 100 50.0 183 Oral 40.0 19.9 34.5 75.6 100 35.0 183 IP 40.0 48.9 85.5 93.3 100 35.0 291 IP 91.1 82.1 77.8 0 14.7 63.3 20.5 0 Definitions H.c. Haemonchus contortus N.s, Ne atodirus spathiger Ost.c. = Ostertagia circumcincta Str.p. Strongyloides papillosus oo T.a. Trichos.trongylus axei Tri( :h.o. = Trichuris ovis T.c. Trichostrongylus colubriformis Oes.v. Oesophagostomum venulosum v so C.c. Cooperia curticei M.e * oniezia expansa 00 1 IX) o σ IX) r→ σ 1 n IX) CM I-j o ro ro f- © © TABLE IIA ©__ ) • VO Percentage Clearance of Adult Worms by SFjecies or • Genera (100 mg/kg 00 CΛ _-> Cmd.„ Route H.c. Ost.Spp. T.a. T.c. C.Spp. I..Spp. Str.Spp. Trich.Spp. Oes.Spp. P" CυL. 2 PO 100 99.2 100 44.4 - 88.3 15.0 0 100 144 O 100 100 100 41.4 LOO 100 61.5 0 100 IP 96.7 96.0 91.1 17.1 :100 97.5 30.8 50.0 100 153 PO 98.9 61.5 65.0 0 - 50.0 0 0 55.6 IP 95.9 97.0 100 83.3 75.0 66.7 78.1 100 16 PO 94.6 90.4 100 50.0 - 64.9 0 61.1 98.5 i <-< n r i 275 PO 100 100 - 58.3 - 92.7 100 0 100 T ' ™ ro IP 100 82.1 100 100 79.2 0 100 .- 160 PO 97.8 90.0 85.7 52.8 - 74.9 - 0 88.2 203 O 99.5 79.6 - 76.7 0 83.6 - 0 82.5 IP 99.3 66.3 33.3. 0 69.1 42.3 87.5 73 PO 99.9 97.5 79.2 73.0 5.6 94.9 53.8 86.7 Definitions: T. © ©o__ VO 00 (Λ TABLE III ( .ompound No. " 144 - Multi-Dose Study Compound Dosage Route H. con¬ .0. circum- T. T. colubri- C. curt- No. (mg/kg;) tortus cincta axei formis ice. 144 100 oral 0 (100) 0 (100) 0 (100) 695 (41.4) 0 (100) 144 50 Oral 16 (99.4) 250 (57.8) 10 (82.1) 1,766 (0) 10 (28.6) VH l-l 144 25 Oral 4 (99.8) 84 (85.8) 4 (92.9) 1,307 (0) 2 (85.7) l-l tr- I _J 144 100 Parenteral 83 (96.7) 24 (96.0) 5 (91.1) 982 (17.1) 0 (100) ω -_ 144 50 Parenteral 14 (99.4) 87 (85.3) 8 (85.7) 828 (30.1) 8 (42.9) 144 25 Parenteral 8 (99.7) 161 (72.8) 12 (78.6) 2,524 (0) ' 0 (100) Levami- 8 Oral 0 (100) 0.(100) 0 (100) 7 (99.4) 0 (100) sole Hydrochloride Non- , Treated — — 2,487 593 56 1,185 14 f*. t ** - © © TABLE III (cont'd.) © vo Compound No, 144 - Multi-Dose Study oo (/_ Compound Dosage Route N. spath- S. papil- T. ovis 0. venu¬ M. expansa H " υ No. (mg/kg) iger losus losum 144 100 Oral 0 (100) 5 (61.5) ' 4 (0) 0 (100) 1 (80.0) 144 50 Oral 39 (80.3) 9 (30.8) 2 (0) 1 (03.3) 0* (100) 144 25 Oral 204 (0) 19 (0) 2 (0) 2 (66.7) 2 (60.0) 144 100 Parenteral 5 (97.5) 9 (30.8) 1 (50.0) 0 (100) 3 (40.0) 144 50 Parenteral 56 (71.1) 11 (15.4) 2 (0) 3 (50-0) 2 (60.0) 144 25 Pa enteral 108 (45.4) 6 (53.8) 0* (100) 4 (33.3) 3 (40.0) Levami- 8 Oral 0 (100) 0 (100) 0* (100) 0 (100) 2 (60.0) sole Hydrochloride Non- ■ Treated 198 13 2 6 5 Mean numbers of worms/species recovered at necropsy and (%clearance+) by species for each treatment * Worms were recovered; however, the mean did not round off to 1. + % clearance = (Mean # worms recovered/species/nontreated control sheep)-(Mean _ worms recovered/species/treated sheep)xl00 r. oo Mean # of worms recovered/species/nontreated control sheep V) ©_ VO " 00 o σ IX) LO CM CM oo OO CHART A Scheme A: 0 II III Scheme B: 0 Z is a halogen atom or other active group, for example, an anhydride. j . Scheme C: VII VIII heteroaromatic IE

Claims: CLAIMS 1. A method of killing parasitic worms in animals which comprises administering to an animal a therapeutic or prophylactic dosage of a pyridinyl acylhydrazone, hydrate thereof or pharmaceutically acceptable salt thereof of the formula: wherein X is selected from (a) hydrogen; (b) C-|-Cιo alkyl; (c) C2~Cg alkenyl; (d) C -C6 alkynyl; (e) cyclo(C3-Cιo)alkyl optionally substituted with one, 2 or 3 C-J-C4 alkyl , C2-C4 alkenyl, C1-C4 alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1-methylpyrrolidinyl; (i) 1 -methyl pipe idinyl; ( j ) C2-C6 alkoxyalkyl; (k) cyclo(C3-C * ιo)alkyl- (C1-C4) alkyl; (1) phenyl (C1-C4) alkyl optionally substituted with one, 2 or 3 C-J-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (m) phenoxy- (C-|-Cij)alkyl optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (n) naphthyl(C*|-C3)alkyl optionally substituted with one or 2 C*|-Cl| alkyl, C-J-C4 alkoxy, halo, or trifluoromethyl; (o) C 1~C6 alkoxy? (p) diphenylmethoxy; (q) cyclo(C3-Cg)alkyloxy optionally substituted with one or two 0*1-03 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C -j -C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (s) benzyloxy optionally substituted with one, 2 or .3 C-*-C.ι alkyl, C*-- C4 alkoxy, halo, or trifluoromethyl; with the proviso that when a 2- pyridinyl acylhydrazone and R*- , R2, R4 are hydrogen, R3 is not benzyl; (t) heteroaromatic optionally substituted with one, 2 or 3 C-*-C_ι alkyl, C1-C3 alkoxy, halo, 0*1-03 alkylthio, or trifluoromethyl; (u) phenyl optionally substituted with one, 2 or 3 C-j— C2. alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C?-C6 dialkylamino, C1-C3 alkylthio, nitro, or phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C3 alkoxy, halo, or trifluoromethyl; (v) phenyl optionally substituted with the divalent C-j-C alkylenedioxy; (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C dialkylamino, C1-C3 alkylthio, nitro; (x) bridged polycyclic hydrocarbon substituents of six to 10 nuclear carbons, optionally substituted with one, 2 or 3 (C1-C3) alkyl groups; (y) perhaloCCi-CγJalkyl; wherein R-j and Rg, being the same or di ferent, are hydrogen; hydroxy; C1-C4 alkyl; C1-C3 alkoxy; C1-C3 alkylthio; halo or trifluoromethyl; wherein R3 is hydrogen; C1-C4 alkyl; cyclo(C3~C6) alkyl optionally substituted with one, 2 or 3 C-j— C3 alkyl; phenyl optionally substituted with one, 2 or 3 C-1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (C1-C3) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; or 1 , 3-dioxacyclohexan-5-yl; wherein R4 is hydrogen; C1-C2 alkyl; cyclo(C3-C6)alkyl optionally substituted with one, 2 or 3 C1-C3 alkyl; phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (C*|-C3)alkyl optionally substituted with one, 2 or 3 C-1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; and ' wherein n is zero or one . 2. The method according to Claim 1 wherein the compound, hydrate or pharmaceutically acceptable salt thereof is a 4-pyridinyl acylhydrazone. 3. The method according to Claim 1 wherein X is phenyl or phenyl substituted with one, 2 or 3 methyl, ethyl, methoxy, ethoxy, trifluoromethyl or chloro. 4. The method according to Claim 1 wherein R-j and R2 are selected from the group consisting of hydrogen, C1-C3 alkyl, C1-C3 alkoxy or a ■ chloro atom. 5. The method according to Claim 1 wherein R3 is selected from the group consisting of hydrogen, methyl or ethyl and R4 is hydrogen. 6. The. method according to Claim 1 wherein the compound, hydrate or pharmaceutically acceptable salt thereof is selected from the group consisting of: benzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #1 ) ; benzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #2); benzoic acid [1-( -pyridinyl )ethylidene]hydrazide (Cpd #3); benzoic acid (3~pyridinylmethylene)hydrazide (Cpd #6); benzoic acid (4-pyridinylmethylene )hydrazide (Cpd #7); benzoic acid (α-4-pyridinylbenzylidene)hydrazide hydrate (Cpd #8) 3-methyl benzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #11) 2-ethoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #1 ) 3-ethoxy benzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #15) 4--ethσxybenzoic acid [1-( 4-pyridinyl) ethyl idene]hydrazide (Cpd #16) 3, 1,5-trimethoxybenzoic acid [1-(1-pyridinyl)ethylidene]hydrazide (Cpd #17); 3, 1-di methoxy ben zoic acid [1-(4-pyridinyl) ethyl idene]hydrazide (Cpd #18); piperonylic acid ( -pyridinylmethylene )hydrazide (Cpd #19); 2-phenoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #20); 3-methoxybenzoicacid [1 -(4-pyridinyl) ethyl idenejhydrazide (Cpd #22); 3,5-dimethoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #23); 2, 4-dichlorobenzoic acid [1-( 4-pyridinyl)ethylidene]hydrazide (Cpd #26); 3, 4-dichlorobenzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #27); 2, 4-dichlorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #28); 2-methoxybenzoic acid ( 4-pyridinylmethylene )hydrazide monohydrate (Cpd #30); 3-methoxybenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #31); 3-methyl enzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #31 A); 4 -ethoxy be zoic acid (4-pyridinylmethylene)hydrazide (Cpd #34); 3,5-dimethoxybenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #35); 2-chlorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #36); 4-(1 , 1 -dimethyl ethyl) enzoic acid (2-pyridinylmethylene)hydrazide hydrate (Cpd #40); 4-(1 ,1 -dimethyl ethyl )benzoic acid (3-pyridinylmethylene)hydrazide he ihydrate (Cpd #41); 4-( 1 , 1-dimethyl3thyl)benzoic acid [1-(3-pyridinyl)ethylidene]*-- hydrazide (Cpd #42); 2-phenoxybenzoic acid (4-ρyridinylmethylene)hydrazide (Cpd #43); 2-ethoxy benzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #44); 2-ethoxybenzoicacid [1-(2-pyridinyl)propylidene]hydrazide (Cpd #45) 2-ethoxybenzoicacid Cl-(3-pyridinyl)propylidene]hydrazide (Cpd #46) benzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #48) 2-phenoxybenzoic acid [1-( 4-pyridinyl ) ethyl i dene ]hydrazide 1-oxide (Cpd #4g); benzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #51); 4- chloro benzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #52); benzoic acid 1-methyl-2-[1-(4-pyridinyl)ethylidene]hydrazide (Cpd #55); 2-methoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #56); 2-methoxybenzoic acid C(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #57); . benzoic acid [1-(4-pyridinyl)pentylidene]hydrazide (Cpd #60); benzoicacid [2-phenyl-1-(4-ρyridinyl)ethylidene]hydrazide (Cpd #61); benzoic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #67); 2-nitrobenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #69); ethyl [1-(2-pyridinyl)ethylidene)carbazate (Cpd #70); ethyl [1-( 4-pyridinyl )ethylidene) carbazate (Cpd #72); ethyl (2- pyridinyl methyl ne) carbazate (Cpd #73) ethyl (3-pyridinylmethylene) ca bazate (Cpd #74) ethyl ( 4-pyridinylmethylene )carbazate (Cpd #75) 1 ,1-dimethyl ethyl [1-( -pyridinyl ) ethyl i dene] ca bazate (Cpd #76); benzyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #79); diphenylmethyl [ 1-( 4- pyridinyl) ethyl idene] carbazate (Cpd #80); diphenylmethyl [1-(2-pyridinyl)ethylidene]carbazate (Cpd #80A); methyl (4-pyridinylmethylene) ca azate hydrate (Cpd #83); benzyl ( 4-pyridinylmethylene )carbazate (Cpd #84); methyl [1-( 4-pyridinyl ) ethyl idene] carbazate (Cpd #85); diphenylmethyl ( 4-pyridinylmethylene )carbazate (Cpd #86); 4- chloro benzoic acid ( -pyridinylmethylene )hydrazide 1-oxide (Cpd #86 A); methyl [1-(3-pyridinyl)ethylidene]carOazate (Cpd #89); 1 , 1-dimethylethyl [1-(4-pyridinyl)propylidene]carbazate (Cpd #91); benzyl [1-(4-pyridinyl)propylidene]carbazate (Cpd #92); methyl [1-(4-pyridinyl)propylidene]carbazate (Cpd #93); phenyl [1-( -pyridinyl ) ethyl idene] carbazate (Cpd #94); phenyl [1-( 4-pyridinyl)ethylidene]carbazate monohydrochloride (Cpd #95); 5-met hyl-2*- ( 1 - ethylethyl )cyclohexyl [ 1 - ( 4-py idinyl ) ethyl idene]- carbazate (Cpd #97); ethyl [1-(4-ρyridinyl)pentylidene]carbazate (Cpd #99); phenyl [1 -(4-pyridinyl) bu yl idene] carbazate monohydrochloride (Cpd #100); phenyl (4-pyridinylmethylene) car azate monohydrochloride (Cpd #101); 1 , 1-dimethylethyl [1-(3-pyridinyl)propylidene]car'oazate (Cpd #103); methyl [1-(2-pyridinyl)propylidene]carbazate (Cpd #104); ethyl [ 1 -(2- pyridinyl) propyl idene ] carbazate (Cpd #105); 1 ,1-ditnethyl ethyl [1-(2-pyridinyl)propylidene]carbazate (Cpd #106); ethyl [1-(3-pyridinyl)propylidene]carbazate (Cpd #107); 1 , 1-dimethylethyl [1-(4-pyridinyl)butylidene]carbazate (Cpd #108); ethyl [1-( 4-pyridinyl )ethylidene]carbazate 1-oxide (Cpd #109); ethyl [1-(4-pyridinyl)butylidene]carbazate (Cpd #110); methyl [1-(4-pyridinyl)ethylidene]carbazate 1-oxide (Cpd #111); phenyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #112); 1 , 1-dimethylethyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #113); ethyl [1-( 4-pyridinyl )butylidene]carbazate 1-oxide (Cpd #114); 1 , 1-dimethylethyl [3-methyl-1-(4-pyridinyl )butylidene]carbazate (Cpd #116); phenyl [1-( 4-pyridinyl )ethylidene]carbazate 1-oxide monohydrochloride (Cpd #118); benzyl [1-(4- i pyridinyl)ethylidene]carbazate 1-oxide hydrate (Cpd #119); 1 , 1-dimethylethyl [1-( 4-pyridinyl)ethylidene]carbazate 1-oxide (Cpd #120); 4-trif luoromethylbenzoic acid [1-( 4-pyridinyl ) ethyl idene ]hydrazide (Cpd #121); 4-dimethylamino benzoic acid (2-pyridinylmethylene)hydrazide (Cpd #1 2); 4-dimethylaminobenzoic acid (3-pyridinylmethylene)hydrazide (Cpd #123); 4-dimethylaminobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #124); 4-dimethylaminobenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #125); 4-dimethylaminobenzoic acid [1-( -pyridinyl )ethylidene]hydrazide (Cpd #126); 4-tri luoromethylbenzoic acid [1-(3-pynidinyl)ethylidene]hydrazide (Cpd #127); 4-methoxybenzyl (3-pyridinylmethylene)carbazate (Cpd #128); 4-methoxybenzyl (4-pyridinylmethylene) carbazate (Cpd #129); 4-methoxybenzyl [1-(3-pyridinyl)ethylidene]carbazate monohydrate (Cpd #130); 4-methoxybenzyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #131 ) ; ethyl C(6-methyl-2-pyridinyl)methylene]carbazate hydrate (Cpd #132) ; 4-metho ybenzyl (2-pyridinylmethylene)carbazate (Cpd #133); acetic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #136); (2, 4, 5-trichlorophenoxy)acetic acid [ 1-( 4-pyridinyl ) ethyl idene ]hydra- zide (Cpd #137); formic acid [(6-methyl- 2-pyridinyl )methylene]hydrazide (Cpd #138); formic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #139); formic acid [1-( 4-pyridinyl )pentylidene]hydrazide (Cpd #141); phenylacetic acid C(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #142); butyric acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #144); butyric acid [1-( 4-pyridinyl ) ethyl i dene ]hydrazide oxalic acid salt (Cpd #145); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide pamoic acid salt (Cpd #146); butyric acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-hydroxy-2- naphthoic acid salt (Cpd #147); butyric acid [1-( 4-pyridinyl)ethylidene]hydrazide 3-hydroxy-2- naphthoic acid salt (Cpd #148); butyric acid [1 -( 4-pyridinyl)ethylidene]hydrazide raalonic acid salt (Cpd #1 9); butyric acid [1-( 4-pyridinyl)ethylidene]hydrazide phenylacetic acid salt (Cpd #150); butyric acid [1-( 4-pyridinyl )ethylidene]hydrazide phenoxyacetic acid salt (Cpd #151); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide phenylthioacetic acid salt (Cpd #152); butyric acid (4-pyridinylmethylene)hydrazide (Cpd #153); butyric acid (4-pyridinylmethylene )hydrazide oxalic acid salt (Cpd #154); formic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #155); butyric acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #156); phenylacetic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #157); 3-cyclohexanepropionic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #160); 1-naphthalenecarbόxylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #161); 2-naphthaleneca o xylic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-naphthaleneacetic acid (4-pyridinylmethylene)hydrazide (Cpd #164); 1-naphthaleneacetic acid [ 1 -( 3-pyridinyl )ethylidine]hydrazide (Cpd #165); 1-naphthaleneacetic acid [1-( 4-pyridinyl )ethylidine]hydrazide (cpd #166); cyclohexanecarboxylic acid [( 6-methyl-2-ρyridinyl)methylene]hydrazide monohydrate (Cpd #167); butyric acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #168); 1 -naphthalene car bo xylic acid [ 1-( -pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #171); 1-naphthylene ca bo xylic acid (3-pyridinylmethylene)hydrazide (Cpd #172); nicotinic acid [1-(3-py-'idinyl)propylidene]hydrazide (Cpd #174); 2-thiophenecar bo xylic acid [ 1-( 4-pyridinyl) ethyl idene ]hydr a zide (cpd #177); 2-thiophenecar bo xylic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #178); 2-thiophenecarboxylic acid (3-pyridinylmethylene)hydrazide (Cpd #179); 1-naphthalenecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #180); 2-thiophenecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #181); 3,1,5-trimethoxybenzoiα acid (l-pyridinylmethylene)hydrazide mono- hydrate (Cpd #132); cyclobutanecarboxylic acid [( 6-methyl-2-pyridinyl)methylene]-- hydrazide (Cpd #183); acetic acid [(6-methyl-2-pyridinyl)raethylene]hydrazide (Cpd #181); 1- chloro ben zoic acid [1-(1-pyridinyl)ethylidene]hydrazide 1-oxide 4-chlorobenzoicacid [1-(3-pyridinyD ethyl idene ]hydrazide (Cpd #190); 4- chloro benzoic acid ( 4-pyridinylmethylene )h ' ydrazide (Cpd #1 3); ' 4-chlorobenzoic acid ' (3~pyridinylmethylene)hydrazide (Cpd #194); phenylacetic acid [1-( 4-pyridinyl )propylidine]hydrazide (Cpd #197); nicotinic acid [1-( -pyridinyl )ethylidene]hydrazide (Cpd #198); 2,2-dimethyl-3-(2-methylpropenyl)cyclopropane carboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #201); 2-methyl propionic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #202); formic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #203) ; acetic acid [1-( 4-pyridinyl ) ethyl i dene ]hydra zide 1-oxide (Cpd #205); eye lopropaneca bo xylic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #206); formic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd ι#207) ; cyclopropanecarboxylic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #208); 2-methyl propionic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #209); butyric acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #211); acetic acid [1 -(4-pyridinyl) but yli dene ]hydra zide 1-oxide (Cpd #212); cyclohexanecarboxylic acid [1-(4-pyridinyl)butylidene]hydrazide 1- oxide (Cpd #213); 2-furoic acid [1-( 3-pyridinyl)ethylidine]hydrazide monohydrate (Cpd #214); 2-furoic acid [1-(2-pyridinyl)ethylidine]hydrazide (Cpd #215); isonicotinic acid [1-( -pyridinyl )ethylidene]hydrazide (Cpd #217); isonicotinic acid (2-pyridinylmethylene)hydrazide (Cpd #221); 1- naphthalene ca bo xylic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #222); 2-furoic acid [1--(3-pyridinyl)ethylidene]hydrazide (Cpd #225); phenyl [1-(3~ pyridinyl )propylidene] carbazate monohydrochloride (Cpd #226); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide 1- oxide (Cpd #227); 3-ethoxypropionic acid [1- (4-pyridinyl) ethyl idene ]hydrazide 1-oxide (Cpd #228); 2-methoxybenzoic acid (4-pyridinylmethylene)hydrazide 1-oxide (Cpd #229); 2-phenoxybenzoic acid (4-pyridinylmethyIene)hydrazide 1-oxide (cpd #236): 2-thiophenecarboxylic acid (4-pyridinylmethylene)hydrazide 1-oxide (Cpd #239); 3-cyclohexanepropionic acid (4-pyridinylmethylene)hydrazide 1-oxide (Cpd 241); butyric acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #242); cyclo pro panecar bo xylic acid [3-methyl-1-( -pyridinyl )butylidene]- hydrazide (Cpd #244); cyclohexaneca boxylic acid (cyσlopentyl-4-pyridinylmethylene)- hydrazide (Cpd #246); butyric acid (cyclopentyl-4-pyridinylmethylene)hydrazide (Cpd #247); cyclo pro panecar bo xylic acid [1-( 4-pyridinyl )butylidene]hydrazide (Cpd #248); 2-methyl propionic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #249); 3-cyclohexanepropionic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #250); cyclohexaneacetic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #252); cyclohexaneca bo ylic acid [1-(4-pyridinyl)butyl idene ]hydrazide (Cpd #253); 2-methyl propionic acid C3-methyl-1-(4-pyridinyl)butyli.dene]hydrazide (Cpd #254); cyclohexanecarboxylic acid [3-methyl- 1-( 4-pyridinyl )butylidene)- hydrazide (Cpd #255); 3-ethoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #262); formic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #263); cyclobutanecarboxylic acid ( 4-pyridinylmethylene )hydrazide (Cpd #264); cyclohexanecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #270); formic acid [1-(3-pyi"idinyl)propylidene]h.ydrazide (Cpd #271); 2-methyl propionic acid ( 4-pyridinylmethylene )hydrazide (Cpd #272); cyclopropaneca bo ylic acid [1 -(4-pyridinyl) ethyl i dene ]hydrazide (Cpd #273); cyclopropaneca bo xylic acid ( 4-pyridinylmethylene )hydrazide (Cpd #274); 2-methyl propionic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #275); 3-cyclohexanepropionic acid [ 4- ( pyridinyl )ethylidene]hydrazide 3-cyclohexanepropionic acid (4-pyridinylmethylene)hydrazide (Cpd #277); cyclohexaneacetic acid (4-pyridinylmethylene)hydrazide (Cpd #278); cyclohexanecarboxylic acid [1-(3-pyridinyl)ethylidene]hydrazide cyclohexaneacetic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #280); 3-ethoxypropionic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #231 ) ; cyclobutanecarboxylic acid [1-(4-pyridinyl)propylidene]hydrazide 3-ethoxypropionic acid (4-pyridinylmethylene)hydrazide (Cpd #283); cyclohexanecar bo xylic acid [1-(4-pyridinyl)ethylidene]hydrazide 1- oxide (Cpd #287); cyclohexaneacetic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #288); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide hydrate (Cpd #289); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #290); 4-nitrobenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #291); 3-trifluoromethylbenzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #301); 2-fluorobenzoic acid (2-pyridinylmethylene)hydrazide (Cpd #303) ; 2-fluoro benzoic acid Cl-(2-pyridinyl)ethylidene]hydrazide (Cpd #304); 3-fluorobenzoicacid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #305); 3-fluoro benzoic acid (2-pyridinylmethylene)hydrazide (Cpd #306); 2-methylcyclopropane carboxylic acid (2-pyridinylmethylene)hydrazide (Cpd #307); piperonylic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #308); propanoic acid [1-(3-pyridinyl)propylidene]hydra . zide (Cpd #310); propanoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #311); 2-methylcyclopropane carboxylic acid [ 1 -( 3~ pyridinyl) propyl idene] - hydrazide (Cpd #313); 3-trifluoromethylbenzoic acid (3-pyr , idinylmethylene)hydrazide (Cpd #315); 3-trifluoromethylbenzoic acid [1-(3 u pyridinyl)ρropylidene]hydrazide (Cpd #316); 3-trifluoromethylbenzoic acid [1-(3~pyridinyl)ethylidene]hydrazide (Cpd #317); 2-fluorobenzoic acid [1-(3~pyridinyl)propylidene]hydrazide (Cpd #318); 3-fluorobe zoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #319); 2-fl orobenzoic acid (3~pyridinylmethylene)hydrazide (Cpd #320); 2-fluorobenzoic acid [1-(3-pyr*idinyl)ethylidene]hydr zide (Cpd #321); 3-flαorobenzoic acid (3-pyridinylmethylene)hydrazide (Cpd #322); 3-fluorobenzoicacid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #323); 4-phenylbutyric acid [1-(3~pypidinyl)propylidene]hydrazide (Cpd #324); 4 -phenyl butyric acid (3-pyridinylmethylene)hydrazide (Cpd #325); acetic acid [1-(6-methyl-3- pyridinyl ) ethyl i dene ]hydr a zide (Cpd #327); 2 * -methyl propionic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #328); butyric acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #329); propanoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #330); ethyl [1-(6-methyl-3-pyridinyl)ethylidene]carbazate (Cpd -#332); 1 , 1 -dimethyl ethyl[1-(6-methyl Λi 3- pyridinyl) ethyl idene] ca bazate (Cpd #333); phenyl[1-(6-methyl-3-pyridinyl)ethylidene]carbazate monohydrochloride (Cpd #334); benzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #336); " 4-chlorobenzoic acid [1-(6-methyl-3-ρyridinyl)ethylidene]hydrazide (Cpd #337); 2-ethoxybenzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #338); 4-ethoxybenzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #339); 2-methyl-1-naphthaleneacetic acid [1-( 4-pyridinyl) ethyl idene ]- hydrazide (Cpd #341); piperonylic " acid [1-( -pyridinyl )ethylidene]hydrazide 1-oxide hydrate (Cpd #316); piperonylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #347); 3, 4-dimethoxy phenylacetic acid [1 -(4-pyridinyl) ethyl idene Jhydrazide 1-oxide hydrate (Cpd #348); 3, 4-dimethoxyphenylacetic acid (4-pyridinylmethylene)hydrazide (Cpd #349); propanoic acid ( 4-pyridinylmethylene )hydrazide (Cpd ..351); propanoic acid [1-( -pyridinyl )ethylidene]hydrazide (Cpd #352); 1-*methyleyclopropanecarboxylic acid [1-(4-pyridinyl)ethylidene]- hydrazide (Cpd #354); 3-trif luoromethylbenzoic acid ( 4-pyr idinylmethylene)hydrazide (Cpd #358); 2-methyl cyclopropanecar bo xylic acid [ 1-( 4-pyridinyl) propyl idene ]- hydrazide (Cpd #360); 2-fluorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #362); 3-fluorobenzoic acid [1-( -pyridinyl )propylidene]hydrazide (Cpd #363 ) ; 2-fluorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #364); 2-fluorobenzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #365); 3-fluorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #366); 4-phenylbutyric acid [1-( 4-pyridinyl ) ethyl idene ]hydrazide (Cpd #367); 4-phenylbutyric acid [1-(4-ρyridinyl)ρropylidene]hydrazide (Cpd #368); 4-phenylbutyric acid (4-pyridinylmethylene)hydrazide (Cpd #369); 3-fluorobenzoic acid [1-( 4-pyridinyl )ethylidene]hydr zide (Cpd #370); 2- methyl ben zoic acid [ 1 -( 4-pyr idinyl) propyl idene ]hydr azide (Cpd #371 ) ; 4-methyl benzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #373); 2-chlorobenzoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #374); acetic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #377); 2-furoic acid [1-( 4-pyridinyl ) propyl i dene ]hydrazide (Cpd #378); isonicotinic acid [1-(4~pyridinyl)propylidene]hydrazide (Cpd #379); propanoic acid [1-( 4-pyridinyl )propylidene]hydr zide (Cpd #380); 2-methyl propanoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #381); 2-thiophenecarboxylic acid [1-( 4-pyridinyl ) propyl idene ]hyd azide (cpd #382); phenyl [1-( 4-pyridinyl)propylidene]carbazate monohydrochloride (Cpd #383); 2-ethoxybenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #385); formic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #386); 4-ethoxybenzoic acid Ci-(4-pyridinyl)propyHdene]hydrazide (cpd #388); 3-chlorobenzoie acid [l- ( 4-pyridinyl)propylidenβ;ihydrazidβ (Cpd #389); butyrio acid (2-c_hloro-3-pyridinyltnethylene)hydrazide (cpd #391) propanoic acid (3 hydroxy-2-pyridinylaethylene)hydpazide (Cpd #393) formic acid C--(3-chloro-4-pyrrdinyl)ethylidene,3hydrazidβ (Cpd #394) butyric acid Cl-(3-chloro-4-pyridinyl)etJιylidenβ] ydrazidβ (Cpd #395); methyl C -(3-chloro-4-pyridinyl)^thylidene]carbazate (Cpd #396); propanoic acid Cl-(2-chloro-3-pyridinyl)ethylidene]__ydrazide (Cpd #399); butyric acid Cl-(2-c loro-3-pyridinyl)ethylidene]hydrazidβ (Cpd #400) 2-methylpropanoicacid [l-(2-cftloro-3-pyridinyl)ethylidenehydrazicte (Cpd #401); cyclopropaneca oxy! ic acid Ci-(2 chloro-3-py idinyl)et ylidene]- hydrazide (Cpd #402); acetic acid Ct-(6-chlcro-3 pyr , idinyl)ethylidene]hydrazide (cpd propanoic acid Ct'-(δ*-chloro-3-pyridiny )ethylidene]hydrazide (#411); butyric acid Cl-(δ-chloro-3-pyridinyl)ethylidene3hydrazide (Cpd #412); 2-aιβt.l.ylpropanoicacid [1"-(6-cf.ioro-3-pyridinyl)ethylidene]hy-_r__zide (cpd #413) j cyclopropaneca o ylic acid ri-(6-chloro-3-pyridinyl)ethylidenβ]- hydrazidβ (Cpd #41 ) S eyolohexaneaceticacid Cl-(6-chloro-3-ρyrldinyl •)ethylidenβ]hydrazid _β (Cpd #415); benzoic acid Cl-(6-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #416); . . benzole acid C( 1 , 3-dioxan-5-yl )-3-pyridinyl. ethylene]hydrazide (Cpd #421); ethyl Cd ι3-dioxan-5-yl)-3-pyfi-_inyl.τιethyl3ne]carιazate (Cpd #422); ,benzoic acid C( i^dioxan-S-yD-l-pyridinylmethylenelhydrazide (Cpd #423); forraic acid ( 4-pyridinylmethylen )hydrazide (Cpd #424); formic acid (3-pyridinyln.ethylene)hyd azide (Cpd #425); butyric acid CO,3-dloxan-5-yl ) -3-pyridinylmethylene)hydrazide (Cpd #430); ethyl C(1,3-dioxan-5-yl)-4-pyridinylraethylene]carbazatβ (Cpd #431); methyl C(1ι3-dioxan-5-yl)-3-pyϊ*idinylmethylene3carbazate (Cpd #432); propanoi c acid [( 1 , 3-dioxan-5-yl )-4-pyridinylmethylβne]hydrazide (Cpd #433); propanoic acid CO ,3-dioxan-5-yl)-3-ρyridinylmethylene]hydrazide (Cpd #434) j butyric acid C( 1 , 3-dioxan*5-yl)-4 * -pyridinylmethylβne3hydrazide (Cpd #435); methyl CO , 3-dioxan-5-yl)-4-pyridinylmethylene]carbazatβ (Cpd #436). 7. A compound, hydrate thereof or pharmaceutically acceptable salt thereof of the formula wherein X is seiacted from (a) hydrogen; (b) C*]-Cι alkyl; (c) C≥-Cδ alkenyl; (d) C2-C6 alkynyl; (e) c cloC3-C o)al l optionally substituted with one, 2 or 3C1-C4 alkyl, C2-C alkenyl, C1-C4 alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; ( ~ ) piperidinyl; (h) 1 -methyl pyrrol dinyl; (i ) 1-methylpiρeridinyl,- ( J) Cjj-Cδ alkoxyalkyl; (k) cyclo C3-Cιo) a lKyl i * (Cf-C4)alkyl{ (l) phenyl (Cι-Ci»)alkyl optionally substituted with one, 2 or 3 Cι-cu alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (a) phenoxy- (C-j-C4)alkyl optionally substituted with C1-C4 alkyl-, > Cι-C alkoxy, halo, or trifluoromethyl; (n) naphthyl (0*1-0 ) alkyl optionally substituted with one or C 1 -C4 alkyl, C 1 -C4 alxoxy, halo, or trifluoromethyl; (0) C-j-Cg alkoxy? (p) di henylmethoxy; (q) cyclo(C3-C6)alkyloxy optionally substituted with one or two C1-C3 al yl; (r) phenoxy optionally substituted with one, 2 or 3 Cj-C alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (3) benzyloxy optionally substituted with one, 2 or 3 C-1-C4 alkyl, Ci*-* C alkoxy, halo, or trifluoromethyl; with the proviso that when a 2- pyridinyl acylhydrazone and Rt , a, R4 are hydrogen, R3 is not benzyl; (t) heteroaromatic optionally substituted with one, 2 or 3 C1-C alkyl, C1-C3 alkoxy, halo, C1-C3 alkylthio, or trifluoromethyl; (u) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, alkoxy, halo, trifluoromethyl, C -C6 dialkylamino, C1-C3 alkylthio, nitro, or phenoxy optionally substituted with' one, 2 or 3 Cι-Cu alkyl. "1-C3 alkoxy, halo, or trifluoromethyl; (v) phenyl optionally substituted .with the divalent C1-C2 alkylenedioxy;' (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, Cj-C3 alkoxy, halo, trifluoromethyl, Cg-Cζ dialkylamino, C1-C3 alkylthio, nitre, (x) bridged polycyclic hydrocarbon substltuents of six to 10 nuclear carbons, optionally substituted with one, 2 or 3 (C1-C3) alkyl groups; (y) perhalo.Ci-CγJalkyl} wherein i and R2 » being the saae or different, are hydrogen; hydroxy; C1-C4 alkyl; C1-C3 alkoxy; C1-C3 alkylthio-, halo or trifluoromethyl; wherein R3 is hydrogen; C1-C4 alkyl; cyclo(C3-C6)alkyl optionally substituted with one, 2 or 3 C1-C3 alkyl ? phenyl optionally substituted with one, 2 or 3 C1-C alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl(Cι-C3)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; or 1,3*-dioxacyclohexan-5-yl; wherein Rn is hydrogen; C1-C2 alkyl; cyclo(C3-C$)alkyl optionally substituted with one, 2 or ,3 C1-C3 alkyl; phenyl optionally substituted with one, 2 or 3 C1-C alkyl, halo, trifluoromethyl, or C1-C3 alkoxy phenyl (C1-C3) alkyl optionally substituted with one, 2 or 3 Cι-Cu alkyl, halo, trifluoromethyl, or Z -C~ alkoxy, and wherein n is zero or one; other than: benzoic acid (2-pyridinylmethylene)hydrazidβ; benzoic acid (3-pyridinylmethylene)hydrazide; benzole acid (4-pyrldinylmethyl3ne)hydrazide; benzoic acid l-(4-pyridinyl)*3thylidene]hydrazida; benzoic acid ri-{2-pyridinyl)e'.hylidene]hydrazlde; benzoic acid C(2-ethyl-4-ρyrldlnyl)methylene3hydrazide; 4 -di e hyl ami no benzole acid ' ( -pyr idinylmethylene)hydrazide; 4-methylbenzoic acid (2-pyridlnylmethylene)hydrazide; 4-methyl enzoic acid ( 2-pyridinylmethylene )hydrazide 1-oxlde; 4-methylbenzoic acid (4-ρyridinylmethylane)hydrazide; 4-methoxybenzolc acid Cl-(4-pyridinyl)ethylidene]hydrazide} 3, 4-diraethoxybenzoic cid C( 2-ethyl-4-pyridinyl)raethylene hydrazide; -t- butyl benzoic acid(3-pyridinylmethylene)hydrazidβ; benzoic acid (cr2-pyridinylbenzylidene)hydrazide; 2-nitrobenzoic acid (4-ρyridinyltnethylene )hydrazide{ ?-nifc- at_9ft _<-l - aoid (2-pyι»id " inylm«bhylβι_β >hydrβsidβ; 2-nitrobenzoic acid (3*pyridinylmethylene)hydrazide; 4-nitrobenzoi c acid C(2-ethyl *i 4-pyridinyl)methylene]hydrazide; 4-nitrobenzoic acid [ 1-<4-ρyridinyl)ethylidenβ]hydrazide; ethylCl-(3-pyridinyl)ethylidene]carbazate; methyl(2-pyridinylmethylene )carbazatβ; ethyl (2 fc pyridinylmethylene)carbazatβ; ethyK 4-pyridinylmethylene )carbazatβ; ethylCl * -(2 * -pyridinyl)ethylidene]carbazatej acetic acid ( -pyridinylmethylene Jhydrazidβ; acetic acid (2-pyridinylmethylene)hydrazide; acetic acid Cl-(2-pyridinyl )ethylidene]hydrazide; 2, , 5-trichlorophenoxyacetic acid ( 4-pyridinylaethylene)hydrazide; 2, 4, 5-trichlorophenoxyacetic acid (3-pyridinylmβthylβne)hydrazide; 2, 4,5-trichlorophenoxyacetic acid (2-pyridinyl βthylene )hydrazide; 2, 4-dichlorophenoxyacet I ic acid ( 4-pyr idinylmethylene)hydr azide ; 2,4-dichlorophenoxyacetic acid (3-pyridinylraethylenβ)hydrazide; 2, 4-dichlorophenoxyacetic acid (2-pyridinylmβthylene)hydrazide; 4-Chl orf-phβnoxyaββti β aoid ( 'ι-pyr»idinylmβfchylβnβ >hjrUr'» _idβ5 4-chlorophenoxyacetic acid (3-pyridinylmethylene)hyd azide; 4-chlorophenoxyacetic acid (2-pyridinylmethyle._e)hydrazidei 1 -napthylacetic acid [l-(3-pyridinyl )ethylide ' ne]hydrazide; 1-napthylaeetic acid Cl-(4-pyrtdinyl)βthylidene]hydrazide; 1-napthylacetic acid [ 1-(_- DV ridinyl . ethyl . d-.n-. _hy / -na2i_-- , 1-napthylacetic acid (2 u pyridinylmethylene )hydrazide; 1-napthylacetic acid (3-pyridinylmethylene)hyd azide; 1-napthylacetic acid ( -pyridinylmethylen )hydrazlde; phenylacetic acid [ 1-(2-pyridinyl )ethylidene3hydrazide; phenylacetic acid C l-(3-pyridinyl)ethylidene]hydrazide; phenylacetic acid [1-( 4-pyridinyl )ethylidene]hydrazide; phenylacetic acid (2-pyridinylmethylene)hydrazide; phenylacetic acid (3-pyridinylmethylene)hydrazide; phenylacetic acid ( -pyridinylmethylene )hydrazide; isonicotinic acid (2-pyridinylmethylene)hydrazide; isonicotinic acid [1 * -(4-pyridinyl)ethylidene]hydrazida; picolinic acid (2-pyridinylmethylene)hydrazide; picolinic acid [1-*(4-pyridinyl)ethylidene]hydrazide; picolinic acid [(6-tπethyl-2-pyridinyl)methylene_hydrazide; quinaldic acid [(6-methyl- 2-pyridinyl )πιethylene]hydrazide; 4, 5-dimethyl-2-f urancarboxylic acid ( -pyridinylmethylene )hydrazide; 4, 5-dimethyl-2-f urancarboxylic acid (3-pyridinylmethylene)hydrazide; 4, 5-dimethyl-2-f urancarboxylic acid (2-pyridinylmethylene)hydrazide; 5-ethyl-2-furancarboxylic acid (4-pyridinylmethylene)hydrazide; 5-ethyl-2-f urancarboxylic acid (3~pyridinylmethylene)hydrazide; 5-ethyl-2-f urancarbo ylic acid (2-pyridinylmethylene)hydrazide; 5-methyl-2- uranca boxylic acid (4-pyridinylmethylene )hydrazide; 5-methyl-2-furancarboxylic acid (3*-pyridinylmethylene)hydrazide; 5-me ' thyl-2-f urancarboxylic acid (2-pyridinylmethylene)hydrazide; nicotinic acid (3~pyridinylmethylene)hydrazide; indole-3- car bo ylic acid ( -pyridinylmethylene )hydrazide; indole-2-carboxylic acid ( -pyridinylmethylene )hyd azide; indole-2-carboxylic acid (3-pyridinylmethylene)hydrazide; indole-2-carboxylic acid (2-pyridinylraethylene)hydrazide; isonicotinic acid (3-pyridinylmethylene)hydrazide; nicotinic acid (2-pyridinylmethylene)hydrazide; nicotinic acid ( -pyridinylmethylene )hydrazide; picolinic acid (2-pyridinylmethylene)hydrazide; picolinic acid (3-pyridinylmethylene)hydrazide; picolinic acid ( -pyridinylmethylene )hydrazide; isonicotinic acid (4-pyridinylmethylene )hydrazide; pyrazine-2-car bo xylic acid [(2-ethyl-4-pyridinyl)methylene]hydrazide; nicotinic acid " [(2-ethyl-4-pyridinyl)methylene]hydrazide; isonicotinic acid C(2-ethyl-4*-pyridinyl)methylene]hydrazide; 2-ethyl pyridine fa 4-car bo ylic acid [(2-ethyl-4- pyridinyl )methyl ene]- hyd azide; 4, 5-dichloroquinolinic-2-carboxylic acid ( 4-py idinyl ethylene )- hydrazide; 4, 5-dichloroquinoline-2-car o ylic acid (3-pyridinylmethylene)- hyd zide; 6-methyl-3-pyridinecar o xylic acid [1-(6-methyl-3-pyridinyl)ethyl- idene]hydrazide; 3~n-propyl-1 , 4-dioxoquinoxaline-2-carboxylic acid (2-py idinyl- methylene ) hydra zide; 3-methyl- 1 , -dioxoquinoxaline-2-car bo xylic acid (2-pyridinylmethyl- ene) hydra zide; 3~ethyl-1 ,4-dioxoquinoxaline-2-car o xylic acid ( 2- pyridinyl ethyl¬ ene )hydrazida; 4-methyl-2-pyridinecarboxylic acid (α-2-pyridinylbenzylidene)- hydrazide; picolinic acid (α-2-pyridinylbenzylidene)hydrazide; 5-n-butyl-2-pyridinecarboxylic acid ( -pyridinylmethylene )hydrazide; 5-n- but yl-2-pyridinecar bo xylic acid (3-pyridinylmethylene)hydrazide; 5-n-butyl-2-pyridine car bo xylic acid (2-pyridinylmethylene)hydrazide; isonicotinic acid N-oxide Cl-(4-pyridinyl)ethylidene]hydrazide; isonicotinic acid [1-( -pyridinyl )ethylidene]hydrazide 1-oxide; isonicotinic acid N-oxide [1-( -pyridinyl )ethylidene]hydrazide 1-oxide; isonicotinic acid [1-(6-methyl-2-pyridinyl)ethylidene]hydrazide; isonicotinic acid [1-(2-pyridinyl)ethylidene]hydrazide; nicotinic acid [1-(2-pyridinyl)ethylidene]hydrazide; nicotinic acid [1-(δ-methyl-2-pyridinyl)ethylidene]hydrazide; isonicotinic acid Cl-(3-pyridinyl)ethylidene]hydrazide-, nicotinic acid [1-(3-pyridinyl)ethylidene]hydrazide; isonicotinic acid (α-2-pyridinylbenzylidene)hydrazide; thiophene-2-carboxylic acid [1-( -pyridinyl )ethylidene]hydrazide; f uran- 2-^car bo xylic acid (2-pyridinyl_nethylane)hydrazide; qαinaldic acid (2-pyridinylmethylene ' )hydrazide; 5-n-butyl-2-pyridine carboxylic acid Cl * -methyl-3-pyridini__π]hydr__zide methanes lfonate; indazole-3-carboxylic acid (4-pyridinylmethylene)hydrazide; isonicotinic acid C(3-hydroxy-4-pyridinyl)methylene]hydrazide; and pyridazinecarboxylic acid ( -pyridinylmethylene )hydrazide . 8. A compound, hydrate or pharmaceutically acceptable salt thereof according to Claim 7 wherein X is selected from (a) hydrogen; Co) C-j- C * ιo alkyl; (c) C -C6 alkenyl; (d) C2-C6 alkynyl; (e) cyclo (C3-C10) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C alkenyl, 0*-- C4 alkoxy, tri luoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1 -methyl pyrrolidinyl; (i) 1-methylpiperidinyl; (j ) C -C6 alkoxyalkyl; (k) cyclo(C3-Cιo)alkyl(C*|-C4)alkyl; (1) phenyl (C1-C4) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (m) phenoxy (C1-C4) alkyl optionally substituted with C-1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; or (n) naphthyl- (Cι~C3)al yl optionally substituted with one or C-j-Ci * . alkyl, C1-C alkoxy, halo, o trifluoromethyl; (o) C*|-C6 alkoxy; (p) diphenylmethoxy; (q) cyclo(C3-C6)alkyloxy optionally substituted with one or two C1-C3 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C-j— C1 alkyl, C-|-C_ι alkoxy, halo, or trifluoromethyl; or (s) benzyloxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or tri¬ fluoromethyl. with the proviso that when a 2-pyridinyl acylhydrazone and R- * , R2 and R4 are hydrogen, R3 is not benzyl; (u) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoro¬ methyl, C -C6 dialkylamino, C1-C3 alkylthio, nitro, or phenoxy optionally substituted with one, 2 or 3 C---C4 alkyl, C-J-C3 alkoxy, halo, or tri¬ fluoromethyl; (v) phenyl optionally substituted with the divalent C1-C alkylenedioxy; and (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C1-C3 alkylthio, nitro; (x) bridged polycyclic hydrocarbon substituents of six to 10 nuclear carbons, optionally substituted with one, 2 or 3 (C -|— C3) alkyl groups; (y) perhalo(C*ι*-C7) alkyl. 9. A compound, hydrate or pharmaceutically acceptable salt thereof according to Claim 7 wherein X is phenyl substituted with one, 2 or 3 CI-C4 alkyl, C1-C3 alkoxy, trifluoromethyl, a halogen atom, 0-1-03 alkylthio, phenoxy optionally substituted with one, 2 or 3 C-1-C4 alkyl, C-J-C3 alkoxy, halo, or trifluoromethyl. 10. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 9 wherein the compound is a 3- or 4-pyridinyl acyl¬ hydrazone. 11. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 9 wherein phenyl is subsituted with one, 2 or 3 C1-C3 alkyl, C1-C3 alkoxy, or a chloro atom. 12. A compound, hydrate or a pharmaceuticall acceptable salt thereof, according to Claim 9 wherein R3 is selected from the group consisting of hydrogen, methyl or ethyl and R4 is hydrogen. 13- A compound, hydrate or a pharmaceutically acceptable salt thereof, according to Claim 9 wherein phenyl is substituted with one, 2 or 3 methyl, ethyl, methoxy, ethoxy, tri luoromethyl, or chloro. 14. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 7 wherein X is (o) C---C6 alkoxy; (p) diphenylmethoxy; (q) cyclo(C3-C6)alkyloxy optionally substituted with one or two 0*1-03 alkyl; (r) phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C*ι -C4 alkoxy, halo, or trifluoromethyl; or (3) benzyloxy optionally substituted with one, 2 or 3 C1-C alkyl, C1-C4 alkoxy, halo, or tri¬ fluoromethyl; with the proviso that when a .2-pyridinyl acylhydrazone and R * ι , R2 and R4 are hydrogen, R3 is not benzyl. 15. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 7 wherein X is (a) hydrogen; (b) C1-C10 alkyl; (c) C -C6 alkenyl; (d) C2-C6 alkynyl; (a) cyclo(C3-Cιo)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C alkenyl, C1-C4 alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1- raethylpyrrolidinyl; (i) 1 -methyl piperidinyl; (j) C2-C6 alkoxyalkyl; (k) cyclo(C3 * -C-Jo )a *kyl ( C * ι-C4 ) alkyl; ( D phenyl ( C * ι-C4 ) alkyl optionally substituted with one, 2 or 3 C-1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (m) phenoxy (C1-C4) alkyl optionally substituted with C-j-04 alkyl, C1-C4 alkoxy, halo, or tri luoromethyl; or (n) naphthyl (0 * 1-03) alkyl optionally substituted with one or 2 C1-C4 alkyl, C-]-C4 alkoxy, halo, or trifluoromethyl. 16. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 7 wherein X is naphthyl or naphthyl substituted with one or 2 methyl, ethyl, methoxy, ethoxy, chloro atom or trifluoromethyl. 17- A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 7 selected from the group consisting of benzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #2); benzoic acid (o_-4-pyridinylbenzylidene)hydrazide hydrate (Cpd #8) 3-methylbenzoicacid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #11) 2-ethoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #14) 3-ethoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #15) 4-ethoxy benzoic acid [1-( 4-pyridinyl ) ethyl i dene ]hyd azide (Cpd #16) 3,4,5-trimethoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #17); 3, 4-dimethoxybenzoic acid [1-(4-pyridinyl)ethyiidene]hydrazide (Cpd #18); piperonylic acid (4-pyridinylmethylene)hydrazide (Cpd #19); 2-phenoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #20); 3-methoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #22); 3,5-dimethoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #23); 2, 4-dichlorobenzoic acid [1-( 4-pyridinyl ) ethyl idene ]hydr azide (Cpd #26); 3, 4-dichlorobenzoic acid [1-( 4-pyridinyl)ethylidene]hydrazide (Cpd #27); 2, 4-dichlorobenzoic acid ( -pyr idinylraethylene)hydr azide (Cpd #28); 2-methoxybenzoic acid ( -pyridinylmethylene )hydrazide monohydrate (Cpd #30); 3 -met o y ben zoic acid (4-pyridinylmethylane)hydrazide (Cpd #31); 3-methylbenzoic acid ( -pyridinylmethylene )hydrazide (Cpd #31 A); -ethox ben zoic acid (4-pyridinylmethylene)hydrazide (Cpd #34); 3,5-dimethoxybenzoic acid ( -pyridinylmethylene )hydrazide (Cpd #35); 2-chlorobenzoic acid ( -pyridinylmethylene )hydrazide (Cpd #36); 4-( 1 , 1-dimethylethyl)benzoic acid (2-pyridinylmethylene)hydrazide hydrate (Cpd #40); 4-( 1 , 1-*dimethylethyl)benzoic acid (3-pyridinylmethylene)hydrazide hemihydrate (Cpd #41); 4-( 1 , 1-dimethylethyl)benzoic acid [1-(3-pyridinyl)ethylidene]- hydrazide (Cpd #42); 2-pheno ybenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #43); 2-ethoxybenzoic acid ( -pyridinylmethylene )hydrazide (Cpd #44); 2-ethoxybenzoic cid [1-(2-pyr.idinyl)propylidene]hydrazide (Cpd #45) 2-ethoxybenzoicacid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #46) benzoicacid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #48) 2-phenoxybenzoic acid [1-( 4-pyridinyl ) ethyl i dene Jnydr zide 1-oxide (Cpd #49); benzoic acid C ' i-(4-pyridinyl)propylidene]hydrazida (Cpd #51); 4-chlcro benzoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #52); benzoic acid 1-methyl-2-[1*-(4-pyridinyl)ethylidene]hydrazide (Cpd #55); ' • 2-methoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #56); 2-methoxybenzoic acid C(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #57); benzoic cid [1-(4-pyridinyl)pentylidene]hydrazide (Cpd #60); benzoicacid [2-phenyl-1-( -pyridinyl ) ethyl i dene ]hydr a zide (Cpd #61 ); benzoic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #67); ethyl [1-( -pyridinyl ) ethyl idene) ca bazata (Cpd #72); ethyl (3-pyridinylmethylene)carbazate (Cpd #74); 1 , 1-dimethylethyl [1-(4-pyridinyl)ethylidene]car'oazate (Cpd #76); benzyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #79); diphenylmethyl [ 1-(4-pyridinyl)ethylidene]car'oazate (Cpd #80); diphenylmethyl [1-(2-pyridinyl)ethylidene]carbazate (Cpd #80 A); methyl (4-pyridinylmethylene) carbazate hydrate (Cpd #83); benzyl (4-pyridinylmethylene)carbazate (Cpd #84); methyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #85); diphenylmethyl (4-pyridinylmethylene)carbazate (Cpd #86); 4-chlorobenzoic acid ( 4-pyridinylmethylene )hydrazide 1-oxide (Cpd #86 A) ; ethyl [ 1-( 3- pyridinyl )ethylidene] carbazate (Cpd #89); 1 , 1-dimethylethyl [1-(4-pyridinyl)propylidene]carbazate (Cpd #91); benzyl [1-( 4-pyridinyl ) propyl idene] car azate (Cpd #92); methyl Cl-(4-pyridinyl)propylidene]carbazate (Cpd #93); phenyl [1-( - pyridinyl) ethyl idene] carbazate (Cpd #94); phenyl [1-(4-pyridinyl)ethylidene]carbazate monohydrochlori e (Cpd #95); 5-methyl-2-(1 -methyl ethyl )cyclohexyl [ 1-( 4-pyridinyl) ethyl idene ]•- carbazate (Cpd #97); ethyl [1-(4*-pyridinyl)pentylidene]carbazate (Cpd #99); phenyl [1-(4-pyridinyl)butylidene]carbazate monohydrochloride (Cpd #100); phenyl (4-pyridinylmethyiene)carbazate monohydrochloride (Cpd #101); 1 , 1-dimethylethyl [1-(3-pyridinyl)propylidene]carbazate (Cpd #103); methyl [1-(2-pyridinyl)propylidene]carbazate (Cpd #104); ethyl [1-(2-pyridinyl)propylidene]carbazate (Cpd. #105); 1 , 1-dimethylethyl [1-(2-pyridinyl)propylidene]carbazata (Cpd #106); ethyl [1-(3-pyridinyl)propylidene]carbazate (Cpd #107); 1 , 1-dimethylethyl [1-(4-pyridinyl)butylidene]carbazate (Cpd #108); ethyl [1-(4*-pyridinyl)ethylidene]carbazata 1-oxide (Cpd #109); ethyl [1-( 4-pyridinyl )butylidene]carbazate (Cpd #110); methyl [1-( 4- pyridinyl) ethyl idene] carbazate 1-oxide (Cpd #111); phenyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #11 ); 1 , 1-dimethylethyl [1-(4-pyridinyl ) butylidene ]car bazate 1-oxide ethyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #114); 1 , 1-dimethylethyl [3-methyl-1-(4-pyridinyl ) butylidene ]ca bazate (Cpd #116); phenyl [1*( 4-pyridinyl )ethylidene]carbazate 1-oxide monohydrochloride (cpd #118); benzyl [1-( 4-pyridinyl )ethylidene]carbazate 1-oxide hydrate (Cpd #119); 1 , 1-dimethyl.ethyl [1- ( 4-pyr idinyl)ethyiidene]carbazate 1-oxide (Cpd #120); 4-trif luoromethylbenzoic acid [1-( 4-pyr idinyl) ethyl idene ]hyd azide (Cpd #121); 4-dimethylaminobenzoic acid (2-pyridinylmethylene)hydrazide (Cpd #122); 4-dimethylaminobenzoic acid (3~pyridinylmethylene)hydrazide (Cpd #123); 4-dimethylaminobenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #125); 4-dimethylaminobenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #126); 4-trifluoromethylbenzoic acid [1-(3~pyridinyl)ethylidene]hydr azide (Cpd #127); 4-methoxybenzyl (3-ρyridinylmethylene)carbazate (Cpd #128); 4-methoxybenzyl (4-pyridinylmethylene) car azate (Cpd #129); 4-metho ybenzyl [ 1 -(3-pyridinyl) ethyl idene ]car bazate monohydrate (Cpd #130); 4-methoxybenzyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #131); ethyl C(6-methyl-2-pyridinyl)methylene]car azate hydrate (Cpd #132); 4-methoxybenzyl (2-pyridinylmethylene)carbazate (Cpd #133); acetic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #136); (2, 4,5-trichlorophenoxy)acetic acid [1- (4-py idinyl)ethylidene]hydra- zide (Cpd #137); formic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #138); formic acid [ 1-( 2-pyridinyl )ethylidene]hydrazide (Cpd #139); formic acid [1-(4-pyridinyl)pentylidene]hydrazide (Cpd #1 1); phenylacetic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #142); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #1 4); butyric acid [1-( -pyridinyl )ethylidene]hydrazide oxalic acid salt (Cpd #145); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide pamoic acid salt (Cpd #1 6); butyric acid [1 -( -py idinyl)ethylidene]hydrazide 1-hydroxy-2- naphthoic acid salt (Cpd #1 7); butyric acid [1 -( 4-py idinyl)ethylidene]hydrazide 3-hydroxy-2- naphthoic acid salt (Cpd #148); butyric acid [1-( 4-pyr idinyl)ethylidene]hydrazide malonic acid salt (Cpd #1 9); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide phenylacetic acid salt (Cpd #150) ; butyric acid [1-( 4-pyridinyl )ethylidene]hydrazide phenoxyacetic acid salt (Cpd #151); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide phenylthioacetic acid salt (Cpd #152); butyric acid ( 4-pyridinylmethylene )hydr azide (Cpd #153); butyric acid (4-pyridinylmethylene )hydrazide oxalic acid salt (Cpd #154); formic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #155); butyric acid [1-(3~pyridinyl)ethylidene]hydrazide (Cpd #156); 3-cyclohe anepropionic acid [1-( -pyridinyl ) ethyl idene]hydr azide 1-oxide (Cpd #160); 1-naphthalenecarboxylic acid [1-( 4-pyridinyl )ethyl idene ]hydr azide (Cpd #161); 2-naphthalenecar bo xylic acid [ 1 * -( 4-pyridinyl) ethyl idene ]hydr azide (Cpd #162); _ . • 1-naphthaleneacetic acid ( 4-pyridinylmethylene )hydrazide (Cpd #164); 1-naphthaleneacetic acid [ 1 -(3~pyridinyl)ethylidine]hydrazide (Cpd #165); 1-naphthaleneacetic acid [1-( 4-pyridinyl )ethylidine]hydrazide (Cpd #166); cyclohexanecarboxylic acid [( 6-methyl-2-pyridinyl)methylene]hydrazide monohydrate (Cpd #167); butyric acid [(6-methyl-2-pyridinyl)raethylene]hydrazide (Cpd #168); 1-naphthalenecarboxylic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #171); 1-naphthylenecarboxylic acid (3~pyridinylmethylene)hydrazide (Cpd #172); nicotinic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #174); 2-thiophenecarboxylic acid [1-( 4-pyridinyl) ethylidene]hydrazide (Cpd #177); 2-thiophenecarboxylic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #178); 2-thiophenecarboxylic acid (3~pyridinylmethylane)hydrazide (Cpd #179); 1-naphthalenecarboxylic acid ( -pyridinylmethylene )hydrazide (Cpd #180); 2-thiophenecarboxylic acid ( -pyridinylmethylene )hydrazide (Cpd #181); 3,4,5-trimethoxybenzoic acid (4-pyridinylmethylene)hydrazide mono¬ hydrate (Cpd #182); cyclobutanecarboxylic acid [( 6-methyl-2-pyridinyl)methylane]- hydrazide (Cpd #183); acetic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #184); 4-chlorobenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #189); 4-chlorobenzoic acid [1-(3-pyridinyl) ethyl idene ]hydrazide (Cpd #190); 4-chlorobenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #193); 4-chlorobenzoic acid (3-pyridinylmethylene)hydrazide (Cpd #194); phenylacetic acid [1-( -pyridinyl )propylidine]hydrazide (Cpd #197); nicotinic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #198); 2,2-dimethyl-3-(2-methylpropenyl).cyclopropane carboxylic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #201); 2-methylpropionic acid [1-( -pyridinyl ) ethyl i dene ]hydra zide 1-ox-ide (Cpd #202); formic acid [1-( 4-pyridinyl )ethylidene]hydrazide 1-oxide (Cpd #203); acetic acid [1-( -pyridinyl ) ethyl i dene ]hydrazide 1-oxide (Cpd #205); cyclopropanecar bo xylic acid [1- (4-pyridinyl) ethyl idene]hydr azide 1-oxide (Cpd #206); formic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #207); cyclo pro pane car bo xylic acid [ 1-( 4-pyridinyl) butyl idene ]hydrazide 1-oxide (Cpd #208); 2-methylpropionic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #209); butyric acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #211); acetic acid [ 1 -( - pyridinyl) butyl i dene ]hydra zide 1-oxide (Cpd #212); cyclohexanecarboxylic acid [1-(4*-pyridinyl)butylidene]hydrazide 1- oxide (Cpd #213); 2-furoic acid [1-(3-pyridinyl)ethylidine]hydrazide monohydrate (Cpd #214); 2-furoic acid [1-(2-pyridinyl)ethylidine]hydrazide (Cpd #215); 1 -naphthalene car o xylic acid [1-(4-pyridinyl) propyl idene ]hydrazide (Cpd #222); 2-furoic acid [1-(3*-pyridinyl)ethylidene]hydrazide (Cpd #225); phenyl [1-(3-pyridinyl)propylidene ]car bazate monohydrochloride (Cpd #226); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide 1- oxide (Cpd #227); 3-ethoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #228); 2-methoxybenzoic acid ( 4-py idinylmethylene)hydrazide 1-oxide (Cpd #229); 2-ρhenoxybenzoic acid ( -pyr idinylmethylene)hydrazide 1-oxide (Cpd #236): 2-thiophenecarboxylic acid (4-pyridinylmethylene)hydrazide 1-oxide (Cpd #239); 3-cyclohexanepropionic acid ( 4-pyr idinylmethylene)hydr azide 1-"oxide (Cpd 241); butyric acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #242); cyclo pro pane ca bo xylic acid [3-methyl-1-( -pyridinyl) but ylidene]- hydrazide (Cpd #244); cyclohexanecarboxylic acid (cyclopentyl-4-pyridinylmethylane)- hydrazide (Cpd #246); butyric acid (cyclopentyl-4-pyridinylmethylene)hydrazide (Cpd #247); cyclopropanecar bo ylic acid [1 -(4-pyridinyl) butylidene ]hydr zide (Cpd #248); 2-methylpropionic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #249); 3-cyclohe anepropionic acid [1-( 4-pyridinyl )butylidene]hydr azide (Cpd #250); cyclohexaneacetic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #252); cyclohexanecar oxylic acid [1 -(-4-pyridinyl )butyl idene ]hydr azide (Cpd #253); ' 2-methylpropionic acid [3 i_ methyl-1-(4-pyridinyl)butylidene]hydrazide (Cpd #254); cyclohexane car bo ylic acid [ 3-methyl- 1 -(4-pyridinyl) ut li dene )- hydrazide (Cpd #255); 3-ethoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #262); formic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #263); cyclobutanecarboxylic acid ( 4-pyridinylmethylene )hydrazide (Cpd #264); cyclohexanecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #270); formic acid [1-(3~pyridinyl)proρylidene]hydrazide (Cpd #271); 2-methylpropionic acid ( -pyridinylmethylene )hydrazide (Cpd #272); cyclopropanecarboxylic acid [1 -(4-pyridinyl) ethyl i den e]hydr azide (Cpd #273); cyclopropanecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #274); 2-methylpropionic acid [1-(4-ρyridinyl)ethylidene]hydrazide (Cpd #275); 3-cyclohexanepropionic acid [4-(pyridinyl)ethyliden.e]hydrazide (Cpd #276); 3-cyclohexanepropionic acid (4-pyridinylmethylene)hydrazide (Cpd #277); cyclohexaneacetic acid (4-pyridinylmethylene)hydrazide (Cpd #278); cyclohexanecarboxylic acid [l-(3-pyridinyl)ethylidene]hydrazide (Cpd #279); cyclohexaneacetic acid [1-( -pyridinyl )ethylidene]hydrazid ' e (Cpd #280); 3-ethoxypropionic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #281); cyclobutanecarboxylic acid [1-( 4-pyridinyl )propylidene]hydr zide (Cpd #282); 3-ethoxypropionic acid ( -pyr idinylmethylene)hydr azide (Cpd #283); cyclohexanecarboxylic acid [1-(4-pyridinyl)athylidene]hydrazide 1- oxide (Cpd #287); cyclohexaneacetic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #288); butyric acid [ 1-(4-pyridinyl)ethylidene]hydrazide 1-oxide hydrate (Cpd #289); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #290); 3-trifluoromethylbenzoic acid [1-( 2-pyridinyl )ethylidene]hydrazide (Cpd #301); 2-fluorobenzoic acid (2-pyridinylmethylene)hydrazide (Cpd #303); 2-fluorobenzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #304); 3-fluorobenzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #305); 3-fluorobenzoic acid (2-pyridinylmethylene)hydrazide (Cpd #306); 2-methylcyclopropane carboxylic acid (2-pyridinylmethylene)hydrazide (Cpd #307); piperonylic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #308); propanoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #310); propanoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #311); 2-methylcyclopropane carboxylic acid [1-(3-pyridinyl)propylidene]- hydrazide (Cpd #313); 3-trifluoromethylbenzoic acid (3-pyr-idinylmethylene)hydrazide (Cpd #315); . . 3-trifluoromethylbenzoic acid [1-(3~pyridinyl)propylidene]hydrazide (Cpd #316); 3-trifluoromethylbenzoic acid [1-(3-pyridinyl )ethyl idene ]hydr azide (Cpd #317); 2-fluorobenzoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #318); 3-fluorobenzoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #319); 2-fluorobenzoic acid (3~pyridinylmethylene)hydrazide (Cpd #320); 2-fluorobenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #321); 3-fluorobenzoic acid (3~pyridinylmethylene)hydrazide (Cpd #322); 3-fluorobenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #323); 4-phenylbutyric acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #324); • 4-phenylbutyric acid (3-pyridinylmethylene)hydrazide (Cpd #325); aceticacid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #327); 2-methyl prop ionic acid [1-( β -methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #328); butyric acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #329); propanoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #330); ethyl [1-(6-methyl-3-pyridinyl)ethylidene]carbazate (Cpd #332); 1 , 1 -dimethyl ethyl[1-(6-methy 1-3- pyridinyl) ethyl idene] car bazate (Cpd #333); phenyl[1-(6-methyl-3-pyridinyl)ethylidene]carba__atemonohydroohloride (Cpd #334); benzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #336); 4-chlorobenzoi c acid [ 1 - ( 6-methyl-3-pyr i inyl )ethyl idene]hydrazide (Cpd #337); 2- et o y ben zoic acid [1-(6-methyl-3-pyr idinyl) ethyl idene ]hydr azide (Cpd #338); 4-ethoxybenzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #339); 2-methyl-1-naphthaleneacetic acid [1-(4-pyridinyl)ethylidene]- hydrazide (Cpd #341); piperonylic acid [1 -( -pyridinyl )ethylidene]hydrazide 1-oxide hydrate (Cpd #346); piperonylic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #347); 3 , -dimethoxyphenylaceti c acid [ 1 -( 4-pyridinyl ) ethylidene ]hydrazide 1-oxide hydrate (Cpd #348); 3, 4-dimethoxyphenylacetic acid (4-pyridinylmethylane)hydrazide (Cpd #349); propanoic acid ( 4-py idinylmethylene)hydr azide (Cpd #351); propanoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #352); 1 -methyl cyclopropanecar bo xylic acid [1- (4-pyridinyl )ethyl idene ]- hydrazide (Cpd #354); 3-trifluoromethylbenzoic acid ( 4-py idinylmethylene)hydrazide (Cpd #358); 2-methylcyclopropanecarboxylic acid [ 1-( -pyr idinyl )propylidene ]- hydrazide (Cpd #360); 2-fluorobenzoic acid [1-( -pyridinyl )propylidene]hydrazids (Opd #362); 3-fluorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #363 ) ; 2-fluorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #364); 2-fluorobenzoic acid [1-(4-pyridinyl ' )ethylidene]hydrazide (Cpd #365); 3-fluorobenzoic acid ( 4-pyridinylmethylene )hydr azide (Cpd #366); 4-phenylbutyric acid [1 -(4-pyridinyl) ethyl idene ]hydrazide (Cpd #367); 4-phenylbutyric acid [1-(4*-pyridinyl)propylidene]hydrazide (Cpd #368); 4-phenylbutyric acid ( 4-py idinylmethylene)hydrazide (Cpd #369); 3-fluorobenzoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #370); 2- methyl ben zoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #371); 4 -methyl ben zoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #373 ) ; 2-chlorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd- #374); acetic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #377); 2-furoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #378); isonicotinic acid [1*^(4-pyridinyl)propylidene]hydrazide (Cpd #379); propanoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #380); 2— methyl propanoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #381); 2-thiophenecarboxylic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #382); phenyl [1-( 4-pyridinyl)propylidene]carbazate monohydrochloride (Cpd #383); 2-ethoxybenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #385); formic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #386); 4-ethoxybenzoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #388); . 3 -chloro ben zoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #389); butyric acid (2-chloro-3-pyridinylmethylene)hydrazide (Cpd #391); propanoic acid (3-hydroxy-2-pyridinylmethylene)hydrazide (Cpd #393); formic acid [1-(3-chloro-4-pyridinyl)ethylidene]hydrazide (Cpd -#394); butyric acid [1-(3-chloro-4-pyridinyl)ethylidene]hydrazide (Cpd #395); methyl [1-(3-chloro-4-pyridinyl)ethylidene]carbazate (Cpd #396); propanoic acid [1-(2-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #399); butyric acid [1-(2-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #400); 2-methylpropanoicacid [1-(2-chloro-3-pyr idinyl) ethyl idene]hydr azide (Cpd #401); cyclopropanecarboxylic acid [1-(2-chloro-3-pyridinyl)ethylidene]- hydrazide (Cpd #402); acetic acid [1-(6-chloro-3-pyridinyl)ethylidene_hydrazide (Cpd #410); propanoic acid [1-(6-chloro-3-pyridinyl)ethylidene]hydr azide (#411); .butyric acid [1-(6-chloro-3-pyridinyl) ethylidene Jhydrazide (Cpd #412); 2-methylpropanoicacid [1-(6-chloro-3-pyr idinyl ) ethyl idene]hydrazide (Cpd #413); cyclopropanecarboxylic acid Cl-(6-chloro-3-pyridinyl) ethyl idene]-* hydrazide (Cpd #414); cyclohexaneacetic acid [1-(6-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #415); benzoic acid [1-(6-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #416); benzoic acid [( 1 , 3~dioxan-5-yl )-3-pyridinylmethylene]hydrazide (Cpd #421); ethyl [(1 ,3-dioxan-5-yl)-3-pyridinylmethylane]carbazate (Cpd #422) ; benzoic acid [( 1 ,3-dioxan-5-yl)-4-pyridinylmethylene]hydrazide (Cpd #423); formic acid ( 4-py idinylmethylene)hydr azide (Cpd #424); formic acid (3~ρyridinylmethylene)hydrazide (Cpd #425); butyric acid [( 1 , 3-dioxan-5-yl )-3~pyridinylmethylane)hydrazide (Cpd #430); ethyl [(1 ,3-dioxan-5-yl)-4-pyridinylmethylene]carbazate (Cpd #431 ) ; ethyl [(1 ,3-dioxan-5-yl)-3-pyridinylmethylene]ca azate (Cpd #432); propanoic acid [( 1 , 3-dioxan-5-yl)-4-pyridinylmethylene]hydrazide (Cpd #433); propanoic acid [(1 , 3-dioxan-5-yl)-3-pyridinylmethylene]hydrazide (Cpd #434); butyric acid [( 1 , 3-dioxan-5-yl)-4-pyridinylmethylene]hydrazide (Cpd #435); methyl [(1 ,3-dioxan-5-yl)-4-pyridinylmethylane]carbazate (Cpd #436). 18. A compound, hydrate or pharmaceutically acceptable salt thereof, according to Claim 7 selected from the group consisting of benzoic acid [1-(3-pyridinyl) ethyl idene ]hydrazide (Cpd #2); 4-ethoxybenzoicacid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #16); butyric acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #1 4); butyric acid ( 4-pyridinylmethylene )hydrazide (Cpd #153); 3-cyclohexanepropionic acid [1-( 4-pyridinyl) ethyl idene ]hyd azide 1-oxide (Cpd #160); formic acid [1-(4-pyridinyl)ethylidene] ' hydrazide 1-oxide (Cpd #203); or 2-methylpropionic acid [1-( 4-py idinyl) ethyl idene ]hydr azide (Cpd #275). 19. An anthelmintic composition for administration to animal3 comprising a physiologically acceptable carrier and adjuvants, and at least an effective anthelmintic amount of a pyridinyl acylhydrazone, hydrate or pharmaceuticall acceptable salt thereof of the formula: " wherein X is selected from (a) hydrogen; (b) C-]-C-*o alkyl; (c) C2-C6 alkenyl; (d) C2-C6 alkynyl; (e) cyclo(C3-C*ιo)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C2-C alkenyl, C1-C4 alkoxy, trifluoromethyl, or halo; (f) pyrrolidinyl; (g) piperidinyl; (h) 1*-methylpyrrolidinyl; (i) 1-methylpiperidinyl; (j) C -C5 alkoxyalkyl; (k) cyclo(C3-Cιo)alkyl- (C 1-0 ) alkyl; (1) phenyl(C*ι-C4)alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (m) phenoxy * - ( C-|-C4)alkyl optionally substituted with C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (n) naphthyl(C*ι-C3)alkyl optionally substituted with one or 2 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (o) C---C6 alkoxy; (p) diphenylmethoxy; (q) cyclo(C3~C6)alkyloxy optionally substituted with one or two C-j— C3 alkyl; r) phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, or trifluoromethyl; (s) benzyloxy optionally substituted with one, 2 or 3 C1-C alkyl, C- j - C4 alkoxy, halo, or trifluoromethyl; with the proviso that when a 2- pyridinyl acylhydrazone and R* , 2 and R4 are hydrogen, R3 is not benzyl; (t) heteroaromatic optionally substituted with one, 2 or 3 C1-C alkyl, C1-C3 alkoxy, halo, C1-C3 alkylthio, or trifluoromethyl; (u) phenyl optionally substituted with one, 2 or 3 C-j -C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, 0*1-03 alkylthio, nitro, or phenoxy optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C3 alkoxy, halo, or trifluoromethyl; (v) phenyl optionally substituted with the divalent C1-C2 alkylenedioxy; (w) naphthyl optionally substituted with one or 2 C1-C4 alkyl, C1-C3 alkoxy, halo, trifluoromethyl, C2-C6 dialkylamino, C1-C3 alkylthio, nitro; (x) bridged polycyclic hydrocarbon substituents of six to 10 nuclear carbons, optionally substituted with one, 2 or 3 ( C1-C3) alkyl groups; (y) perhaloζCi-Cγ) alkyl; wherein R* and R , being the same or different, are hydrogen; hydroxy; C-J-C alkyl; C1-C3 alkoxy; C1-C3 alkylthio; halo or trifluoromethyl; wherein R3 is hydrogen; C1-C4 alkyl; cyclo(C3-C6)alkyl optionally substituted with one, 2 or 3 C1-C3 alkyl; phenyl optionally substituted with one, 2 or 3 C-1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (0*1-03) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or 0*1-03 alkoxy; or 1 , 3-dioxacyclohexan-5-yl; wherein R4 is hydrogen; C1-C2 alkyl; cyclo(C3-C6)alkyl optionally substituted with one, 2 or 3 C-J-C3 alkyl; phenyl optionally substituted with one, 2 or 3 C1-C alkyl " , ' halo, trifluoromethyl, or C1-C3 alkoxy; phenyl (C1-C3) alkyl optionally substituted with one, 2 or 3 C1-C4 alkyl, halo, trifluoromethyl, or C1-C3 alkoxy; and wherein n is zero or one . 20. The composition of Claim 19 in which the compound, hydrate or pharmaceutically acceptable salt thereof is selected from the group consisting of benzoic acid [1-( 2-pyridinyl) ethyl idene ]hydr azide (Cpd #1) benzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #2) benzoic acid [1-(4-pyridi._yl)ethylidene]hydrazide (Cpd #3) benzoic acid (3-pyridinylmethylene)hydrazide (Cpd #6); benzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #7); benzoic acid (α-4-pyridinylbenzylidene)hydrazide hydrate (Cpd #8) 3-methylbenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #11) 2-ethoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #14) 3-ethoxybenzoicacid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #15) 4-ethoxybenzoicacid [1 -(4-pyridinyl) ethylidene Jnydrazide (Cpd #16) 3,4,5-trimethoxybenzoic acid [1- (4-pyr idinyl) ethyl idene ]hydrazide (Cpd #17); 3, 4-dimethoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #18); piperonylic .acid (4-pyridinylmethylene)hydrazide ' (Cpd #19); 2-phenoxybenzoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #20); 3-methoxybenzoicacid [1-(4 pyridinyl)ethylidene]hydrazide (Cpd #22); 3,5-dimethoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #23); 2, 4--dichlorobenzoic acid [1-(4-pyridinyl )ethylidene]hydrazide (Cpd #26); 3, 4-dichlorobenzoic acid [1 -( 4-pyridinyl )ethylidene]hydrazide (Cpd #27); 2, 4-dichlorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #28); 2-methoxybenzoic acid (4-pyridinylπ_ethylene)hydrazide monohydrate (Cpd #30); 3 -methoxy ben zoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #31); 3-methylbenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #31 A); 4-ethoxybenzoic acid ( 4-pyr idinylmethylene)hydrazide (Cpd #34); • 3,5-dimethoxybenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #35); 2-chlorobenzoic acid ( 4-pyr idinylmethylene )hydrazi e * (Cpd #36); 4-( 1 , 1-dimethylethyl)benzoic acid (2-pyridinylmethylene )hydrazide hydrate (Cpd #40); 4-0 , 1-dimethylethyl )benzoic acid (3-pyridinylmethylene)hydrazide hemihydrate (Cpd #41); 4-0 , 1-dimethylethyl)benzoic acid [1-(3-pyridinyl)ethylidene]- hydrazide (Cpd #42); 2-phenoxybenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #43); 2-ethoxybenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #44); 2-ethoxybenzoicacid [1-(2-pyridinyl)propylidene]hydrazide (Cpd #45) 2-ethoxybenzoicacid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #46) benzoicacid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #48) 2-phenoxybenzoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide 1-oxide (Cpd #49); benzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #51); 4-chlorobenzoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #52); benzoic acid 1-methyl-2-[1-(4 ' -pyridinyl)ethylidene]hydrazide (Cpd #55).; 2-methoxybenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #56); 2-methoxybenzoic acid [(6-methyl-2-pyr idinyl )methylene]hydrazide (Cpd #57); benzoic acid [1*-(4-pyridinyl)pentylidene]hydrazide (Cpd #60); benzoicacid [2-phenyl-1-(4-pyridinyl)ethylidene]hydrazide (Cpd #61 ); benzoicacid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #67); 2-nitrobenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #69); ethyl [1-(2-pyridinyl)ethylidene)carbazate (Cpd #70); ethyl [1-( -pyridinyl) ethyl idene) car azate (Cpd #72); ethyl ( 2-pyridinylmethylene )carbazate (Cpd #73); ethyl (3-pyridinylmethylene)car bazate (Cpd #74); ethyl (4-pyridinylmethylene)carbazate (Cpd #75); 1 , 1-dimethylethyl [1-( 4-pyridinyl) ethyl idene] car bazate (Cpd #76); benzyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #79); diphenylmethyl [1-( 4-pyridinyl )ethyli dene ]car bazate (Cpd #80); di henylmethyl [1-(2-pyridinyl)ethylidene]carbazate (Cpd #80A) ; methyl (4-pyridinylmethylene) carbazate hydrate (Cpd #83); benzyl ( 4-pyridinylmethylene )carbazate (Cpd #84); methyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #85); diphenylmethyl (4-pyridinylmethylene)carbazate (Cpd #86); 4-chlorobenzoic acid ( 4-pyridinylmethylene )hydrazide 1-oxide (Cpd #86 A) ; methyl [1 i -(3-pyridinyl)ethylidene]carbazate (Cpd #89); 1 , 1-dimethylethyl [1-( 4-pyridinyl ) propyl idene] ca bazate (Cpd #91); benzyl [1-(4-pyridinyl)propylidene]carbazate (Cpd #92); methyl [1-*( 4-pyridinyl )propylidene]car bazate (Cpd #93); phenyl [1-(4-pyridinyl)ethylidene]carbazate (Cpd #94); phenyl [1-(4-pyridinyl)ethylidene]carbazate monohydrochloride (Cpd #95); 5 -met hyl-2- ( 1 - ethylethyl )cyclohexyl [ 1 - ( 4-pyr i dinyl )ethyl idene]- carbazate (Cpd #97); ethyl [1-(4-pyridinyl)pentylidene]carbazate (Cpd #99); phenyl [1-(4-pyridinyl)butylidene]carbazate monohydrochloride (Cpd #100); phenyl (4-pyridinylmethylene)car ' bazate monohydrochloride (Cpd #101); 1 , 1-dimethylethyl [1-(3-pyridinyl)propylidene]carbazate (Cpd #103); methyl [1-(2-pyridinyl)propylidene]carbazate (Cpd #104); ethyl [1 -(2-pyridinyl )propylidene]carbazate (Cpd #105); 1 , 1-dimethylethyl [1-(2--pyridinyl)propylidene]carbazate (Cpd #106); ethyl C 1 -( 3- py idinyl) propyl idene ]σa bazate (Cpd #107); 1 , 1-dimethylethyl [1-(4-pyridinyl)butylidene]carbazate (Cpd #108); ethyl [1-(4-pyridinyl)ethylidene]carbazate 1-oxide (Cpd #109); ethyl [1-(4-pyridinyl)butylidene]carbazate (Cpd #110); methyl [1-(4-pyridinyl)ethylidene]carbazate 1-oxide (Cpd #111); phenyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #112); 1 , 1-dimethylethyl [1-( 4-pyridinyl ) butylidene ]car bazate 1-oxide (Cpd #113); athyl [1-(4-pyridinyl)butylidene]carbazate 1-oxide (Cpd #114); 1 , 1-dimethylethyl [3-methyl-1-( 4-pyridinyl) but lidene] car bazate (Cpd #116); phenyl [1-(4-pyridinyl)ethylidene]car bazate 1-oxide monohydrochloride (Cpd #118); benzyl [1-(4-pyridinyl)ethylidene]carbazate 1-oxide hydrate (Cpd #119); 1 , 1-dimethylethyl [1-(4-pyridinyl ) ethylidene ]car bazate 1-oxide (Opd #120); 4-trif luoromethylbenzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #121); 4-dimethylaminobenzoic acid (2-pyridinylmethylene)hydrazide (Cpd #122); 4-dimethylaminobenzoic acid (3 _ pyridinylmethylene)hydrazide (Cpd #123); 4-dimethylaminobenzoic acid [1-(3~pyridinyl)ethylidene]hydrazide (Cpd #125); 4-dimethylaminobenzoic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #126); 4-trif luoromethylbenzoic acid [1-(3--pyridinyl)ethylidene]hydr azide (Cpd #127); 4-methoxybenzyl (3-pyridinylmethylene)carbazate (Cpd #128); 4-methoxybenzyl (4-pyridinylmethylene) carbazate (Cpd #129); 4-methoxybenzyl [1-(3-pyridinyl)ethylidene]carbazate monohydrate (Cpd #130); 4-methoxybe zyl [1-(4*-pyridinyl)ethylidene]carbazate (Cpd #131'); ethyl C(6-methyl-2-pyridinyl)methylene]ca bazate hydrate (Cpd #132); 4-methoxybenzyl (2-pyridinylmethylene)carbazate (Cpd #133); acetic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #136); ( 2, 4, 5-tri chlor ophenoxy) acetic acid [1 -(4-pyridinyl )ethylidene]hydra~ zide (Cpd #137); formic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #138); formic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #139); formic acid [1-(4-pyridinyl)pentylidene]hydrazide (Cpd #141 ) ; phenylacetic acid [(6-methyl-2-pyridinyl)methylene]hydrazide (Cpd #1 2); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide (Opd #144); butyric acid [1 -(4-pyridinyl) ethyl idene ]hydrazide oxalic acid salt (Cpd #145); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide pamoic acid salt (Cpd #146); butyric acid [1-( 4-pyridinyl)ethylidene]hydrazide 1-hydroxy-2- naphthoic acid salt (Cpd #147); butyric acid [1-( -pyridinyl )ethylidene]hydrazi da 3-hydroxy-2- naphthoic acid salt (Cpd #1 8); butyric acid [1-( 4-pyr idinyl )ethylidene]hydrazide malonic acid salt (Cpd #149); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide phenylacetic acid salt (Cpd #150); butyric acid [1 -(4-pyridinyl )ethylidene]hydrazide phenoxyacetic acid salt (Cpd #151); ' butyric acid [1-( 4-pyr idinyl) ethyl idene ]hyd azide phenylthioacetic acid salt (Cpd #152); butyric acid (4-pyridinylmethylene)hydrazide (Cpd #153); butyric acid (4-pyridinylmethylene ) hydra zide oxalic acid salt (Cpd #154); formic acid [1-( 4-pyridinyl) ethyl idene ]hyd azide (Cpd #155); butyric acid [1-(3-pyridinyl) ethylidene ]hydrazide (Cpd #156); phenylacetic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #157); 3-cyclohexanepropionic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #160); 1 -naphthalene carboxylic acid [ 1 - ( 4-py idinyl )ethyl idene ]hydr azide (Cpd #161); 2-naphthalenecar bo xylic acid [1-( 4-pyridinyl )ethyl idene Jhyd azide (Cpd #162); 1-naphthalεneacetic acid ( -pyridinylmethylene )hydrazide (Cpd #164); 1-naphthaleneacetic acid [1-(3-pyridinyl)ethylidine]hydrazide (Cpd #165); 1-naphthaleneacetic acid [1-( 4-pyr idinyl )ethylidine]hydrazide (Cpd #166); cyclohexanecarboxylic acid [( 6-methyl-2-pyridinyl)methylene]hydrazide monohydrate (Cpd #167); butyric acid [(6-methyl-2-pyridinyl)methylsne]hydrazide (Cpd #168); 1 -naphthalenecar boxyli c acid [ 1 -( 4-pyridinyl ) ethylidene Jhydrazide 1-oxide (Cpd #171); 1 -naphthylenecar bo xylic acid (3-pyridinylmethylene)hydrazide (Cpd #172); nicotinic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #174); 2-thiophenecarboxylic acid [ 1 -( -pyr idinyl ) ethyl i dene ]hydr a zide (Cpd #177); 2-thiophenecarboxyiic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #178); 2-thiophenecarboxylic acid (3-pyridinylmethylene)hydrazide (Cpd #179); 1-naphthalenecarboxylic acid ( -pyridinylmethylene )hydrazide (Cpd #180); 2-thiophenecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #181); 3, ,5- tri methoxy ben zoic acid ( -pyridinylmethylene )hydrazide mono¬ hydrate (Cpd #182); cyclobutanecarboxylic acid [( 6-methyl-2-pyridinyl)methylene]^ hydrazide (Cpd #183); acetic acid [(6-methyl-2-pyridinyl)methylane]hydrazide (Cpd #184); 4-chlorobenzoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide 1-oxide (Cpd #189); 4-chlorobenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #190) ; 4-chlorobenzoic acid ( -pyridinylmethylene )hydrazide (Cpd #193); 4-chlorobenzoic acid (3-pyridinylmethylene)hydrazide (Cpd #1 4); phenylacetic acid [1-( -pyridinyl )propylidine]hydrazide (Cpd #197); nicotinic acid [1-( 4-pyridinyl )ethyl idene ]hydr azide (Cpd #198); 2,2-dimethyl-3-(2-methylpropenyl)cyclopropane carboxylic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #201); 2-methylpropionic acid [1 -(4-pyridinyl) ethylidene Jhydrazide 1-oxide (Cpd #202); formic acid [1-( 4-pyridinyl )ethylidene]hyd azide 1-oxide (Cpd #203) ; acetic acid [1 -(4-pyridinyl) ethylidene ]hydrazide 1-oxide (Cpd #205); cyclopropanecarboxylic acid [1-( 4-pyridinyl )ethylidene]hydr azide 1-oxide (Cpd #206); formic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #207); cyclopropanecarboxylic acid [1 -(4-pyridinyl) butylidene ]hydr a zide 1-oxide (Cpd #208); 2-methylpropionic acid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #209); butyric acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #211); aceticacid [1-(4-pyridinyl)butylidene]hydrazide 1-oxide (Cpd #212); cyclohexanecarboxylic acid [1-(4-pyridinyl)butylidene]hydrazide 1- oxide (Cpd #213); 2-furoic acid [1-( 3 i_ pyridinyl)ethylidine]hydrazide monohydrate (Cpd #214); 2-furoic acid [1-(2-pyridinyl)ethylidine]hydrazide (Cpd #215); isonicotinic acid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #217); isonicotinic acid (2-pyridinylmethylene)hydrazide (Cpd #221); 1-naphthalenecarboxylic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #222); 2-furoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #225); phenyl [1-(3-pyridinyl)propylidene]carbazate monohydrochloride (Cpd #226); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide 1- oxide (Cpd #227); 3-ethoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #228); 2-methoxybenzoic acid (4-pyridinylmethylane)hydrazide 1-oxide (Cpd #229); 2-phenoxybenzoic acid (4-pyridinylmethylane)hydrazide 1-oxide (Cpd #236): 2-thiophenecarboxylic acid ( 4-pyridinylmethylene )hydrazide 1-oxide (Cpd #239); 3-cyclohexanepropionic acid ( 4-pyridinylmethylene )hydrazide 1-oxide (Cpd 241); butyric acid [1-(4*-pyridinyl) butyl idene ]hydrazide (Cpd #242); cyclopropanecarboxylic acid [ 3-methyl- 1-( 4-pyr idinyl) but ylidena]- hydrazide (Cpd #244); cyclohexanecarboxylic acid (cyclopentyl-4-pyridinylmethylane)- hydrazide (Cpd #246); butyric acid (cyclopentyl-4--pyridinylmethylene)hydrazide (Cpd #247); cyclopropanecarboxylic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #248); ' 2-methylpropionic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #249); 3-cyclohexanepropionic acid [ 1-( -pyridinyl) utylidene ]hyd azide (Opd #250); cyclohe aneacetic acid [ 1 -(4-py idinyl) butyl idene ]hyd azide (Cpd #252); cyclohexanecarboxylic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #253); 2-methylpropionic acid [ 3-methyl- 1 -(4-pyr idinyl )but lidene]hydrazide (Cpd #254); cyclohexanecarboxylic acid [3-methyl-1-(4<"-pyridinyl )butylidene)- hydrazide (Cpd #255); 3-ethoxypropionic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #262); formic acid [1-(4-pyridinyl)butylidene]hydrazide (Cpd #263); cyclobutanecarboxylic acid ( 4-pyridinylmethylene )hydrazide (Cpd #264); cyclohexanecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #270); formic acid [1-(3~pyridinyl)propylidene]hydrazide (Cpd #271); 2-methylpropionic acid ( 4-pyridinylmethylene )hydrazide (Cpd #272); cyclopropanecarboxylic acid [ 1-( 4-pyr idinyl) ethyl idene ]hydr azide (Cpd #273); cyclopropanecarboxylic acid (4-pyridinylmethylene)hydrazide (Cpd #274); 2-methylpropionic acid [1-( 4-pyridinyl )ethylidene]hydrazide (Cpd #275); 3-cyclohexanepropionic acid [4-(pyridinyl)ethylidene]hydrazide (Cpd #276); 3-cyclohexanepropionic acid ( -pyridinylmethylene )hydrazide (Cpd #277); cyclohexaneacetic acid ( -pyridinylmethylene )hydrazide (Cpd #278); cyclohexanecarboxylic acid [1-(3~pyridinyl) ethyl idene ]hydr a zide (Cpd #279); cyclohexaneace ic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #280); 3-ethoxypropionic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #281); cyclobutanecarboxylic acid [1 -(4-pyridinyl) propyl idene ]hydr azide (Cpd #282); 3-ethoxypropionic acid (4-pyridinylmethylene)hydrazide (Cpd #283); cyclohexanecarboxylic acid [1 -(4-pyridinyl) ethylidene ]hydrazide 1- oxide (Cpd #287); cyclohexaneacetic acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide (Cpd #288); butyric acid [1-(4-pyridinyl)ethylidene]hydrazide 1-oxide hydrate (Cpd #289); cyclobutanecarboxylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #290); 4-nitrobenzoic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #291); 3-trifluoromethylbenzoic acid [1 -(2-pyridinyl) ethylidene Jhydrazide (Cpd #301); 2-fluorobenzoic acid (2-pyridinylmethylene)hydr azide (Cpd #303); 2-fluorobenzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #304); 3-fluorobenzoic acid [1-(2-pyridinyl)ethylidene]hydrazide (Cpd #305); 3-fluorobenzoic acid (2-pyridinylmethylene )hydrazide (Cpd #306); 2-methylcyclopropane carboxylic acid (2-pyridinylmethylene)hydrazide (Cpd #307); piperonylic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #308); propanoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #310); propanoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #311); 2-methylcyclopropane carboxylic acid [1-(3-pyridinyl)propylidene]-- hydrazide (Cpd #313); 3-trifluoromethylbenzoic acid ( 3-pyridinylmethylene)hydrazide (Cpd #315); 3-trifluoromethylbenzoic acid [1-(3-pyi"idinyl)propyl idene ]hydr azide (Cpd #316); 3-trifluoromethylbenzoic acid [1-(3-pyridinyl)ethylidene]hydrazide (Cpd #317); 2-fluorobenzoic acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #318); - 3-fluorobenzoic acid [1-(3-pyr idinyl) propyl idene ]hydr azide (Cpd #319); 2-fluorobenzoic acid (3-pyridinylmethylane)hydrazide (Cpd #320); 2-fluorobenzoicacid [l-(3-pyridinyl)ethylidene]hydrazide (Cpd #321) 3-fluorobenzoic acid (3-pyridinyl)methylene)hydrazide (Cpd #322) 3-fluorobenzoic acid C 1-(3-pyridinyl)ethylidene]hydrazide (Cpd #323) 4-phenylbutyric acid [1-(3-pyridinyl)propylidene]hydrazide (Cpd #324); 4-phenylbutyric acid (3-pyridinylmethylane)hydrazide (Cpd #325); acetic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #327); 2-methylpropionic acid [1-(6-methyl-3-py idinyl) ethyl idene]hydrazide (Cpd #328); butyric acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #329); propanoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #330); ethyl [1-(6-methyl-3-pyridinyl)ethylidene]carbazate (Cpd #332); 1 , l-dimethylethyl[1-(6-methyl-3-pyridinyl)ethylidene]carbazata (Cpd #333); phenylC 1-( 6-methyl-3-pyridinyl )ethylidene]car bazate mono ydrochlcride (Cpd #334); benzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #336); 4-chlorobenzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #337); 2-ethoxybenzoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydr azide (Cpd #338); -ethoxy e zoic acid [1-(6-methyl-3-pyridinyl)ethylidene]hydrazide (Cpd #339); 2-methyl-1-naphthaleneacetic acid [1-(4-pyridinyl)ethylidene]- hydrazide (Cpd #341); piperonylic acid [1-( 4-pyridinyl)ethylidene]hydrazide 1-oxide hydrate (Cpd #346); piperonylic acid [1-(4-pyridinyl)ethylidene]hydrazide (Cpd #347); 3,4-dimethoxyphenylacetic acid [1 -(4-pyridinyl) ethylidene ]hydrazide 1-oxide hydrate (Cpd #348); 3,4-dimethoxyphenylacetic acid ( 4-pyr idinylmethylene)hydr azide (Cpd #349); propanoic acid ( -pyridinylmethylene )hydrazide (Cpd #351); propanoic acid [1 -(4-pyridinyl) ethylidene ]hydrazide (Cpd #352); 1 -methyl cyclopropanecar bo xylic acid [1- (4-pyridinyl ) ethylidene ]- hydrazide (Cpd #354); 3-tri luoromethylbenzoic acid ( 4-pyr idinylmethylene)hydrazide (Cpd #358); 2-methyl cyclopropanecar bo xylic acid [1-( 4-pyr idinyl )propyl idene]-* hydrazide (Cpd #360); 2-fluorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #362); 3-fluorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #363 ) ; 2-fluorobenzoic acid ( 4-pyridinylmethylene )hydrazide (Cpd #364); 2-flu<_robenzoicacid-[1-(4-pyridinyl)ethylidene]hydrazide (Cpd #365); 3-fluorobenzoic acid (4-pyridinylmethylene)hydrazide (Cpd #366); 4-phenylbutyric acid [1-( 4-pyridinyl) ethylidene ]hydrazide (Cpd #367); 4-phenylbutyric acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #368); 4-phenylbutyric acid (4-pyridinylmethylene)hydrazide (Cpd #369); 3-fluorobenzoic acid [1 -(4-pyridinyl) ethylidene Jnydrazide (Cpd #370); 2-methyl benzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #371); 4 -methyl ben zoic acid [1-(4-pyridinyl)propylidene]hydrazida (Cpd #373 ) ; 2-chlorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #374); acetic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #377); 2-furoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #378); i 3oni cot inic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd τ.379) ; propanoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #380); 2-methyl propanoic acid [1-(4--pyridinyl)propylidene_hydrazide (Cpd #381); 2-thiophenecarboxylic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #382); phenyl [1-( 4-pyridinyl)propylidene]carbazate monohydrochloride (Cpd #383); 2-ethoxybenzoic acid [1-( 4-pyridinyl )propylidene]hydrazide (Cpd #385); formic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #386); 4-ethoxybenzoic acid [1-( -pyridinyl )propylidene]hydrazide (Cpd #388); 3-chlorobenzoic acid [1-(4-pyridinyl)propylidene]hydrazide (Cpd #389); butyric acid (2-chloro-3-pyridinylmethylene)hydrazide (Cpd #391); propanoic acid (3-hydroxy-2-pyridinylmethylene)hydrazide (Cpd #393); formic acid [1-(3 * -chloro-4-pyridinyl)ethylidene]hydrazide (Cpd #394); butyric acid [1-(3-chloro-4-pyridinyl) ethylidene ]hydrazide (Cpd #395); methyl [1-(3-chloro-4-pyridinyl)ethylidene]carbazate (Cpd #396); propanoic acid [1-(2-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #399); butyric acid [1-(2-chloro-3-pyridinyl)ethylidene]hydrazide . (Cpd #400); 2-methylpropanoicacid [1-(2-chloro-3-py idinyl )ethylidene]hydrazide (Cpd #401); cyclopropanecarboxylic acid [1-(2-chloro-3-pyridinyl)ethylidene]- hydrazide (Cpd #402); acetic acid [1-(6-chloro-3-pyridinyl)ethylidene]hydrazide (Cpd #410); propanoic acid [ ό-chloro-S^pyridinyl) ethyl idene ]hydr azide (#411) ; butyric acid [1-(6-chloro-3-pyridinyl) ethylidene ]hydrazide (Cpd #412); 2-methylpropanoicacid [1-(6-chloro-3-ρyr idinyl )ethylidene]hydrazide (Cpd #413); cyclopropanecarboxylic acid [ 1-(6-chlor 0-3-pyr idinyl ) ethyl idene ]- hydrazide (Cpd #414); cyclohexaneacet i c aci d [ 1 - ( 6-chlor 0-3-ρyr i dinyl ) ethyl idene ]hydr azide (Cpd #415); benzoic acid [1-(6-chlor ' ό-3-pyridinyl)ethylidene]hydrazide (Cpd #416); benzoic acid [( 1 , 3-dioxan-5-yl )-3-pyridinylmethylene]hydrazide (Cpd #421); ethyl [( 1 ,3-dioxan-5-yl)-3-pyr , idinylmethylene]carbazate (Cpd #422); benzoic acid [( 1 , 3-dioxan-5-yl )-4-pyridinylmethylene]hydrazide (Cpd #423); formic acid ( 4-pyridinylmethylene )hydrazide (Cpd #424); formic acid (3 _ pyridinylmethylene)hydrazide (Cpd #425); butyric acid [( 1 , 3-dioxan-5-yl)-3-pyridinylmethylene)hydrazide (Cpd #430); ethyl C(1 , 3-dioxan-5-yl)-4-pyridinylmethylene]carbazate (Cpd #431 ) ; methyl [0 ,3-dioxan-5-yl)-3-pyridinylmethylene]carbazate (Cpd #432); propanoic acid [( 1 ,3-dioxan-5-yl)-4-pyridinylmethylene]hydrazide (Cpd #433); propanoic acid CO ,3-dioxan-5-yl)-3-ρyridinylmethylene]hydrazide (Cpd #434); butyric acid C( 1 , 3-dioxan-5-yl)-4-pyridinylmethylene]hydrazide (Cpd #435); methyl CO ,3-dioxan-5-yl)-4-pyridinylmethylene]car bazate (Cpd #436).

Inventors: CONDER GEORGE A, FOLZ SYLVESTER D, RECTOR DOUGLAS L, CONDER, GEORGE, A., FOLZ, SYLVESTER, D., RECTOR, DOUGLAS, L.
Applicants: UPJOHN CO, THE UPJOHN COMPANY
Application year: 1986
Main classification: C07D213
IPC codes: C07D213, C07D405, C07D409